{
"id":"mk19_b_en_s1",
"subspecialtyId":"en",
"title":"Disorders of Glucose Metabolism",
"jsonContent":{
"type":"section",
"id":"mk19_b_en_s1",
"title":{
"__html":"Disorders of Glucose Metabolism"
},
"titleNode":{
"type":"section-title",
"hlId":"7fe13b",
"children":[
"Disorders of Glucose Metabolism"
]
},
"children":[
{
"type":"section",
"id":"mk19_b_en_s1_0",
"children":[
{
"type":"p",
"hlId":"8f9dbe",
"children":[
"Hyperglycemia results from abnormal carbohydrate metabolism secondary to insulin deficiency, peripheral resistance to insulin action, or both. Hyperglycemia that exceeds the normal glucose range but does not meet the diagnostic criteria for diabetes mellitus is defined as prediabetes, which increases the risk for the development of diabetes."
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s1_1",
"title":{
"__html":"Diabetes Mellitus"
},
"titleNode":{
"type":"section-title",
"hlId":"983bb7",
"children":[
"Diabetes Mellitus"
]
},
"children":[
{
"type":"section",
"id":"mk19_b_en_s1_1_1",
"title":{
"__html":"Screening for Diabetes Mellitus"
},
"titleNode":{
"type":"section-title",
"hlId":"8164d3",
"children":[
"Screening for Diabetes Mellitus"
]
},
"children":[
{
"type":"p",
"hlId":"0c573d",
"children":[
"Screening for type 2 diabetes in the general adult population is indicated because (1) type 2 diabetes is often preceded by a prolonged asymptomatic hyperglycemic period in which microvascular and macrovascular damage may occur, (2) lifestyle interventions and medications have demonstrated the ability to delay or prevent onset of type 2 diabetes in persons with prediabetes, and (3) early intensive glucose control and management of hyperlipidemia and hypertension may prevent or reduce the progression of microvascular disease and macrovascular cardiovascular disease (CVD)."
]
},
{
"type":"p",
"hlId":"8c1cb6",
"children":[
"The American Diabetes Association (ADA) and the U.S. Preventive Services Task Force (USPSTF) offer screening recommendations for prediabetes and type 2 diabetes ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_en_t01",
"wrapId":"1",
"children":[
"Table 1"
]
}
]
},
")"
]
},
"."
]
},
{
"type":"inline-wrap",
"wrapId":"1",
"contentIds":[
"mk19_b_en_t01"
]
},
{
"type":"p",
"hlId":"ac4c3b",
"children":[
"Screening for type 1 diabetes is not recommended. For a person at high risk who has a relative with type 1 diabetes, antibody testing is recommended in the setting of a research study or can be considered for first-degree family members of a proband with type 1 diabetes."
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s1_1_2",
"title":{
"__html":"Diagnostic Criteria for Diabetes Mellitus"
},
"titleNode":{
"type":"section-title",
"hlId":"1b528e",
"children":[
"Diagnostic Criteria for Diabetes Mellitus"
]
},
"children":[
{
"type":"p",
"hlId":"fcb58a",
"children":[
"Diabetes mellitus can be diagnosed by an abnormal result on one of three tests: hemoglobin A",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1c"
]
},
", fasting plasma glucose, or oral glucose tolerance test (OGTT) ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_en_t02",
"wrapId":"2",
"children":[
"Table 2"
]
}
]
},
")"
]
},
". An abnormal result in asymptomatic persons should be confirmed with repeat testing and/or two abnormal test results from the same sample (i.e., hemoglobin A",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1c"
]
},
" and fasting plasma glucose from the same sample). Additionally, a single random plasma glucose value 200 mg/dL (11.1 mmol/L) or greater in the setting of symptomatic hyperglycemia (e.g., polyuria, polydipsia) is diagnostic of diabetes and does not require further confirmatory testing."
]
},
{
"type":"inline-wrap",
"wrapId":"2",
"contentIds":[
"mk19_b_en_t02"
]
},
{
"type":"p",
"hlId":"adac47",
"children":[
"The advantages and disadvantages of these tests must be considered when determining the best screening option for a patient ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_en_t03",
"wrapId":"3",
"children":[
"Table 3"
]
}
]
},
")"
]
},
"."
]
},
{
"type":"inline-wrap",
"wrapId":"3",
"contentIds":[
"mk19_b_en_t03"
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"c0a95d",
"children":[
"Diabetes mellitus can be diagnosed by an abnormal result on one of the following screening tests: hemoglobin A",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1c"
]
},
", fasting plasma glucose, or oral glucose tolerance test."
]
},
{
"type":"keypoint",
"hlId":"30479a",
"children":[
"An abnormal plasma glucose screening test result in asymptomatic persons should be confirmed with repeat testing and/or two abnormal test results from the same sample."
]
},
{
"type":"keypoint",
"hlId":"1d75bc",
"children":[
"A single plasma glucose measurement of 200 mg/dL (11.1 mmol/L) or greater plus symptoms of hyperglycemia is diagnostic of diabetes mellitus."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s1_1_3",
"title":{
"__html":"Classification of Diabetes Mellitus"
},
"titleNode":{
"type":"section-title",
"hlId":"2a48d8",
"children":[
"Classification of Diabetes Mellitus"
]
},
"children":[
{
"type":"p",
"hlId":"3b6b33",
"children":[
"The underlying insulin abnormality is important for classifying the type of diabetes and has implications for treatment ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_en_t04",
"wrapId":"4",
"children":[
"Table 4"
]
}
]
},
")"
]
},
"."
]
},
{
"type":"inline-wrap",
"wrapId":"4",
"contentIds":[
"mk19_b_en_t04"
]
},
{
"type":"section",
"id":"mk19_b_en_s1_1_3_1",
"title":{
"__html":"Insulin Deficiency"
},
"titleNode":{
"type":"section-title",
"hlId":"a1acd8",
"children":[
"Insulin Deficiency"
]
},
"children":[
{
"type":"section",
"id":"mk19_b_en_s1_1_3_1_1",
"title":{
"__html":"Type 1 Diabetes Mellitus"
},
"titleNode":{
"type":"section-title",
"hlId":"b31a06",
"children":[
"Type 1 Diabetes Mellitus"
]
},
"children":[
{
"type":"p",
"hlId":"3affd4",
"children":[
"Type 1 diabetes is characterized by a state of insulin deficiency secondary to the destruction of the insulin-producing β cells in the pancreas. The destruction may be secondary to autoimmune, idiopathic, or acquired insulin deficiency (e.g., pancreatectomy, pancreatitis)."
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s1_1_3_1_2",
"title":{
"__html":"Immune-Mediated Diabetes Mellitus"
},
"titleNode":{
"type":"section-title",
"hlId":"4e38a1",
"children":[
"Immune-Mediated Diabetes Mellitus"
]
},
"children":[
{
"type":"p",
"hlId":"2961ff",
"children":[
"Immune-mediated type 1 (type 1A) diabetes is the underlying cause of diabetes in 5% to 10% of persons newly diagnosed. The mechanism of the β-cell destruction is multifactorial and likely caused by environmental factors in persons with genetic susceptibilities. Specific HLA alleles demonstrate a strong association with type 1A diabetes. At diagnosis, one or more autoantibodies directed at the following targets are typically present: glutamic acid decarboxylase (GAD65), tyrosine phosphatases IA-2 and IA-2β, islet cells, insulin, and zinc transporter. Because of highly automated and widely available assays, GAD65 and IA-2 autoantibodies are recommended as initial testing for type 1A diabetes in newly diagnosed disease. GAD65 autoantibodies have a high prevalence (70%) at the time of diagnosis and may remain detectable for years."
]
},
{
"type":"p",
"hlId":"647f10",
"children":[
"Type 1A diabetes has a variable presentation depending on the rate of β-cell destruction and ranges from moderate hyperglycemia to life-threatening diabetic ketoacidosis (DKA). Eventually β-cell function declines to the point of little to no insulin secretion, as evidenced by a low or undetectable serum C-peptide level. Initiating insulin at the time of diagnosis may decrease toxicity associated with extreme hyperglycemia, allowing the β cells to regain some ability to produce insulin. Although this “honeymoon period” can last several weeks to years, insulin use should be continued to decrease stress on the remaining functioning β cells and prolong their lifespan. Insulin deficiency requires life-long use of insulin therapy."
]
},
{
"type":"p",
"hlId":"35c8c8",
"children":[
"Patients with type 1A diabetes also have an increased risk for other autoimmune disorders, including celiac disease, thyroid disorders, vitiligo, and autoimmune primary adrenal gland failure."
]
},
{
"type":"p",
"hlId":"af7853",
"children":[
"Late autoimmune diabetes in adults is characterized by autoantibody development leading to β-cell destruction and ultimately to insulin deficiency. Typically, individuals with this type of diabetes are not initially insulin dependent and are frequently misclassified as having type 2 diabetes. A slow progression toward insulin dependence occurs over months to years after diagnosis in the setting of positive autoantibodies."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"f1d189",
"children":[
"Autoantibodies glutamic acid decarboxylase and tyrosine phosphatase IA-2 demonstrate a strong association with immune-mediated type 1 diabetes mellitus and should be measured at initial diagnosis to confirm cause."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s1_1_3_1_3",
"title":{
"__html":"Idiopathic Type 1 Diabetes Mellitus"
},
"titleNode":{
"type":"section-title",
"hlId":"a1ec70",
"children":[
"Idiopathic Type 1 Diabetes Mellitus"
]
},
"children":[
{
"type":"p",
"hlId":"de47f5",
"children":[
"Idiopathic type 1 diabetes (type 1B) is characterized by variable insulin deficiency because of β-cell destruction in the absence of autoantibodies. Patients with type 1B diabetes may develop episodic DKA. Typically, persons with type 1B diabetes have a strong family history of type 2 diabetes."
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s1_1_3_1_4",
"title":{
"__html":"Acquired Type 1 Diabetes Mellitus"
},
"titleNode":{
"type":"section-title",
"hlId":"a2a8d7",
"children":[
"Acquired Type 1 Diabetes Mellitus"
]
},
"children":[
{
"type":"p",
"hlId":"ba3ad6",
"children":[
"β-Cell destruction may occur from diseases affecting the pancreas or from the effect of drugs or infections (see ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_en_t04",
"wrapId":"5",
"children":[
"Table 4"
]
}
]
},
")"
]
},
". This type of diabetes may result in impaired insulin production or secretion with the subsequent development of type 1 diabetes."
]
},
{
"type":"inline-wrap",
"wrapId":"5",
"contentIds":[
"mk19_b_en_t04"
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s1_1_3_2",
"title":{
"__html":"Insulin Resistance"
},
"titleNode":{
"type":"section-title",
"hlId":"7aa869",
"children":[
"Insulin Resistance"
]
},
"children":[
{
"type":"p",
"hlId":"30e479",
"children":[
"The ineffective use of insulin by the peripheral cells to process glucose and fatty acids characterizes insulin resistance. Blood glucose levels remain in the normal range as long as the β cells can increase insulin production. Hyperglycemia results from a relative insulin deficiency when the pancreas can no longer produce sufficient insulin to overcome the peripheral resistance. Obesity increases the risk for insulin resistance and predisposes to the development of type 2 diabetes."
]
},
{
"type":"section",
"id":"mk19_b_en_s1_1_3_2_1",
"title":{
"__html":"Metabolic Syndrome"
},
"titleNode":{
"type":"section-title",
"hlId":"47568e",
"children":[
"Metabolic Syndrome"
]
},
"children":[
{
"type":"p",
"hlId":"7ef97a",
"children":[
"Metabolic syndrome is a constellation of risk factors for development of type 2 diabetes and CVD. Multiple organizations define metabolic syndrome differently ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_en_t05",
"wrapId":"6",
"children":[
"Table 5"
]
}
]
},
")"
]
},
". The Endocrine Society recommends screening patients aged 40 to 75 years at metabolic risk every 3 years with fasting plasma glucose, fasting lipid panel, blood pressure, and waist circumference. Patients at metabolic risk often have elements of the metabolic syndrome. Calculation of the 10-year CVD risk, using either the Framingham Risk Score or the American College of Cardiology/American Heart Association Pooled Cohort Equations, is recommended for patients with metabolic syndrome."
]
},
{
"type":"inline-wrap",
"wrapId":"6",
"contentIds":[
"mk19_b_en_t05"
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s1_1_3_2_2",
"title":{
"__html":"Type 2 Diabetes Mellitus"
},
"titleNode":{
"type":"section-title",
"hlId":"5a7aa7",
"children":[
"Type 2 Diabetes Mellitus"
]
},
"children":[
{
"type":"p",
"hlId":"c72a3f",
"children":[
"Hyperglycemia accompanied by insulin resistance or relative insulin deficiency defines type 2 diabetes. The extent of β-cell dysfunction determines the degree of hyperglycemia, which may worsen over time with progressive decrease in insulin production. The pathogenesis of type 2 diabetes is multifactorial, with influence from both genetic and environmental factors. Type 2 diabetes is commonly present in first-degree relatives of both individuals diagnosed with or at high risk (see ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_en_t01",
"wrapId":"7",
"children":[
"Table 1"
]
}
]
},
")"
]
},
" for type 2 diabetes."
]
},
{
"type":"inline-wrap",
"wrapId":"7",
"contentIds":[
"mk19_b_en_t01"
]
},
{
"type":"p",
"hlId":"a1af31",
"children":[
"Type 2 diabetes typically presents in adults, although the incidence is increasing among children and adolescents as the rate of overweight and obesity increases in these populations. Type 2 diabetes has a gradual onset, with most affected persons remaining asymptomatic for several years. Clinical manifestations of insulin resistance may be present on physical examination before diagnosis. At the time of diagnosis, patients may already have microvascular or macrovascular complications."
]
},
{
"type":"p",
"hlId":"6a6c0d",
"children":[
"Acanthosis nigricans ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"figure-link",
"target":"mk19_b_en_f01",
"wrapId":"8",
"children":[
"Figure 1"
]
}
]
},
")"
]
},
" is typically associated with insulin resistance but also rarely with malignant and paraneoplastic syndromes. Therefore, a diagnosis of acanthosis nigricans should prompt screening for diabetes and, if of acute onset, screening for malignancy."
]
},
{
"type":"inline-wrap",
"wrapId":"8",
"contentIds":[
"mk19_b_en_f01"
]
},
{
"type":"p",
"hlId":"b273e5",
"children":[
"The development of type 2 diabetes in high-risk individuals can be delayed or prevented with modifications to lifestyle (i.e., diet, exercise), pharmacologic intervention, or metabolic surgery ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_en_t06",
"wrapId":"9",
"children":[
"Table 6"
]
}
]
},
")"
]
},
". The goal of these interventions is weight loss and the reduction of insulin resistance. In the Diabetes Prevention Program (DPP), lifestyle modifications reduced the incidence of type 2 diabetes in persons with prediabetes by 58%. Thus, the ADA recommends referral to an intensive lifestyle behavior change program to achieve (and maintain) a 7% weight loss over 6 months and at least 150 min/week of moderate-intensity exercise to reduce the risk for diabetes. A diet rich in monounsaturated fat, whole grains, vegetables, whole fruits, and nuts is recommended."
]
},
{
"type":"inline-wrap",
"wrapId":"9",
"contentIds":[
"mk19_b_en_t06"
]
},
{
"type":"p",
"hlId":"912972",
"children":[
"Several pharmacologic interventions have demonstrated efficacy in diabetes risk reduction (see ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_en_t06",
"wrapId":"10",
"children":[
"Table 6"
]
}
]
},
")"
]
},
". Safety data, cost, and long-term durability of each intervention must be considered for each patient. Metformin is the preferred agent because it reduced the incidence of diabetes by 31% in the DPP and has long-term safety data. The ADA recommends considering metformin for type 2 diabetes prevention in persons with prediabetes, particularly those aged 25 to 59 years with a BMI of 35 or greater, higher fasting plasma glucose (≥110 mg/dL [6.11 mmol/L]), and hemoglobin A",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1c"
]
},
" values of 6% or greater, as well as in women with a history of gestational diabetes. The CDC Diabetes Prevention Recognition Program additionally endorses technology-assisted modalities via smart phones, web-based applications, or telehealth as effective tools for DPP-based interventions."
]
},
{
"type":"inline-wrap",
"wrapId":"10",
"contentIds":[
"mk19_b_en_t06"
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s1_1_3_2_3",
"title":{
"__html":"Ketosis-Prone Diabetes Mellitus"
},
"titleNode":{
"type":"section-title",
"hlId":"78beed",
"children":[
"Ketosis-Prone Diabetes Mellitus"
]
},
"children":[
{
"type":"p",
"hlId":"6d0095",
"children":[
"The term “ketosis-prone diabetes” (KPD) incorporates several glycemic syndromes previously known as ketosis-prone type 2 diabetes, type 1B diabetes, or atypical diabetes. KPD presents with episodic DKA resulting from insulin deficiency but has variable periods of insulin dependence and independence. Initially, insulin therapy is required until DKA has resolved and the β cells are no longer impaired by glucose toxicity and can potentially produce sufficient amounts of insulin to suppress lipolysis."
]
},
{
"type":"p",
"hlId":"ded728",
"children":[
"Given the variable clinical course exhibited with KPD, uncertainty prevails regarding the need for short- and long-term insulin treatment regimens. Four classification systems, based on autoantibody status (A) and β-cell function (β), have been developed to provide predictive guidance on the length of insulin therapy. Longitudinal data from KPD cohorts indicate individuals without β-cell reserve regardless of the antibody status (A",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"+"
]
},
"β",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"−"
]
},
" and A",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"−"
]
},
"β",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"−"
]
},
") are more likely to have poor glycemic control and develop long-term insulin dependence after the development of DKA compared with individuals with preserved β-cell function (A",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"+"
]
},
"β",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"+"
]
},
" and A",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"−"
]
},
"β",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"+"
]
},
"). Patients with β-cell functioning are often able to discontinue insulin, but treatment with metformin or injectable agents is often required."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"8575fb",
"children":[
"Lifestyle modifications, including weight loss, healthy diet, and exercise reduce the incidence of type 2 diabetes mellitus in persons with prediabetes."
]
},
{
"type":"keypoint",
"hlId":"99480f",
"children":[
"Metformin is recommended for type 2 diabetes mellitus prevention in individuals with prediabetes, particularly those aged 25 to 59 years with a BMI of 35 or greater, higher fasting plasma glucose (≥110 mg/dL [6.11 mmol/L]), and hemoglobin A",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1c"
]
},
" values of 6% or greater, as well as in women with a history of gestational diabetes."
]
}
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s1_1_3_3",
"title":{
"__html":"Gestational Diabetes Mellitus"
},
"titleNode":{
"type":"section-title",
"hlId":"ff2061",
"children":[
"Gestational Diabetes Mellitus"
]
},
"children":[
{
"type":"p",
"hlId":"32af43",
"children":[
"Gestational diabetes is defined as hyperglycemia during the second or third trimester in women without a prepregnancy diagnosis of type 1 or type 2 diabetes. However, patients commonly have preexisting and undiagnosed diabetes that is first noticed during pregnancy, which is not classified as gestational diabetes. In women who are planning pregnancy, the ADA recommends screening those with risk factors ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_en_t01",
"wrapId":"11",
"children":[
"Table 1"
]
}
]
},
")"
]
},
" and considering testing for all women. Adverse maternal and neonatal outcomes related to diabetes increase with worsening hyperglycemia. Complications include macrosomia, labor and delivery complications, preeclampsia, neonatal hypoglycemia, spontaneous abortion, and intrauterine fetal demise."
]
},
{
"type":"inline-wrap",
"wrapId":"11",
"contentIds":[
"mk19_b_en_t01"
]
},
{
"type":"p",
"hlId":"a1e615",
"children":[
"Given the increased prevalence of undiagnosed type 2 diabetes in the general population, the ADA recommends standard screening for any pregnant woman with risk factors for diabetes before 15 weeks of gestation and considering testing all women at the initial prenatal visit. Women with hyperglycemia identified during the first trimester are classified as having type 2 diabetes versus gestational diabetes. For all other pregnant women without a previous diabetes diagnosis, diabetes screening should occur between 24 and 28 weeks' gestation. The USPSTF recommends screening at 24 weeks or after. The screening method recommended varies among expert groups. The “one-step” OGTT involves blood glucose measurements at baseline (fasting) and 1 and 2 hours after a 75-g oral glucose load. One abnormal value above the cut-point is diagnostic of gestational diabetes. The “two-step” OGTT involves an initial blood glucose measurement 1 hour after a 50-g oral glucose load. If the blood glucose is abnormal, then the second step is initiated. Glucose is measured at baseline (fasting) and 1, 2, and 3 hours after a 100-g oral glucose load. Two abnormal blood glucose values after the 100-g load are diagnostic for gestational diabetes."
]
},
{
"type":"p",
"hlId":"0d51a7",
"children":[
"Most women with gestational diabetes have glucose normalization after pregnancy, but they are at an increased risk for development of recurrent gestational diabetes and type 2 diabetes. The ADA recommends a 75-g OGTT 4 to 12 weeks postpartum to confirm resolution of hyperglycemia. If the results of initial postpartum evaluation are normal, life-long screening should continue at least every 3 years (see ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_en_t02",
"wrapId":"12",
"children":[
"Table 2"
]
}
]
},
")"
]
},
"."
]
},
{
"type":"inline-wrap",
"wrapId":"12",
"contentIds":[
"mk19_b_en_t02"
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s1_1_3_4",
"title":{
"__html":"Uncommon Types of Diabetes Mellitus"
},
"titleNode":{
"type":"section-title",
"hlId":"04f2ed",
"children":[
"Uncommon Types of Diabetes Mellitus"
]
},
"children":[
{
"type":"p",
"hlId":"aa6974",
"children":[
"Genetic defects impairing either insulin secretion or insulin action are rare forms of diabetes (see ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_en_t04",
"wrapId":"13",
"children":[
"Table 4"
]
}
]
},
")"
]
},
". Maturity-onset diabetes of the young (MODY) is characterized as an autosomal dominant monogenetic defect on different chromosomal loci. MODY has at least 14 known gene mutations. Although insulin action remains normal in MODY, glucose sensing and insulin secretion are altered. Autoantibodies are typically absent. Individuals with MODY present with a clinical course that is frequently atypical of type 1 or type 2 diabetes. The onset of symptoms typically occurs before age 25 years, and a strong family history of atypical diabetes is often present in patients without obesity. Treatment varies based on the gene mutation, and thus genetic counseling and testing is recommended."
]
},
{
"type":"inline-wrap",
"wrapId":"13",
"contentIds":[
"mk19_b_en_t04"
]
},
{
"type":"p",
"hlId":"d40cbe",
"children":[
"Excess hormone production associated with several endocrinopathies can also impair insulin secretion or insulin action, inducing hyperglycemia (see ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_en_t04",
"wrapId":"14",
"children":[
"Table 4"
]
}
]
},
")"
]
},
"."
]
},
{
"type":"inline-wrap",
"wrapId":"14",
"contentIds":[
"mk19_b_en_t04"
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s1_1_4",
"title":{
"__html":"Management of Diabetes Mellitus"
},
"titleNode":{
"type":"section-title",
"hlId":"a9b4bb",
"children":[
"Management of Diabetes Mellitus"
]
},
"children":[
{
"type":"p",
"hlId":"41178a",
"children":[
"Effective diabetes management is best achieved through a patient-centered approach with patients and their caregivers developing individualized goals and treatment plans compatible with patient preferences, lifestyle requirements, comorbidities, and safety. Management should also incorporate patient education, blood glucose monitoring (BGM), lifestyle modifications, and pharmacologic therapies."
]
},
{
"type":"section",
"id":"mk19_b_en_s1_1_4_1",
"title":{
"__html":"Patient Education"
},
"titleNode":{
"type":"section-title",
"hlId":"834faf",
"children":[
"Patient Education"
]
},
"children":[
{
"type":"p",
"hlId":"020ebb",
"children":[
"Diabetes self-management education and support (DSMES) provides the knowledge and skills for patients to perform diabetes-related self-care and develop effective problem-solving strategies. The ADA recommends considering referral for DSMES at several critical periods in care, including at the time of diagnosis, annually to reassess needs during care transitions, and when self-management skills are influenced by health status changes. DSMES has been shown to improve outcomes, such as hemoglobin A",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1c"
]
},
" and quality of life. DSMES also reduces costs by decreasing use of acute care and inpatient facilities for diabetes management. The ADA suggests that digital coaching and digital self-management can be effective methods for delivering diabetes self-management education and support."
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s1_1_4_2",
"title":{
"__html":"Blood Glucose Monitoring"
},
"titleNode":{
"type":"section-title",
"hlId":"cd6f2d",
"children":[
"Blood Glucose Monitoring"
]
},
"children":[
{
"type":"p",
"hlId":"ff3890",
"children":[
"BGM is recommended for patients with intensive insulin regimens (multiple-dose insulin regimens or insulin pump therapy). Specific regimens for BGM are individualized and may include monitoring glucose levels when fasting, before meals, at bedtime, before and after exercise, when hypoglycemia is suspected, after treating hypoglycemia until normoglycemia is achieved, and before and while performing critical tasks, such as driving or operating machinery. Measuring postprandial blood glucose levels may identify undetected hyperglycemia in which preprandial blood glucose values are at the target goal, but the hemoglobin A",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1c"
]
},
" is above goal. BGM may also be used to detect and correct hypoglycemia."
]
},
{
"type":"p",
"hlId":"b1414b",
"children":[
"In motivated patients with nonintensive insulin regimens, BGM can be considered; however, the optimal testing frequency has not been determined. In patients with type 2 diabetes not using insulin, routine glucose monitoring may be of limited additional clinical benefit."
]
},
{
"type":"p",
"hlId":"df6b92",
"children":[
"Hemoglobin A",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1c"
]
},
" generally correlates with average 3-month blood glucose level in patients without hemoglobinopathies or increased erythrocyte turnover; therefore, treatment efficacy can be measured by combining BGM and hemoglobin A",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1c"
]
},
" data ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_en_t07",
"wrapId":"15",
"children":[
"Table 7"
]
}
]
},
")"
]
},
". Glycemic goals may vary based on individual patient characteristics ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_en_t08",
"wrapId":"15",
"children":[
"Table 8"
]
}
]
},
")"
]
},
"."
]
},
{
"type":"inline-wrap",
"wrapId":"15",
"contentIds":[
"mk19_b_en_t07",
"mk19_b_en_t08"
]
},
{
"type":"p",
"hlId":"424393",
"children":[
"Another option is a continuous glucose monitoring (CGM) system, which can alert the user to retrospective and current glucose trends (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"video-link",
"target":"mk19_b_en_v01",
"wrapId":"16",
"children":[
"Video 1"
]
}
]
},
", ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"video-link",
"target":"mk19_b_en_v02",
"wrapId":"16",
"children":[
"Video 2"
]
}
]
},
"). The goals of using a CGM system are to improve diabetes care by lowering hemoglobin A",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1c"
]
},
" and avoiding hypoglycemia, which is critical for those with hypoglycemia unawareness. The ADA recommends real-time CGM or intermittently scanned CGM for diabetes management in adults requiring multiple daily injections or continuous subcutaneous insulin infusion. Such monitoring can be used in adults taking basal insulin. Real-time CGM devices should be used as close to daily as possible for maximal benefit. Intermittently scanned CGM devices should be scanned at least every 8 hours. Data demonstrate improved glycemic control with longer duration of CGM system use."
]
},
{
"type":"inline-wrap",
"wrapId":"16",
"contentIds":[
"mk19_b_en_v01",
"mk19_b_en_v02"
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"6db57b",
"children":[
"Blood glucose monitoring or the use of a continuous glucose monitoring system is recommended for patients with intensive insulin regimens (multiple-dose insulin regimens or insulin pump therapy)."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s1_1_4_3",
"title":{
"__html":"Recommended Vaccinations and Screening"
},
"titleNode":{
"type":"section-title",
"hlId":"8db292",
"children":[
"Recommended Vaccinations and Screening"
]
},
"children":[
{
"type":"p",
"hlId":"8b5054",
"children":[
"Persons with diabetes should receive age-appropriate vaccinations as recommended by the Advisory Committee on Immunization Practices guidelines (see ",
{
"type":"cross-reference",
"target":"mk19_b_gm_s1_3_1",
"children":[
"MKSAP 19 General Internal Medicine 2"
]
},
"). Patients with diabetes are more likely to have serious morbidity and mortality from COVID-19, and vaccination is strongly recommended. All currently authorized COVID-19 vaccines are effective in preventing severe COVID-19 disease, hospitalizations, and death."
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s1_1_4_4",
"title":{
"__html":"Nonpharmacologic Approaches to Diabetes Management"
},
"titleNode":{
"type":"section-title",
"hlId":"b1a259",
"children":[
"Nonpharmacologic Approaches to Diabetes Management"
]
},
"children":[
{
"type":"p",
"hlId":"b820e0",
"children":[
"Lifestyle changes are essential for the long-term management of diabetes and prevention of complications. Although these changes should be individualized, diet and physical activity are critical components for patients with type 1 and type 2 diabetes."
]
},
{
"type":"p",
"hlId":"79425e",
"children":[
"Nutrition therapy with a registered dietitian provides individualized diabetes-specific education to promote healthy diet choices to achieve glycemic and weight management goals and has also been associated with reductions in hemoglobin A",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1c"
]
},
" in patients with type 1 and type 2 diabetes. The ADA does not recommend a specific diet; however, evidence suggests that a decrease in overall carbohydrate intake results in improved glycemic control. The ADA recommends that, when carbohydrates are consumed, nutrient-dense carbohydrate sources that are high in fiber (≥14 g fiber/1000 kcal) and minimally processed should be emphasized; eating plans should focus on nonstarchy vegetables, fruits, and whole grains, as well as dairy products, with minimal added sugars. In patients with overweight and obesity with type 2 diabetes, a goal of at least 5% weight loss is recommended and has been shown to improve glycemic control, although weight loss of 15% or more may be necessary to achieve the desired results."
]
},
{
"type":"p",
"hlId":"42bb28",
"children":[
"Physical activity recommendations include moderate- to vigorous-intensity aerobic activity for 150 minutes/week, vigorous-intensity aerobic activity for 75 minutes/week, or a combination of both. This level of activity has been shown to reduce hemoglobin A",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1c"
]
},
", decrease weight, improve well-being, and improve CVD risk factors. Resistance training is recommended two or more times per week. Older adults with diabetes should engage in flexibility and balance training two to three times per week, if possible. Prolonged sedentary behavior should be interrupted at 30-minute intervals with light activity or standing."
]
},
{
"type":"p",
"hlId":"ce9c62",
"children":[
"Weight loss medications (see ",
{
"type":"cross-reference",
"target":"mk19_b_gm_s5_3_2",
"children":[
"MKSAP 19 General Internal Medicine 2"
]
},
") or metabolic surgery (see ",
{
"type":"cross-reference",
"target":"mk19_b_gm_s5_3_3",
"children":[
"MKSAP 19 General Internal Medicine 2"
]
},
") are alternatives to consider if medical nutrition therapy and physical activity are unsuccessful. Metabolic surgery is recommended to treat type 2 diabetes in patients with BMI of 40 or greater (≥37.5 in Asian Americans) and in patients with BMI of 35.0 to 39.9 (32.5-37.4 in Asian Americans) for whom medical interventions are unsuccessful to achieve weight loss goals and improvement in comorbidities, including hyperglycemia. Metabolic surgery may be considered for similar indications in adults with type 2 diabetes and BMI 30.0 to 34.9 (27.5-32.4 in Asian Americans)."
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s1_1_4_5",
"title":{
"__html":"Pharmacologic Therapy"
},
"titleNode":{
"type":"section-title",
"hlId":"6951bd",
"children":[
"Pharmacologic Therapy"
]
},
"children":[
{
"type":"p",
"hlId":"1f7506",
"children":[
"Pharmacologic therapy should be individualized based on the patient's age, health status, weight, pathophysiology of hyperglycemia, specific risks and benefits of a potential therapeutic agent, medication cost, lifestyle, and personal treatment goals. Most clinical practice guidelines, including the ADA guidelines, recommend target hemoglobin A",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1c"
]
},
" thresholds based on a patient's health status (see ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_en_t08",
"wrapId":"17",
"children":[
"Table 8"
]
}
]
},
")"
]
},
"."
]
},
{
"type":"inline-wrap",
"wrapId":"17",
"contentIds":[
"mk19_b_en_t08"
]
},
{
"type":"p",
"hlId":"1db8bb",
"children":[
"The American College of Physicians recommends a hemoglobin A",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1c"
]
},
" level between 7% and 8% in most patients with type 2 diabetes; clinicians should consider deintensifying pharmacologic therapy in patients who achieve hemoglobin A",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1c"
]
},
" levels less than 6.5%. The rationale for these targets is based on evidence that collectively shows treating to targets less than 7% compared with targets around 8% did not reduce death or macrovascular events over 5 to 10 years of treatment but did result in substantial harms. More stringent targets may be appropriate for patients who have a long life expectancy (>15 years) and are interested in more intensive glycemic control with pharmacologic therapy despite the risk for harms, including but not limited to hypoglycemia, patient burden, and pharmacologic costs. The American College of Physicians also recommends avoiding a specific target hemoglobin A",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1c"
]
},
" level in patients with a life expectancy less than 10 years at an advanced age (80 years or older), residence in a nursing home, or chronic medical conditions because the harms outweigh the benefits in this population."
]
},
{
"type":"p",
"hlId":"e75634",
"children":[
"Several landmark studies provide guidance on glycemic goals and CVD risk reduction. Intensive glycemic control compared with standard control significantly reduces the incidence and progression of microvascular complications in patients with type 1 and type 2 diabetes, as demonstrated by the Diabetes Control and Complications Trial and the UK Prospective Diabetes Study. Long-term follow-up demonstrated continued reductions in microvascular complications despite convergence in glycemic control between the study arms. Multiple subsequent studies further reinforced the association of reduced microvascular complications with tight glycemic control, but also highlighted that patients and clinicians must balance the risks and benefits of a labor-intensive regimen with the potential morbidity and mortality in specific populations."
]
},
{
"type":"p",
"hlId":"a73098",
"children":[
"Long-term follow-up evaluation of participants in the intensive insulin arms of the Diabetes Control and Complications Trial and the UK Prospective Diabetes Study who were early in the course of diabetes demonstrated a significant reduction in CVD and mortality. In contrast, other trials evaluating tight glycemic control in older persons with more advanced type 2 diabetes and preexisting CVD or CVD risk factors demonstrated no change in cardiovascular or overall mortality."
]
},
{
"type":"p",
"hlId":"84610a",
"children":[
"Recent trials have established the use of other specific pharmacologic therapies in decreasing the long-term complications of diabetes. In patients with established CVD, the sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin reduced the composite outcome of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke, as well as hospitalization for heart failure, and all-cause mortality. Another SGLT2 inhibitor, canagliflozin, demonstrated a reduction in cardiovascular events, but not cardiovascular death, in patients with type 2 diabetes at high risk for CVD. Similarly, the SGLT2 inhibitor dapagliflozin lowered the rate of cardiovascular death and hospitalization for heart failure. SGLT2 inhibitors also have favorable outcomes for kidney function, with a large meta-analysis demonstrating a reduced risk of kidney disease by 45%, although the extent of reduction varied based on kidney function. Whereas the mechanisms contributing to these clinical outcomes are not well-described, SGLT2 inhibitor–related natriuresis is proposed to account for a favorable effect on blood pressure. Similarly, altered myocardial metabolism and weight loss could account for additional benefits to reduction in CVD-related mortality."
]
},
{
"type":"p",
"hlId":"afd10e",
"children":[
"Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) have also shown specific use in decreasing long-term complications. In patients at risk for CVD, liraglutide significantly reduced the primary composite outcome of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke, as well as all-cause mortality. Semaglutide reduced the composite of nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death in patients with established or at high risk for CVD. A meta-analysis of seven GLP-1 RAs on cardiovascular outcomes trials found that this drug class reduced major adverse cardiovascular events, all-cause mortality, hospitalization for heart failure, and a composite of various kidney outcomes. This class benefit is likely related to improvement in nonglycemic effects such as weight loss, especially visceral fat, and reduction in triglycerides."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"195427",
"children":[
"Most clinical practice guidelines recommend target hemoglobin A",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1c"
]
},
" thresholds based on a patient's health status."
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s1_1_4_5_1",
"title":{
"__html":"Therapy for Type 1 Diabetes Mellitus"
},
"titleNode":{
"type":"section-title",
"hlId":"d167a7",
"children":[
"Therapy for Type 1 Diabetes Mellitus"
]
},
"children":[
{
"type":"p",
"hlId":"43b4c0",
"children":[
"Because of the destruction of the β cells and subsequent insulin deficiency, life-long insulin therapy is required for persons with type 1 diabetes. Ideally, an intensive insulin regimen should be prescribed, which includes multiple daily doses of insulin (MDI) to mimic the physiologic action of the pancreas. The insulin regimen should include basal coverage to maintain glycemic control while fasting and between meals, prandial coverage, and supplemental insulin for correction of hyperglycemia. This coverage can be accomplished with subcutaneous insulin injections, inhaled insulin preparations, or continuous subcutaneous insulin infusions (CSII) with an insulin pump, such as a patch pump (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"video-link",
"target":"mk19_b_en_v03",
"wrapId":"18",
"children":[
"Video 3"
]
}
]
},
") or tubing pump (",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"video-link",
"target":"mk19_b_en_v04",
"wrapId":"18",
"children":[
"Video 4"
]
}
]
},
")."
]
},
{
"type":"inline-wrap",
"wrapId":"18",
"contentIds":[
"mk19_b_en_v03",
"mk19_b_en_v04"
]
},
{
"type":"p",
"hlId":"83bd09",
"children":[
"Initial total daily insulin dosing typically ranges from 0.4 to 1.0 U/kg/day in patients with type 1 diabetes. Basal insulin typically encompasses approximately 50% of the total daily dose of insulin, with prandial insulin covering the remaining 50%. The available insulin formulations and their activity profiles are summarized in ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_en_t09",
"wrapId":"19",
"children":[
"Table 9"
]
}
]
},
"."
]
},
{
"type":"inline-wrap",
"wrapId":"19",
"contentIds":[
"mk19_b_en_t09"
]
},
{
"type":"p",
"hlId":"3a583f",
"children":[
"The timing and mode of prandial insulin delivery varies based on patient needs, preferences, and dietary habits. MDI prandial dosing can be accomplished with fixed dosing, carbohydrate counting, or modified carbohydrate counting. In general, 1 unit of insulin covers 10 to 20 g of carbohydrates consumed. A modified carbohydrate counting method can be used when the grams of carbohydrates consumed cannot be accurately counted. With this method, regular or analogue insulin doses can be adjusted by 50% based on the portion of food consumed. For example, the dose for the size of the meal would be as follows: small (50%), regular (100%), large (150%). MDI should also incorporate supplemental insulin to correct hyperglycemia. A common method to calculate the correction dose of insulin is to give an additional 1 unit of regular or analogue insulin at the time of the premeal measurement for every glucose value 50 mg/dL (2.8 mmol/L) above the target glucose value in insulin-sensitive individuals and 1 unit for every 25 mg/dL (1.4 mmol/L) in insulin-resistant individuals."
]
},
{
"type":"p",
"hlId":"dbca85",
"children":[
"Premixed insulin formulations combine intermediate- or long-acting basal insulin and rapid- or short-acting insulin in fixed concentrations. These formulations are typically administered twice daily and should be considered for those who are unable or unwilling to perform more frequent daily insulin injections. Premixed formulations are nonphysiologic and can increase glycemic excursions, including hypoglycemia."
]
},
{
"type":"p",
"hlId":"306078",
"children":[
"Inhaled insulin is a rapid-acting formulation for prandial dosing. The availability of inhaled insulin in cartridges with preset doses of insulin (4, 8, and 12 units) limits the flexibility of insulin dosing. Pulmonary function should be assessed at baseline and monitored because lung function may decline with use of inhaled insulin."
]
},
{
"type":"p",
"hlId":"51030d",
"children":[
"CSII provides continuous delivery of basal insulin and uses a bolus calculator, programmed to achieve individual glycemic goals, to calculate prandial and bolus correction doses. The Endocrine Society recommends CSII over MDI for all adults with type 1 diabetes who have not attained their hemoglobin A",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1c"
]
},
" goal and for those who have attained their hemoglobin A",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1c"
]
},
" goal but have large glycemic variability, severe hypoglycemia, or hypoglycemia unawareness. Additional considerations include a need for flexibility in insulin delivery, early morning hyperglycemia (“dawn phenomenon”), active lifestyle, or patient preference. A sensor-augmented CSII system may be used in conjunction with a CGM system to decrease or stop delivery of insulin if glucose levels fall below a threshold value that is set within the CSII system and to increase delivery if glucose levels are above a threshold value. Insulin delivery is then reinitiated and either increased or decreased back to baseline when the threshold is no longer met."
]
},
{
"type":"p",
"hlId":"cc00b9",
"children":[
"Hypoglycemia and weight gain are risks associated with insulin use. The risk of hypoglycemia is lower with analogue insulin compared with regular insulin because of a shorter duration of action. Hypoglycemia caused by insulin stacking occurs when insulin dosing is too frequent and overlaps with the duration of action of a previous insulin injection. This effect can be avoided by allowing at least 3 to 4 hours between sequential injections of analogue insulin."
]
},
{
"type":"p",
"hlId":"0f0bb2",
"children":[
"An adjunctive therapy approved for use with insulin in type 1 diabetes is pramlintide, an amylin analogue. Pramlintide can lead to improved glycemic control, decreased insulin doses, and weight loss through delayed gastric emptying, increased satiety, and decreased glucagon secretion."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"9cbde7",
"children":[
"The Endocrine Society recommends continuous subcutaneous insulin infusions over multiple daily doses of insulin for all adults with type 1 diabetes mellitus who have not attained their hemoglobin A",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1c"
]
},
" goal and for those who have attained their hemoglobin A",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1c"
]
},
" goal but have large glycemic variability, severe hypoglycemia, or hypoglycemia unawareness."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s1_1_4_5_2",
"title":{
"__html":"Therapy for Type 2 Diabetes Mellitus"
},
"titleNode":{
"type":"section-title",
"hlId":"283fc7",
"children":[
"Therapy for Type 2 Diabetes Mellitus"
]
},
"children":[
{
"type":"p",
"hlId":"6a3b3f",
"children":[
"As β-cell function declines, pharmacologic therapies must often be combined with lifestyle modifications to obtain glycemic control. Therapeutic options may include monotherapy or a combination of oral agents with injectable agents ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_en_t10",
"wrapId":"20",
"children":[
"Table 10"
]
}
]
},
")"
]
},
"."
]
},
{
"type":"inline-wrap",
"wrapId":"20",
"contentIds":[
"mk19_b_en_t10"
]
},
{
"type":"p",
"hlId":"aad4e3",
"children":[
"For any patient with type 2 diabetes, comprehensive lifestyle modification, including weight management and physical activity, is the first-line therapy. For individuals who do not meet glycemic targets with lifestyle modification alone, a patient-centered approach is recommended when choosing appropriate pharmacologic therapy ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_en_t11",
"wrapId":"21",
"children":[
"Table 11"
]
}
]
},
")"
]
},
". Clinicians should consider comorbidities such as atherosclerotic CVD (ASCVD) and ASCVD risk factors, established kidney disease, and heart failure when selecting medications because some agents have a beneficial impact on these conditions. Other important considerations include hypoglycemia risk, weight, adverse effects, cost, and patient preference ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"figure-link",
"target":"mk19_b_en_f02",
"wrapId":"21",
"children":[
"Figure 2"
]
}
]
},
")"
]
},
"."
]
},
{
"type":"inline-wrap",
"wrapId":"21",
"contentIds":[
"mk19_b_en_t11",
"mk19_b_en_f02"
]
},
{
"type":"p",
"hlId":"6d3753",
"children":[
"Metformin is the recommended first-line oral agent for newly diagnosed type 2 diabetes because of its known effectiveness and inability to cause hypoglycemia. Gastrointestinal adverse effects are common and may be reduced by slow titration of doses, administration with food, or use of an extended-release formulation. Lactic acidosis is a rare risk associated with metformin use; risk of this effect is increased by heart failure requiring pharmacologic treatment, hepatic dysfunction, and kidney disease. An estimated glomerular filtration rate (eGFR) greater than 45 mL/min/1.73 m",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"2"
]
},
" is recommended for metformin initiation. Clinicians should assess benefits and risks of continuing therapy in patients whose eGFR decreases to less than 45 mL/min/1.73 m",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"2"
]
},
" during therapy. Metformin is contraindicated at eGFR less than 30 mL/min/1.73 m",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"2"
]
},
"."
]
},
{
"type":"p",
"hlId":"014d03",
"children":[
"Metformin should also be held in situations that may result in kidney dysfunction, such as vomiting or diarrhea. If an iodinated contrast agent is administered with an eGFR between 30 and 60 mL/min/1.73 m",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"2"
]
},
", metformin should be held until kidney function is stable for 48 hours. Metformin causes reduction in vitamin B",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"12"
]
},
" intestinal absorption in up to 30% of patients, and 5% to 10% of patients develop vitamin B",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"12"
]
},
" deficiency; annual vitamin B",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"12"
]
},
" level testing is recommended."
]
},
{
"type":"p",
"hlId":"e9a51a",
"children":[
"Glycemic control should be assessed every 3 months with adjustments to therapy until the glycemic target is achieved, and every 6 months if at goal. However, intensification of treatment should not be delayed in patients with uncontrolled glycemia. Metformin should be continued as long as it is tolerated and there are no contraindications, even if additional agents are added."
]
},
{
"type":"p",
"hlId":"7beaf4",
"children":[
"For patients who do not achieve target glycemic goals with lifestyle modification and metformin, additional agents should be added in a stepwise approach, with patient-specific goals in mind (see ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"figure-link",
"target":"mk19_b_en_f02",
"wrapId":"22",
"children":[
"Figure 2"
]
}
]
},
")"
]
},
". Agents that result in improved clinical outcomes are preferred. In patients with type 2 diabetes and established ASCVD, multiple ASCVD risk factors, or diabetic kidney disease, the next preferred therapy is an SGLT2 inhibitor or a GLP-1 RA because these agents have shown benefits in cardiovascular risk reduction. In patients with established heart failure with reduced ejection fraction, an SGLT2 inhibitor with proven benefit in this patient population is recommended to reduce the risk for worsening heart failure and cardiovascular death (see ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_en_t11",
"wrapId":"22",
"children":[
"Table 11"
]
}
]
},
")"
]
},
". Renal dose adjustment is required for all SGLT2 inhibitors. The GLP-1 RAs exenatide and lixisenatide should be avoided in patients with an eGFR less than 30 mL/min/1.73 m",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"2"
]
},
". For patients without ASCVD, ASCVD risk factors, or established kidney disease, therapy should be patient-centered and consider the risk of hypoglycemia, impact on weight, and cost. Additional agents should be added in stepwise progression if glycemic goals are not met, again considering the clinical characteristics of the patient."
]
},
{
"type":"inline-wrap",
"wrapId":"22",
"contentIds":[
"mk19_b_en_f02",
"mk19_b_en_t11"
]
},
{
"type":"p",
"hlId":"145e82",
"children":[
"In most patients who need the greater glucose-lowering effect of an injectable medication, GLP-1 RAs are preferred to insulin. Patients with uncontrolled type 2 diabetes may require insulin therapy to achieve glycemic targets. If insulin is used, the ADA recommends combination therapy with a GLP-1 RA for greater efficacy and durability of treatment effect. Algorithms provide guidance on initiation and dosing of basal and prandial insulin regimens ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_en_t12",
"wrapId":"23",
"children":[
"Table 12"
]
}
]
},
")"
]
},
". The ADA recommends combination injectable therapy initially in the setting of symptomatic hyperglycemia (polydipsia, polyuria), ongoing catabolism (weight loss), hemoglobin A",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1c"
]
},
" 10% or higher, or a glucose level of 300 mg/dL (16.7 mmol/L) or higher. The American Association of Clinical Endocrinologists/American College of Endocrinology recommends initiating insulin therapy with other agents if the initial hemoglobin A",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1c"
]
},
" is more than 9% in a symptomatic individual. After optimizing the basal insulin dose, prandial insulin should be added before the largest meal if hyperglycemia persists. A basal-bolus insulin regimen, with prandial insulin before two or more meals, should be used for continued hyperglycemia."
]
},
{
"type":"inline-wrap",
"wrapId":"23",
"contentIds":[
"mk19_b_en_t12"
]
},
{
"type":"p",
"hlId":"06fd52",
"children":[
"Ultralong-acting basal analogue insulins may be advantageous compared with long-acting basal analogue insulins because of a prolonged action profile (>24 hours), peakless insulin delivery, and decreased variability in action between and within individuals. The pharmacodynamic profile may decrease hypoglycemia in high-risk patients, improve glycemic fluctuations, and allow for flexibility in dosing beyond 24-hour time periods."
]
},
{
"type":"p",
"hlId":"488e3b",
"children":[
"In patients with type 2 diabetes not at glycemic goal despite adherence to glucose monitoring and multiple treatment modalities, CSII may be considered."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"bd1b20",
"children":[
"Metformin is the recommended first-line oral agent for newly diagnosed type 2 diabetes mellitus because of its known effectiveness and low hypoglycemia risk."
]
},
{
"type":"keypoint",
"hlId":"9c76a0",
"children":[
"Glucagon-like peptide 1 receptor agonists or sodium-glucose cotransporter 2 (SGLT2) inhibitor therapy is recommended for patients with diabetes mellitus and atherosclerotic cardiovascular disease, multiple atherosclerotic cardiovascular disease risk factors, or diabetic kidney disease; an SGLT2 inhibitor is recommended for patients with heart failure."
]
},
{
"type":"keypoint",
"hlId":"15374e",
"children":[
"Glycemic control in patients with type 2 diabetes should be assessed every 3 months with subsequent adjustments to therapeutic agents until the glycemic target is achieved, and every 6 months if at goal."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s1_1_4_5_3",
"title":{
"__html":"Therapy for Gestational Diabetes Mellitus"
},
"titleNode":{
"type":"section-title",
"hlId":"d3e92a",
"children":[
"Therapy for Gestational Diabetes Mellitus"
]
},
"children":[
{
"type":"p",
"hlId":"2aa63c",
"children":[
"Pharmacologic therapy should be prescribed for patients with gestational diabetes to improve perinatal outcomes if lifestyle interventions do not achieve glycemic targets. Insulin is the recommended therapy. Although metformin or sulfonylurea therapy may be considered, both therapies cross the placenta, and no long-term safety data are available for their use during pregnancy. Additionally, sulfonylurea therapy has been associated with higher rates of neonatal macrosomia and hypoglycemia."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s1_1_4_6",
"title":{
"__html":"Diabetes Technology"
},
"titleNode":{
"type":"section-title",
"hlId":"1fdaa5",
"children":[
"Diabetes Technology"
]
},
"children":[
{
"type":"p",
"hlId":"87e97d",
"children":[
"Diabetes technology continues to evolve rapidly, with advancements in hardware, software, and devices that patients use to achieve glycemic goals. Hybrid CGM systems and insulin pump systems that both monitor and modify insulin delivery via sensor-augmented, algorithm-derived insulin delivery are now available. Use of diabetes technology should be individualized based on each patient's interest, skill level, and needs."
]
}
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s1_2",
"title":{
"__html":"Drug-Induced Hyperglycemia"
},
"titleNode":{
"type":"section-title",
"hlId":"aa7bc5",
"children":[
"Drug-Induced Hyperglycemia"
]
},
"children":[
{
"type":"p",
"hlId":"de6f17",
"children":[
"Several drugs can induce hyperglycemia through multiple mechanisms ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_en_t13",
"wrapId":"24",
"children":[
"Table 13"
]
}
]
},
")"
]
},
". Persons at risk for hyperglycemia and the development of diabetes caused by medications should be monitored periodically."
]
},
{
"type":"inline-wrap",
"wrapId":"24",
"contentIds":[
"mk19_b_en_t13"
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s1_3",
"title":{
"__html":"Inpatient Management of Hyperglycemia"
},
"titleNode":{
"type":"section-title",
"hlId":"bf45ce",
"children":[
"Inpatient Management of Hyperglycemia"
]
},
"children":[
{
"type":"p",
"hlId":"ff4338",
"children":[
"Tight inpatient glycemic control (80-110 mg/dL [4.4-6.1 mmol/L]) is not consistently associated with improved outcomes and may increase mortality. As a result, current inpatient glycemic goals strive to avoid complications from severe hypoglycemia and hyperglycemia, such as electrolyte abnormalities and dehydration."
]
},
{
"type":"p",
"hlId":"c3ec44",
"children":[
"All inpatients with a known history of diabetes or hyperglycemia should have a hemoglobin A",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1c"
]
},
" test if not performed within the past 3 months. Clinical status changes, especially in kidney function, may increase the risk of adverse events associated with noninsulin therapies. Similarly, several factors may predispose inpatients to hypoglycemia, including altered mental status, fasting (expected or unexpected), illness, insulin–meal timing mismatch, poor oral intake, and alterations in hyperglycemia-inducing therapies. Treatment with insulin is thus preferred for inpatient management of hyperglycemia 180 mg/dL (10.0 mmol/L) and higher and adjusted to maintain a glucose level between 140 and 180 mg/dL (7.8-10.0 mmol/L) for most patients. According to the ADA and American Association of Clinical Endocrinology, glucose values less than 140 mg/dL (7.8 mmol/L) may be reasonable in select noncritically ill patients if hypoglycemia is avoided. In contrast, the American College of Physicians does not recommend glucose values less than 140 mg/dL (7.8 mmol/L) because of increased hypoglycemia risk."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"708095",
"hvc":true,
"children":[
"Tight inpatient glycemic control (80-110 mg/dL [4.4-6.1 mmol/L]) is not consistently associated with improved outcomes and may increase mortality."
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s1_3_1",
"title":{
"__html":"Hospitalized Patients With Diabetes Mellitus"
},
"titleNode":{
"type":"section-title",
"hlId":"54491a",
"children":[
"Hospitalized Patients With Diabetes Mellitus"
]
},
"children":[
{
"type":"p",
"hlId":"72ed41",
"children":[
"In critically ill patients with type 1 and type 2 diabetes, intravenous insulin therapy is recommended. Intravenous insulin dose adjustments should be based on a validated algorithm that incorporates point-of-care (POC) monitoring every 1 to 2 hours."
]
},
{
"type":"p",
"hlId":"24f21d",
"children":[
"For noncritically ill patients, subcutaneous insulin is appropriate. Persons with type 1 diabetes require continuous insulin therapy. Basal insulin must be provided to avoid development of DKA. Persons with type 2 diabetes with glucose values 180 mg/dL (10.0 mmol/L) or higher should also receive insulin therapy."
]
},
{
"type":"p",
"hlId":"b33df8",
"children":[
"If the patient is eating, ideal insulin management is a basal-bolus regimen with prandial coverage and correction boluses for premeal hyperglycemia. POC measurements and prandial insulin injections should occur before meal consumption. Postprandial insulin administration may be appropriate to allow for dose reduction for patients with decreased oral intake or those with delayed gastric emptying. Overnight POC measurements are warranted if undetected hypoglycemia is a concern; otherwise, glucose checks overnight should be avoided because of sleep disruption and increased risk of insulin stacking and hypoglycemia. The sole use of correction insulin (termed “sliding-scale insulin”) is not recommended because it is a reactive, nonphysiologic approach that leads to large glucose fluctuations."
]
},
{
"type":"p",
"hlId":"14797c",
"children":[
"Continuation of outpatient CSII therapy may be appropriate for patients with a healthy mental status who can manage the device under the supervision of health care providers proficient in this technology. If a hospitalized patient becomes unable to safely manage CSII therapy, it should be discontinued and replaced with either a subcutaneous insulin regimen or intravenous insulin."
]
},
{
"type":"p",
"hlId":"d77272",
"children":[
"Continuation of outpatient oral or noninsulin injectable agents is not recommended when patients are admitted because of the potential for hemodynamic or nutritional changes. Insulin therapy should be initiated for glycemic management. As a patient nears hospital discharge with stable nutritional status and hemodynamics, reinitiation of these agents may be considered if organ function has returned to baseline."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"2db62a",
"children":[
"Critically ill patients with type 1 or type 2 diabetes mellitus require intravenous insulin therapy with dosing based on a validated algorithm incorporating point-of-care monitoring every 1 to 2 hours."
]
},
{
"type":"keypoint",
"hlId":"1e3b95",
"children":[
"Noncritically ill hospitalized persons with type 1 diabetes mellitus require basal insulin in addition to prandial insulin therapy; persons with type 2 diabetes with glucose values 180 mg/dL (10.0 mmol/L) or higher should also receive insulin therapy."
]
},
{
"type":"keypoint",
"hlId":"cb71fe",
"hvc":true,
"children":[
"The sole use of correction insulin (“sliding-scale insulin”) in hospitalized patients is not recommended because it is a reactive, nonphysiologic approach that leads to large glucose fluctuations."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s1_3_2",
"title":{
"__html":"Hospitalized Patients Without Diabetes Mellitus"
},
"titleNode":{
"type":"section-title",
"hlId":"654739",
"children":[
"Hospitalized Patients Without Diabetes Mellitus"
]
},
"children":[
{
"type":"p",
"hlId":"912ded",
"children":[
"Stress associated with acute illness, enteral and parenteral nutrition, and hyperglycemia-inducing medications in the inpatient setting may induce glucose abnormalities in persons without diabetes."
]
},
{
"type":"p",
"hlId":"63661e",
"children":[
"Hyperglycemia management should follow the same guidelines as hospitalized patients with diabetes."
]
},
{
"type":"p",
"hlId":"dd71b2",
"children":[
"It is important to recognize that inpatient hyperglycemia may occur in the setting of previously unrecognized diabetes. An inpatient hemoglobin A",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1c"
]
},
" measurement of 6.5% or higher is indicative of glucose abnormalities before the hospitalization, and these patients require follow-up for diagnosis of possible diabetes."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s1_4",
"title":{
"__html":"Acute Complications of Diabetes Mellitus"
},
"titleNode":{
"type":"section-title",
"hlId":"625d51",
"children":[
"Acute Complications of Diabetes Mellitus"
]
},
"children":[
{
"type":"section",
"id":"mk19_b_en_s1_4_1",
"title":{
"__html":"Diabetic Ketoacidosis/Hyperglycemic Hyperosmolar Syndrome"
},
"titleNode":{
"type":"section-title",
"hlId":"80a472",
"children":[
"Diabetic Ketoacidosis/Hyperglycemic Hyperosmolar Syndrome"
]
},
"children":[
{
"type":"p",
"hlId":"e5b090",
"children":[
"DKA and hyperglycemic hyperosmolar syndrome (HHS) occur with extreme hyperglycemia and must be treated early and aggressively to avoid life-threatening consequences from dehydration and electrolyte abnormalities. Severe hyperglycemia is a consequence of insufficient insulin levels coupled with an increase in counterregulatory hormones. This condition impairs efficient glucose use and subsequently initiates glycogenolysis and gluconeogenesis."
]
},
{
"type":"p",
"hlId":"e5aaaa",
"children":[
"DKA typically occurs in individuals with type 1 diabetes younger than 65 years. DKA is a relative or absolute insulin deficiency state resulting in unsuppressed lipolysis. Fatty acid oxidation occurs with subsequent ketone body production and development of metabolic acidosis. In type 2 diabetes DKA may rarely occur in the setting of extreme stress or illness."
]
},
{
"type":"p",
"hlId":"e9edbc",
"children":[
"HHS typically occurs in individuals with type 2 diabetes who are older than 65 years and is associated with a higher mortality rate compared with DKA. HHS is characterized as a partial insulin deficiency that is able to suppress lipolysis and prevent ketone body production, but is unable to correct hyperglycemia or prevent the subsequent dehydration and electrolyte abnormalities. HHS is associated with more extreme hyperglycemia compared with DKA because patients with type 1 diabetes are younger, have higher glomerular filtration rates, and greater glucose excretion."
]
},
{
"type":"p",
"hlId":"4030ec",
"children":[
"Inciting factors for the development of DKA or HHS include infection, myocardial infarction, nonadherence to diabetes therapy, stress, trauma, and confounding medications (e.g., atypical antipsychotics, glucocorticoids, and SGLT2 inhibitors). DKA or HHS may also be the initial presentation of a person with undiagnosed diabetes. Euglycemic DKA has been described in patients taking SGLT2 inhibitors, and a high level of suspicion is necessary during initial evaluation."
]
},
{
"type":"p",
"hlId":"0b2dbd",
"children":[
"DKA and HHS may present with many symptoms and plasma glucose levels ranging from normal to very high. Symptoms from DKA typically occur within 24 hours of onset, whereas symptoms from HHS may not appear for several days. Symptoms may include abdominal pain, nausea, vomiting, polyuria, polydipsia, weight loss, or shortness of breath. Extreme glucosuria causes an osmotic diuresis and severe volume depletion, which may be exacerbated by gastrointestinal losses of volume and electrolytes. Progression to lethargy, obtundation, and death may occur if the hyperglycemia, dehydration, and electrolyte abnormalities are not treated aggressively and early."
]
},
{
"type":"p",
"hlId":"e003c8",
"children":[
"Initial evaluation includes the measurement of serum glucose level, serum electrolytes, serum ketones, blood urea nitrogen and serum creatinine, plasma osmolality, complete blood count, arterial blood gases, urinalysis, and urine ketones. An ECG should also be reviewed. Cultures of blood, sputum, and urine and a chest radiograph may be obtained if an infection is suspected."
]
},
{
"type":"p",
"hlId":"b4f87a",
"children":[
"Multiple laboratory abnormalities are present with DKA and HHS. An increased anion gap metabolic acidosis is present in DKA secondary to production of acetoacetic acid and β-hydroxybutyrate. Although some patients with HHS may have an increased anion gap, typically with glucose levels higher than 400 to 600 mg/dL (22.2-33.3 mmol/L), they do not develop significant ketoacidosis as seen in DKA."
]
},
{
"type":"p",
"hlId":"c6149c",
"children":[
"A moderate to severe reduction in serum bicarbonate levels is present in DKA, but levels may remain normal or mildly reduced (>20 mEq/L [20 mmol/L]) in HHS. Serum pH may be profoundly low in DKA but is typically greater than 7.3 in HHS. Hypertonic hyponatremia may occur in DKA and HHS with extreme hyperglycemia and osmotic shifts of water from intracellular to extracellular compartments. A normal or elevated sodium level indicates severe dehydration. Increased osmolality, frequently greater than 320 mOsm/kg H",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"2"
]
},
"O, is often present in HHS secondary to more severe hyperglycemia and water loss from osmotic diuresis compared with DKA. Serum potassium levels may be elevated because of shifts from the intracellular to extracellular spaces caused by ketoacidosis and the absence of sufficient insulin. Normal or low serum potassium levels indicate a depletion of body stores and require supplementation before insulin therapy to avoid cardiac arrhythmias. Similarly, total body phosphorus is depleted, and the level should be checked. Stress may induce mild leukocytosis, but higher levels may indicate an infectious cause for DKA or HHS. Elevated amylase and lipase levels can also occur."
]
},
{
"type":"p",
"hlId":"ce14ec",
"children":[
"A multipronged approach is required to treat DKA and HHS ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
"(",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_en_t14",
"wrapId":"25",
"children":[
"Table 14"
]
}
]
},
")"
]
},
". Intravenous hydration is necessary for volume repletion. Electrolyte deficits, such as potassium, should be repleted. Hyperglycemia should be corrected, preferably with intravenous insulin and hourly glucose measurements to guide dose adjustments. Frequent electrolyte measurements are necessary to guide repletion as hydration and insulin therapy continue. Most patients with DKA or HHS are treated in the ICU because of the complexity of care required. Conditions that contributed to the development of DKA or HHS, such as infection and myocardial infarction, should be identified and treated."
]
},
{
"type":"inline-wrap",
"wrapId":"25",
"contentIds":[
"mk19_b_en_t14"
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"73e405",
"children":[
"Diabetic ketoacidosis and hyperglycemic hyperosmolar syndrome must be treated early and aggressively to avoid life-threatening consequences from dehydration and electrolyte abnormalities."
]
},
{
"type":"keypoint",
"hlId":"4e084b",
"children":[
"Inciting factors for the development of diabetic ketoacidosis and hyperglycemic hyperosmolar syndrome include infection, myocardial infarction, nonadherence to diabetes therapy, stress, trauma, and confounding medications."
]
},
{
"type":"keypoint",
"hlId":"390490",
"children":[
"Treatment of diabetic ketoacidosis and hyperglycemic hyperosmolar syndrome requires correction of hyperglycemia, intravenous hydration, electrolyte repletion, and identification and treatment of inciting factors."
]
}
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s1_5",
"title":{
"__html":"Chronic Complications of Diabetes Mellitus"
},
"titleNode":{
"type":"section-title",
"hlId":"0a4caf",
"children":[
"Chronic Complications of Diabetes Mellitus"
]
},
"children":[
{
"type":"section",
"id":"mk19_b_en_s1_5_1",
"title":{
"__html":"Cardiovascular Morbidity"
},
"titleNode":{
"type":"section-title",
"hlId":"4f2f34",
"children":[
"Cardiovascular Morbidity"
]
},
"children":[
{
"type":"p",
"hlId":"8901cb",
"children":[
"A major cause of morbidity and mortality in persons with diabetes mellitus is CVD. Diabetes is an independent risk factor for CVD, along with hypertension, dyslipidemia, tobacco use, family history, and albuminuria. Simultaneous management of CVD risk factors is recommended to decrease morbidity and mortality. Screening interval guidelines for risk factors are listed in ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_en_t15",
"wrapId":"26",
"children":[
"Table 15"
]
}
]
},
"."
]
},
{
"type":"inline-wrap",
"wrapId":"26",
"contentIds":[
"mk19_b_en_t15"
]
},
{
"type":"p",
"hlId":"34e3ad",
"children":[
"In patients with type 2 diabetes with established CVD, multiple cardiovascular risk factors, or diabetic kidney disease, SGLT2 inhibitors or GLP-1 RAs with proven CVD benefit are recommended as part of the antihyperglycemic regimen. The ADA suggests that combined therapy with an SGLT2 inhibitor and GLP-1 RA can be considered for additive reduction of the risk for adverse cardiovascular and kidney events."
]
},
{
"type":"p",
"hlId":"55037b",
"children":[
"Hypertension contributes to the development of macrovascular and microvascular complications. Based on concerns for increased treatment complications with a lower blood pressure target of below 130/80 mm Hg, the ADA treatment goal for most persons is below 140/90 mm Hg. Persons at high risk for CVD may aim for lower blood pressure targets if this goal can be achieved safely. In contrast, guidelines from the American Association of Clinical Endocrinology/American College of Endocrinology and the American College of Cardiology/American Heart Association advocate for a treatment target below 130/80 mm Hg for most patients with diabetes. ADA-recommended treatment strategies include lifestyle modifications (for blood pressure >120/80 mm Hg) and pharmacologic therapies (for blood pressure >140/90 mm Hg). Initial recommended antihypertensive regimens include ACE inhibitors, angiotensin receptor blockers (ARBs), dihydropyridine calcium channel blockers, and thiazide diuretics. Multiple agents are often required to reach the blood pressure target. Underlying comorbidities should guide selection of therapeutic agents, such as the use of an ACE inhibitor or ARB in the presence of moderately increased albuminuria."
]
},
{
"type":"p",
"hlId":"660d96",
"children":[
"Patients aged 40 to 75 years with diabetes should be started on a moderate-intensity statin; a high-intensity statin is reasonable if multiple ASCVD risk factors are present (see ",
{
"type":"cross-reference",
"target":"mk19_a_gm_s8_2_2_1",
"children":[
"MKSAP 19 General Internal Medicine 1"
]
},
")."
]
},
{
"type":"p",
"hlId":"04366a",
"children":[
"Antiplatelet therapy with aspirin (75-162 mg/day) is recommended by the ADA for secondary prevention in persons with diabetes and ASCVD. Aspirin for primary prevention of ASCVD in persons with diabetes may not provide universal benefit. Reflecting this uncertainty, the ADA recommends a patient discussion on the benefits of aspirin versus increased risk of bleeding before considering therapy. Primary prevention should be considered in patients between ages 40 and 70 years with high ASCVD risk who do not have an increased risk of bleeding."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"f8a314",
"children":[
"The American Diabetes Association recommends a blood pressure treatment target of 140/90 mm Hg or lower for persons at high risk for cardiovascular disease if this goal can be achieved safely; other organizations recommend a target below 130/80 mm Hg for most patients with diabetes mellitus."
]
},
{
"type":"keypoint",
"hlId":"c68541",
"children":[
"Patients aged 40 to 75 years with diabetes mellitus should be started on a moderate-intensity statin; a high-intensity statin is reasonable if multiple atherosclerotic cardiovascular disease risk factors are present."
]
},
{
"type":"keypoint",
"hlId":"84f4fe",
"children":[
"Antiplatelet therapy with aspirin (75-162 mg/d) is recommended for secondary prevention in persons with diabetes mellitus and atherosclerotic cardiovascular disease."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s1_5_2",
"title":{
"__html":"Diabetic Retinopathy"
},
"titleNode":{
"type":"section-title",
"hlId":"74ef99",
"children":[
"Diabetic Retinopathy"
]
},
"children":[
{
"type":"p",
"hlId":"e29e37",
"children":[
"Retinopathy is the leading cause of preventable blindness among persons with diabetes between ages 20 and 74 years in developed countries. Risk factors include duration of diabetes, degree of hyperglycemia, hypertension, albuminuria, and dyslipidemia."
]
},
{
"type":"p",
"hlId":"ed1c66",
"children":[
"Diabetic retinopathy changes are classified as nonproliferative (occurs within the retina) or proliferative (occurs in the vitreous or retinal inner surface). Nonproliferative retinopathy findings may include microaneurysms, dot and blot hemorrhages, hard exudates (lipid deposition), soft exudates or cotton-wool spots (ischemic superficial nerve fibers), venous bleeding, and intraretinal microvascular abnormalities. Neovascularization caused by chronic ischemia characterizes proliferative retinopathy, which may cause intraocular hemorrhage, retinal detachment, and vision loss."
]
},
{
"type":"p",
"hlId":"b26aba",
"children":[
"Macular edema may occur with nonproliferative and proliferative retinopathy."
]
},
{
"type":"p",
"hlId":"e85c7a",
"children":[
"Screening guidelines were developed for early detection of asymptomatic abnormalities to allow for treatment interventions to prevent vision loss (see ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_en_t15",
"wrapId":"27",
"children":[
"Table 15"
]
}
]
},
")"
]
},
"."
]
},
{
"type":"inline-wrap",
"wrapId":"27",
"contentIds":[
"mk19_b_en_t15"
]
},
{
"type":"p",
"hlId":"29a97d",
"children":[
"Optimal control of blood pressure, glucose, and lipid parameters can prevent and delay the progression of retinopathy. Panretinal laser photocoagulation can treat high-risk proliferative diabetic retinopathy and severe nonproliferative retinopathy. In addition, intravitreal injection with anti-vascular endothelial growth factor (anti-VEGF) is not inferior to panretinal laser photocoagulation for reducing vision loss associated with proliferative retinopathy. Retinopathy may develop or accelerate during pregnancy or with rapid glycemic improvements and may require laser photocoagulation to decrease the risk of vision loss. Macular edema is preferentially treated with anti-VEGF intravitreal injections to improve vision loss. Anti-VEGF therapy requires monthly injections for at least 12 months followed by intermittent injections to prevent recurrent macular edema."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"09a3bb",
"children":[
"Patients with type 2 diabetes mellitus should have a dilated and comprehensive eye examination at the time of diagnosis."
]
},
{
"type":"keypoint",
"hlId":"57947d",
"children":[
"Optimal control of glucose, blood pressure, and lipid parameters can prevent and delay the progression of diabetic retinopathy."
]
},
{
"type":"keypoint",
"hlId":"81fb49",
"children":[
"Panretinal laser photocoagulation or intravitreal injections of anti-vascular endothelial growth factor can treat high-risk proliferative diabetic retinopathy and severe nonproliferative retinopathy."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s1_5_3",
"title":{
"__html":"Diabetic Nephropathy"
},
"titleNode":{
"type":"section-title",
"hlId":"8d9df3",
"children":[
"Diabetic Nephropathy"
]
},
"children":[
{
"type":"p",
"hlId":"fa52be",
"children":[
"Diabetic nephropathy is the leading cause of end-stage kidney disease. Diabetes is typically present for 5 to 10 years before the development of nephropathy."
]
},
{
"type":"p",
"hlId":"ede55f",
"children":[
"Measurement of eGFR and screening for the presence of albuminuria is recommended for early detection of kidney disease (see ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_en_t15",
"wrapId":"28",
"children":[
"Table 15"
]
}
]
},
")"
]
},
". Urinary albumin excretion can be determined from a random urine collection as the urine albumin-to-creatinine ratio (UACR). An elevated UACR level (≥30 mg/g) should be confirmed by multiple measurements over 3 to 6 months because temporary elevations may occur with biologic variability, illness, hyperglycemia, heart failure, hypertension, exercise, and menstruation. Annual measurements of eGFR and UACR may identify progression of nephropathy and guide therapeutic decisions. More frequent assessments may be necessary with worsening kidney function. An eGFR less than 30 mL/min/1.73 m",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"2"
]
},
" warrants a referral to a nephrologist."
]
},
{
"type":"inline-wrap",
"wrapId":"28",
"contentIds":[
"mk19_b_en_t15"
]
},
{
"type":"p",
"hlId":"69ab34",
"children":[
"Uncontrolled hypertension and hyperglycemia are risk factors for diabetic nephropathy; thus, treatment to attain blood pressure and glucose goals is recommended. The ADA strongly recommends an ACE inhibitor or an ARB as first-line therapy to slow progression of nephropathy and prevent CVD in nonpregnant persons with diabetes, hypertension, a reduced eGFR (<60 mL/min/1.73 m",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"2"
]
},
"), and an elevated UACR (≥300 mg/g). An ACE inhibitor or an ARB is also recommended for treatment of an elevated UACR between 30 and 299 mg/g in nonpregnant persons with hypertension. Treatment with an ACE inhibitor or ARB is not recommended for patients with diabetes who have a normal blood pressure, a UACR level less than 30 mg/g, and an eGFR level greater than 60 mL/min/1.73 m",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"2"
]
},
"."
]
},
{
"type":"p",
"hlId":"b443bb",
"children":[
"For patients with type 2 diabetes, chronic kidney disease, and UACR of 300 mg/g or greater, the ADA recommends an SGLT2 inhibitor to reduce chronic kidney disease progression and cardiovascular events. In patients with chronic kidney disease who are at increased risk for cardiovascular events or chronic kidney disease progression or unable to use an SGLT2 inhibitor, the ADA recommends a nonsteroidal mineralocorticoid receptor antagonist (finerenone)."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"4d43d2",
"children":[
"Measurement of estimated glomerular filtration rate and screening for the presence of albuminuria are recommended for early detection of kidney disease in persons with diabetes mellitus."
]
},
{
"type":"keypoint",
"hlId":"b39798",
"children":[
"The American Diabetes Association strongly recommends an ACE inhibitor or an angiotensin receptor blocker as first-line therapy to slow progression of nephropathy and prevent cardiovascular disease in nonpregnant persons with diabetes mellitus, hypertension, a reduced estimated glomerular filtration rate (<60 mL/min/1.73 m",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"2"
]
},
"), and an elevated urine albumin-to-creatinine ratio (≥300 mg/g)."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s1_5_4",
"title":{
"__html":"Diabetic Neuropathy"
},
"titleNode":{
"type":"section-title",
"hlId":"21cbd7",
"children":[
"Diabetic Neuropathy"
]
},
"children":[
{
"type":"p",
"hlId":"fde216",
"children":[
"Diabetic neuropathy involves damage to nerves or nerve roots caused by hyperglycemia. Neuropathy may occur peripherally or affect the autonomic nervous system. Symptoms depend on the affected nerve(s) and may be focal or diffuse in nature. Glycemic control may prevent peripheral neuropathy and cardiac autonomic neuropathy in individuals with type 1 diabetes and can delay progression of neuropathy in type 2 diabetes."
]
},
{
"type":"p",
"hlId":"8e5257",
"children":[
"Diabetic peripheral neuropathy (distal symmetric polyneuropathy) typically has an ascending presentation with a “stocking and glove” distribution. This neuropathy may involve damage to both small and large nerve fibers. Symptoms from small nerve fiber damage include pain, burning, and tingling. Small nerve fiber abnormalities can be detected on examination by assessment of pinprick and temperature sensations. Abnormalities in position sense, vibration, and light touch are indicative of large nerve fiber damage and convey an increased risk for foot ulcerations. Assessment of large nerve fiber damage can be achieved by assessing ankle reflexes and with a 128-Hz tuning fork and a 10-g monofilament. Because diabetic peripheral neuropathy may be asymptomatic, screening should occur for early detection to prevent limb loss (see ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_en_t15",
"wrapId":"29",
"children":[
"Table 15"
]
}
]
},
")"
]
},
"."
]
},
{
"type":"inline-wrap",
"wrapId":"29",
"contentIds":[
"mk19_b_en_t15"
]
},
{
"type":"p",
"hlId":"3fa012",
"children":[
"Autonomic neuropathy may affect one or multiple organs. Symptoms may include hypoglycemia unawareness, gastroparesis, constipation, diarrhea, erectile dysfunction, and bladder dysfunction. Symptoms from cardiac autonomic dysfunction may include orthostatic hypotension, resting sinus tachycardia, and exercise intolerance. Cardiac autonomic neuropathy is an independent risk factor for sudden death."
]
},
{
"type":"p",
"hlId":"f38d24",
"children":[
"The goal of treatment of diabetic neuropathy is to reduce symptoms, although it may be impossible to eliminate pain. The ADA recommends pregabalin, duloxetine, or gabapentin as initial therapy for neuropathic pain. The American Academy of Neurology recommends tricyclic antidepressants, serotonin-norepinephrine reuptake inhibitors, gabapentinoids, and sodium channel blockers to reduce pain; however, valproic acid should not be offered to women of reproductive age. Of the aforementioned agents, only pregabalin and duloxetine are FDA approved for the treatment of diabetic neuropathy; the capsaicin (8%) patch is approved to treat painful diabetic neuropathy of the feet. Opioids, tramadol, or tapentadol are not recommended."
]
},
{
"type":"p",
"hlId":"bf300a",
"children":[
"The primary treatment of orthostatic hypotension is diet, use of compression stockings, and changing positions slowly. Medications that cause or worsen the orthostatic changes should be discontinued and other agents (fludrocortisone, midodrine, or droxidopa) added for refractory symptoms."
]
},
{
"type":"p",
"hlId":"ccb36f",
"children":[
"Small and frequent low-fat, low-fiber meals may improve symptoms of gastroparesis. Metoclopramide is the only prokinetic agent approved by the FDA for the treatment of gastroparesis. Given the risk of adverse effects, including dystonia, careful assessment of risks and benefits should be undertaken before prescribing (see ",
{
"type":"cross-reference",
"target":"mk19_a_gi_s2_6_3",
"children":[
"MKSAP 19 Gastroenterology and Hepatology"
]
},
")."
]
},
{
"type":"p",
"hlId":"3be677",
"children":[
"Diabetic amyotrophy is a rare condition affecting the lumbosacral plexus that may occur secondary to infarction or immune vasculopathy. Presentation is acute and associated with severe asymmetric pain or proximal weakness in a leg with associated muscle wasting. Partial remission may occur over many months. Treatment is supportive."
]
},
{
"type":"p",
"hlId":"42c975",
"children":[
"Mononeuropathies and nerve compression syndromes (carpal tunnel syndrome, peroneal palsy) can occur in patients with diabetes. Mononeuropathies frequently resolve without intervention within a few months. Compression syndromes may respond to conservative management, or surgery may be necessary for symptom relief."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"2ea73a",
"children":[
"Diabetic peripheral neuropathy presents with a “stocking and glove” distribution, involving damage to both small and large nerve fibers; symptoms include pain, burning, and tingling."
]
},
{
"type":"keypoint",
"hlId":"21d7c1",
"children":[
"Glycemic control may prevent peripheral neuropathy and cardiac autonomic neuropathy in type 1 diabetes mellitus and can delay progression of neuropathy in type 2 diabetes."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s1_5_5",
"title":{
"__html":"Diabetic Foot Ulcers"
},
"titleNode":{
"type":"section-title",
"hlId":"a574ed",
"children":[
"Diabetic Foot Ulcers"
]
},
"children":[
{
"type":"p",
"hlId":"06df66",
"children":[
"Lower extremity ulcers are associated with significant morbidity, including amputations, and mortality (see ",
{
"type":"cross-reference",
"target":"mk19_a_id_s10_4",
"children":[
"MKSAP 19 Infectious Disease"
]
},
"). The ADA recommends performing a comprehensive evaluation at least annually to identify risk factors for ulcers. Risk factors for ulcer include hyperglycemia, peripheral artery disease, history of foot ulcer or amputation, foot deformity, peripheral neuropathy, impaired vision, tobacco use, and diabetic nephropathy. The foot examination should include inspection of the skin; assessment of foot deformities; neurologic assessment by 10-g monofilament testing with at least one other assessment, such as pinprick, temperature, or vibration; and vascular assessment, including pulses in the legs and feet. Patients with evidence of sensory loss or previous ulceration or amputation should have their feet inspected at every visit. Vascular assessment should be done in persons with absent pedal pulses or symptoms concerning for claudication. Foot care specialists should be involved in the care of individuals at high risk. Patients should be educated on the importance of daily foot inspections and properly fitting footwear."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s1_6",
"title":{
"__html":"Neuropsychologic Complications"
},
"titleNode":{
"type":"section-title",
"hlId":"d73848",
"children":[
"Neuropsychologic Complications"
]
},
"children":[
{
"type":"p",
"hlId":"147344",
"children":[
"Additional factors to consider and address in patients with diabetes mellitus include anxiety, depression, diabetes-related distress, and cognitive impairment. Screening for psychosocial issues and behavioral health conditions should occur at the time of diabetes diagnosis and periodically thereafter. These conditions can adversely affect glycemic control directly and through challenges with patient adherence to management plans. A list of assessment tools is available in the ADA position statement “Psychosocial Care for People with Diabetes.” Providers should take a collaborative, multidisciplinary approach with patient referral to a mental health provider for evaluation and treatment when appropriate."
]
},
{
"type":"p",
"hlId":"c27222",
"children":[
"The ADA recommends that cognitive capacity be monitored throughout the lifespan in all persons with diabetes, particularly those with documented cognitive disabilities, those who experience severe hypoglycemia, and older adults."
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s1_7",
"title":{
"__html":"Hypoglycemia"
},
"titleNode":{
"type":"section-title",
"hlId":"f8f006",
"children":[
"Hypoglycemia"
]
},
"children":[
{
"type":"p",
"hlId":"e8c160",
"children":[
"Hypoglycemia is defined as a glucose value less than 70 mg/dL (3.9 mmol/L). Glucose values less than 54 mg/dL (3.0 mmol/L) are serious and clinically significant. Severe hypoglycemia is any glucose value at which a person requires external assistance to correct the glucose."
]
},
{
"type":"p",
"hlId":"ce0347",
"children":[
"Hyperadrenergic symptoms (sweating, tremors, anxiety, tachycardia) are the normal physiologic response to the development of hypoglycemia and result from the release of counterregulatory hormones (glucagon, epinephrine, norepinephrine, cortisol, and growth hormone). Neuroglycopenic signs (altered mental status, dysarthria, confusion) are associated with severe hypoglycemia. Obtundation, seizures, and death may occur if severe hypoglycemia is not corrected rapidly."
]
},
{
"type":"section",
"id":"mk19_b_en_s1_7_1",
"title":{
"__html":"Hypoglycemia in Patients With Diabetes Mellitus"
},
"titleNode":{
"type":"section-title",
"hlId":"e9d167",
"children":[
"Hypoglycemia in Patients With Diabetes Mellitus"
]
},
"children":[
{
"type":"p",
"hlId":"81e4b7",
"children":[
"Hypoglycemia can become a rate-limiting step in achieving glycemic goals for many persons with diabetes. Severe recurrent hypoglycemia is associated with acquired cognitive deficits and can lead to dementia. Therapies must be adjusted to eliminate hypoglycemia, and glycemic goals should be individualized to accommodate targets that can be safely achieved."
]
},
{
"type":"p",
"hlId":"b2a2c0",
"children":[
"Several factors contribute to hypoglycemia, including a mismatch of food consumption and insulin delivery, increased physical exertion, weight loss, worsening kidney impairment, abnormalities in gastrointestinal motility and absorption, and accidental or intentional overdose of insulin."
]
},
{
"type":"p",
"hlId":"d77129",
"children":[
"Hypoglycemia can also occur with the use of oral antidiabetic agents (especially sulfonylureas or meglitinides) because of incorrect dosages, drug-drug interactions, and intercurrent illnesses that alter the metabolism or excretion of drugs."
]
},
{
"type":"p",
"hlId":"027e5a",
"children":[
"Hypoglycemia treatment in an alert person includes consumption of 15 to 20 g of a fast-acting carbohydrate followed by a BGM test 15 to 20 minutes later. If the glucose has not improved, repeat treatment with 15 g of carbohydrates should occur. After glucose normalization (>70 mg/dL [3.9 mmol/L]), a meal or snack should be consumed to avoid recurrent hypoglycemia. Glucagon (intramuscular or intranasal) should be provided to patients at risk for developing clinically significant hypoglycemia (<54 mg/dL [3.0 mmol/L]) by close contacts if the person is not able to safely consume carbohydrates to correct hypoglycemia."
]
},
{
"type":"p",
"hlId":"059e96",
"children":[
"Hospitalized patients with or without diabetes can experience hypoglycemia, which is often preventable. Hospitals should have standardized protocols in place for preventing, recognizing, treating, and documenting hypoglycemia."
]
},
{
"type":"p",
"hlId":"bd52f6",
"children":[
"Hypoglycemia unawareness is characterized by insufficient release of counterregulatory hormones and an inadequate autonomic response to hypoglycemia. Previous episodes of hypoglycemia increase the risk of developing hypoglycemia unawareness. Treatment involves relaxation of glycemic targets and modifications of hypoglycemia-inducing diabetes therapies to avoid continued hypoglycemia. Avoidance of hypoglycemia for several weeks may reverse hypoglycemia unawareness in some persons and result in the return of adrenergic symptoms with glucose levels less than 70 mg/dL (3.9 mmol/L). A CGM system may be beneficial in appropriate individuals to provide early detection of impending severe hypoglycemia for early intervention."
]
},
{
"type":"p",
"hlId":"f2f62f",
"children":[
"Relative hypoglycemia characterizes symptoms of hypoglycemia in the setting of plasma glucose values greater than 70 mg/dL (3.9 mmol/L). This condition may occur with a large, rapid decrease in glucose or rapid normalization of glucose with treatment intensification in an individual with prolonged plasma glucose values above 200 mg/dL (11.1 mmol/L). Relative hypoglycemia can be prevented by avoiding large glycemic excursions and by slow correction of long-standing hyperglycemia to goal to allow a longer adjustment period."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"d12390",
"children":[
"Hypoglycemia is defined as a glucose value less than 70 mg/dL (3.9 mmol/L) and serious hypoglycemia as less than 54 mg/dL (3.0 mmol/L)."
]
},
{
"type":"keypoint",
"hlId":"ef10f4",
"children":[
"Initial treatment of hypoglycemia requires oral consumption of carbohydrates or administration of glucagon with a goal of increasing the glucose to greater than 70 mg/dL (3.9 mmol/L)."
]
},
{
"type":"keypoint",
"hlId":"6e03be",
"children":[
"Relative hypoglycemia can be prevented by avoiding large glycemic excursions and by slow correction of long-standing hyperglycemia to goal to allow a longer adjustment period."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s1_7_2",
"title":{
"__html":"Hypoglycemia in Patients Without Diabetes Mellitus"
},
"titleNode":{
"type":"section-title",
"hlId":"289ea5",
"children":[
"Hypoglycemia in Patients Without Diabetes Mellitus"
]
},
"children":[
{
"type":"p",
"hlId":"28d25d",
"children":[
"Hypoglycemia without concomitant diabetes is uncommon and warrants further assessment. A hypoglycemia evaluation should be performed if the criteria for Whipple triad are met: neuroglycopenic symptoms, hypoglycemia at or below 55 mg/dL (3.1 mmol/L), and resolution of symptoms with glucose ingestion. Laboratory measurement of glucose must confirm true hypoglycemia because POC glucose values are not reliable in this scenario. Hypoglycemia in persons without diabetes may be attributable to medications, alcohol, illness, organ dysfunction (kidney or liver), hormonal deficiencies (adrenal insufficiency), malnutrition, and, rarely, pancreatogenous insulinoma or noninsulinoma (endogenous hyperinsulinemic hypoglycemia that is not caused by an insulinoma). Other rare conditions are post–gastric bypass hypoglycemia (nesidioblastosis) and insulin autoimmune hypoglycemia."
]
},
{
"type":"p",
"hlId":"421dbc",
"children":[
"Although presentation may overlap, hypoglycemia typically occurs in the fasting or postprandial state. Diagnostic blood and urine studies should be obtained during a hypoglycemic episode in which the Whipple triad has been demonstrated. If a spontaneous episode is not witnessed, measures should be implemented to recreate circumstances that normally induce hypoglycemia (fasting or ingestion of a typical meal that causes an episode in that particular patient). Imaging studies for tumor localization should only occur after confirmation of endogenous hyperinsulinism from the diagnostic blood and urine studies."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"2f9243",
"hvc":true,
"children":[
"Imaging studies for pancreatogenous insulinoma or noninsulinoma should only occur after confirmation of endogenous hyperinsulinism."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s1_7_3",
"title":{
"__html":"Fasting Hypoglycemia"
},
"titleNode":{
"type":"section-title",
"hlId":"4d4f95",
"children":[
"Fasting Hypoglycemia"
]
},
"children":[
{
"type":"p",
"hlId":"8ed476",
"children":[
"A prolonged fast, up to 72 hours, should be initiated if the hypoglycemia typically occurs while fasting. Consultation with an endocrinologist is strongly recommended."
]
},
{
"type":"p",
"hlId":"522516",
"children":[
"During the fast, the plasma glucose should be drawn every 6 hours and immediately sent to the laboratory. If the plasma glucose is less than 60 mg/dL (3.3 mmol/L), four tests should be performed: C-peptide, insulin, proinsulin, and β-hydroxybutyrate. Insulin antibodies and an oral hypoglycemic agent screen should also be measured at the beginning of the fast. Blood specimen collection of the four tests should increase to every 1 to 2 hours when the glucose measurement is less than 60 mg/dL (3.3 mmol/L)."
]
},
{
"type":"p",
"hlId":"a65c7b",
"children":[
"Testing is complete when one of the following parameters is met: plasma glucose 45 mg/dL (2.5 mmol/L) or less with neuroglycopenia, or plasma glucose less than 55 mg/dL (3.1 mmol/L) if Whipple triad was documented previously. POC glucose values and hyperadrenergic symptoms should not be used to determine the end of the fast. Blood specimens should be collected again at the end of the 72-hour period if neither of these two criteria were met."
]
},
{
"type":"p",
"hlId":"c9eed2",
"children":[
"The interpretation of the diagnostic testing results is found in ",
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_en_t16",
"wrapId":"30",
"children":[
"Table 16"
]
}
]
},
"."
]
},
{
"type":"inline-wrap",
"wrapId":"30",
"contentIds":[
"mk19_b_en_t16"
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"dd21d5",
"hvc":true,
"children":[
"For fasting hypoglycemia, the plasma glucose should be drawn every 6 hours; if the plasma glucose is less than 60 mg/dL (3.3 mmol/L), C-peptide, insulin, proinsulin, and β-hydroxybutyrate should be measured."
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s1_7_4",
"title":{
"__html":"Postprandial Hypoglycemia"
},
"titleNode":{
"type":"section-title",
"hlId":"bb0fbf",
"children":[
"Postprandial Hypoglycemia"
]
},
"children":[
{
"type":"p",
"hlId":"84b66a",
"children":[
"Postprandial hypoglycemia typically occurs within 5 hours of the last meal. Altered gastrointestinal anatomy, as occurs after Roux-en-Y gastric bypass surgery, is frequently the cause of the postprandial hypoglycemia. Meals consisting of simple carbohydrates (e.g., pancakes, syrup, juice) are frequently the culprit. A mixed-meal test consisting of the types of food that normally induce the hypoglycemia should be performed to determine the cause. Baseline laboratory studies, including glucose, C-peptide, insulin, and proinsulin, should be obtained before meal consumption. Plasma glucose should be repeated every 30 minutes for 5 hours; if it is less than 60 mg/dL (3.3 mmol/L), then the other three tests should be obtained. If neuroglycopenia occurs, the tests should be repeated before administration of carbohydrates."
]
},
{
"type":"p",
"hlId":"25de52",
"children":[
"Screening should also occur for insulin antibodies and oral hypoglycemic agents if symptomatic hypoglycemia occurs. Interpretation of the results is similar to those obtained during fasting hypoglycemia (see ",
{
"type":"tag",
"tagName":"span",
"attrs":{
"className":"text-nowrap"
},
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
},
"children":[
{
"type":"table-link",
"target":"mk19_b_en_t16",
"wrapId":"31",
"children":[
"Table 16"
]
}
]
},
")"
]
},
"."
]
},
{
"type":"inline-wrap",
"wrapId":"31",
"contentIds":[
"mk19_b_en_t16"
]
},
{
"type":"p",
"hlId":"c6aedf",
"children":[
"Treatment generally consists of small frequent mixed meals with a balance of protein, fat, and carbohydrates."
]
},
{
"type":"keypoints",
"children":[
{
"type":"keypoint",
"hlId":"56ebdb",
"hvc":true,
"children":[
"For postprandial hypoglycemia, baseline laboratory studies, including glucose, C-peptide, insulin, and proinsulin, should be obtained before meal consumption; plasma glucose should be repeated every 30 minutes for 5 hours, and if it is less than 60 mg/dL (3.3 mmol/L), the other three tests should be obtained."
]
}
]
}
]
}
]
},
{
"type":"section",
"id":"mk19_b_en_s1_8",
"bibliography":true,
"title":{
"__html":"Bibliography"
},
"titleNode":{
"type":"section-title",
"hlId":"a7cc81",
"children":[
"Bibliography"
]
},
"children":[
{
"type":"references",
"children":[
{
"type":"reference",
"children":[
"American Diabetes Association Professional Practice Committee. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes—2022. Diabetes Care. 2022;45:S17-S38. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/34964875",
"target":"_blank"
},
"children":[
"PMID: 34964875"
]
},
" doi:10.2337/dc22-S002"
]
},
{
"type":"reference",
"children":[
"American Diabetes Association Professional Practice Committee. 3. Prevention or delay of type 2 diabetes and associated comorbidities: standards of medical care in diabetes—2022. Diabetes Care. 2022;45:S39-S45. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/34964876",
"target":"_blank"
},
"children":[
"PMID: 34964876"
]
},
" doi:10.2337/dc22-S003"
]
},
{
"type":"reference",
"children":[
"American Diabetes Association Professional Practice Committee. 10. Cardiovascular disease and risk management: standards of medical care in diabetes—2022. Diabetes Care. 2022;45:S144-S174. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/34964815",
"target":"_blank"
},
"children":[
"PMID: 34964815"
]
},
" doi:10.2337/dc22-S010"
]
},
{
"type":"reference",
"children":[
"Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;140:e596-e646. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/30879355",
"target":"_blank"
},
"children":[
"PMID: 30879355"
]
},
" doi:10.1161/CIR.0000000000000678"
]
},
{
"type":"reference",
"children":[
"Bersoff-Matcha SJ, Chamberlain C, Cao C, et al. Fournier gangrene associated with sodium-glucose cotransporter-2 inhibitors: a review of spontaneous postmarketing cases. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"https://www.acpjournals.org/doi/10.7326/M19-0085",
"target":"_blank"
},
"children":[
"Ann Intern Med"
]
},
". 2019;170:764-769. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/31060053",
"target":"_blank"
},
"children":[
"PMID: 31060053"
]
}
]
},
{
"type":"reference",
"children":[
"Cappon G, Vettoretti M, Sparacino G, Facchinetti A. Continuous glucose monitoring sensors for diabetes management: a review of technologies and applications. Diabetes Metab J. 2019;43(4):383–397. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/31441246",
"target":"_blank"
},
"children":[
"PMID: 31441246"
]
},
" doi:10.4093/dmj.2019.0121"
]
},
{
"type":"reference",
"children":[
"Das SR, Everett BM, Birtcher KK, et al. 2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J Am Coll Cardiol. 2018;72:3200-3223. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/30497881",
"target":"_blank"
},
"children":[
"PMID: 30497881"
]
},
" doi:10.1016/j.jacc.2018.09.020"
]
},
{
"type":"reference",
"children":[
"Davidson KW, Barry MJ, Mangione CM, et al; U.S. Preventive Services Task Force. Screening for prediabetes and type 2 diabetes: U.S. Preventive Services Task Force recommendation statement. JAMA. 2021;326:736-743. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/34427594",
"target":"_blank"
},
"children":[
"PMID: 34427594"
]
},
" doi:10.1001/jama.2021.12531"
]
},
{
"type":"reference",
"children":[
"Draznin B, Aroda VR, Bakris G, et al; American Diabetes Association Professional Practice Committee. 5. Facilitating behavior change and well-being to improve health outcomes: standards of medical care in diabetes—2022. Diabetes Care. 2022;45:S60-S82. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/34964866",
"target":"_blank"
},
"children":[
"PMID: 34964866"
]
},
" doi:10.2337/dc22-S005"
]
},
{
"type":"reference",
"children":[
"Draznin B, Aroda VR, Bakris G, et al; American Diabetes Association Professional Practice Committee. 7. Diabetes technology: standards of medical care in diabetes—2022. Diabetes Care. 2022;45:S97-S112. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/34964871",
"target":"_blank"
},
"children":[
"PMID: 34964871"
]
},
" doi:10.2337/dc22-S007"
]
},
{
"type":"reference",
"children":[
"Draznin B, Aroda VR, Bakris G, et al; American Diabetes Association Professional Practice Committee. 9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes—2022. Diabetes Care. 2022;45:S125-S143. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/34964831",
"target":"_blank"
},
"children":[
"PMID: 34964831"
]
},
" doi:10.2337/dc22-S009"
]
},
{
"type":"reference",
"children":[
"Draznin B, Aroda VR, Bakris G, et al; American Diabetes Association Professional Practice Committee. 11. Chronic kidney disease and risk management: standards of medical care in diabetes—2022. Diabetes Care. 2022;45:S175-S184. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/34964873",
"target":"_blank"
},
"children":[
"PMID: 34964873"
]
},
" doi:10.2337/dc22-S011"
]
},
{
"type":"reference",
"children":[
"Evert AB, Dennison M, Gardner CD, et al. Nutrition therapy for adults with diabetes or prediabetes: a consensus report. Diabetes Care. 2019;42:731-754. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/31000505",
"target":"_blank"
},
"children":[
"PMID: 31000505"
]
},
" doi:10.2337/dci19-0014"
]
},
{
"type":"reference",
"children":[
"Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm–2018 Executive Summary. Endocr Pract. 2018;24:91-120. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/29368965",
"target":"_blank"
},
"children":[
"PMID: 29368965"
]
},
" doi:10.4158/CS-2017-0153"
]
},
{
"type":"reference",
"children":[
"Hayward RA, Reaven PD, Wiitala WL, Bahn GD, Reda DJ, Ge L, et al; VADT investigators. Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;372:2197-206. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/26039600",
"target":"_blank"
},
"children":[
"PMID: 26039600"
]
},
" doi:10.1056/NEJMoa1414266"
]
},
{
"type":"reference",
"children":[
"LeRoith D, Jan Biessels G, Braithwaite SS, Casaneuva FF, Draznin B, Halter JB, Hirsch IB, McDonnell ME, Molitch ME, Murad MH, Sinclair AJ. Treatment of diabetes in older adults: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2019;104:1520–1574. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/30903688",
"target":"_blank"
},
"children":[
"PMID: 30903688"
]
},
" doi:10.1210/jc.2019-00198."
]
},
{
"type":"reference",
"children":[
"Nathan DM, Zinman B, Cleary PA, Backlund JY, Genuth S, Miller R, et al; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group. Modern-day clinical course of type 1 diabetes mellitus after 30 years' duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983-2005). Arch Intern Med. 2009;169:1307-16. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/19636033",
"target":"_blank"
},
"children":[
"PMID: 19636033"
]
},
" doi:10.1001/archinternmed.2009.193"
]
},
{
"type":"reference",
"children":[
"Peters AL, Ahmann AJ, Battelino T, et al. Diabetes technology-continuous subcutaneous insulin infusion therapy and continuous glucose monitoring in adults: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016;101:3922-3937. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/27588440",
"target":"_blank"
},
"children":[
"PMID: 27588440"
]
},
" doi:10.1210/jc.2016-2534"
]
},
{
"type":"reference",
"children":[
"Price R, Smith D, Franklin G, et al. Oral and topical treatment of painful diabetic polyneuropathy: practice guideline update summary: report of the AAN Guideline Subcommittee. Neurology. 2022;98:31-43. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/34965987",
"target":"_blank"
},
"children":[
"PMID: 34965987"
]
},
" doi:10.1212/WNL.0000000000013038"
]
},
{
"type":"reference",
"children":[
"Qaseem A, Wilt TJ, Kansagara D, Horwitch C, Barry MJ, Forciea MA; Clinical Guidelines Committee of the American College of Physicians. Hemoglobin A1c targets for glycemic control with pharmacologic therapy for nonpregnant adults with type 2 diabetes mellitus: a guidance statement update from the American College of Physicians. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"https://www.acpjournals.org/doi/10.7326/M17-0939",
"target":"_blank"
},
"children":[
"Ann Intern Med"
]
},
". 2018 Mar 6. [Epub ahead of print] ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/29507945",
"target":"_blank"
},
"children":[
"PMID: 29507945"
]
}
]
},
{
"type":"reference",
"children":[
"Reaven PD, Emanuele NV, Wiitala WL, et al; VADT Investigators. Intensive glucose control in patients with type 2 diabetes - 15-year follow-up. N Engl J Med. 2019;380:2215-2224. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/31167051",
"target":"_blank"
},
"children":[
"PMID: 31167051"
]
},
" doi:10.1056/NEJMoa180680"
]
},
{
"type":"reference",
"children":[
"Rosenzweig JL, Bakris GL, Berglund LF, et al. Primary prevention of ASCVD and T2DM in patients at metabolic risk: an Endocrine Society* Clinical Practice Guideline. J Clin Endocrinol Metab. 2019. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/31365087",
"target":"_blank"
},
"children":[
"PMID: 31365087"
]
},
" doi:10.1210/jc.2019-01338"
]
},
{
"type":"reference",
"children":[
"U.S. Department of Veterans Affairs/U.S. Department of Defense. VA/DoD clinical practice guidelines for the management of diabetes mellitus in primary care. 2017. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.healthquality.va.gov/guidelines/cd/diabetes",
"target":"_blank"
},
"children":[
"www.healthquality.va.gov/guidelines/cd/diabetes"
]
},
". Accessed May 16, 2018."
]
},
{
"type":"reference",
"children":[
"Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guidelines for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2017; doi:10.1016/j.jacc.2017.11.006."
]
},
{
"type":"reference",
"children":[
"Young-Hyman D, de Groot M, Hill-Briggs F, Gonzalez JS, Hood K, Peyrot M. Psychosocial care for people with diabetes: a position statement of the American Diabetes Association [published correction appears in Diabetes Care. 2017 Feb;40(2):287] [published correction appears in Diabetes Care. 2017 May;40(5):726]. Diabetes Care. 2016;39(12):2126–2140. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/27879358",
"target":"_blank"
},
"children":[
"PMID: 27879358"
]
},
" doi:10.2337/dc16-2053"
]
}
]
}
]
}
]
},
"tablesContent":{
"mk19_b_en_t01":{
"id":"mk19_b_en_t01",
"number":1,
"bookId":"en",
"title":{
"__html":"Screening Guidelines for Prediabetes or Type 2 Diabetes Mellitus in Asymptomatic Adults"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"daa97e",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 1. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_en_t01"
}
]
},
"Screening Guidelines for Prediabetes or Type 2 Diabetes Mellitus in Asymptomatic Adults"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"col hd l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"cc9fff",
"class":"col hd l",
"children":[
"ADA (2022)",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"70dcba",
"class":"col hd l",
"children":[
"USPSTF (2021)"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"667a37",
"class":"cell txt l",
"children":[
"Screening criteria"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d88c2b",
"class":"cell txt l",
"children":[
"Screen overweight adults (BMI ≥25 or ≥23 in Asian Americans) with at least one additional risk factor:"
]
},
" ",
{
"type":"p",
"hlId":"c66d8d",
"class":"cell txt li",
"children":[
"First-degree relative with diabetes"
]
},
" ",
{
"type":"p",
"hlId":"3daa43",
"class":"cell txt li",
"children":[
"High-risk race/ethnicity (e.g., African American, Latino, Native American, Asian American, Pacific Islander)"
]
},
" ",
{
"type":"p",
"hlId":"a5ac95",
"class":"cell txt li",
"children":[
"History of CVD"
]
},
" ",
{
"type":"p",
"hlId":"4d56a5",
"class":"cell txt li",
"children":[
"Physical inactivity"
]
},
" ",
{
"type":"p",
"hlId":"b49d72",
"class":"cell txt li",
"children":[
"Hypertension (≥140/90 mm Hg or on antihypertensive therapy)"
]
},
" ",
{
"type":"p",
"hlId":"21cb45",
"class":"cell txt li",
"children":[
"HDL cholesterol <35 mg/dL (0.90 mmol/L) and/or triglyceride >250 mg/dL (2.82 mmol/L)"
]
},
" ",
{
"type":"p",
"hlId":"e0eff6",
"class":"cell txt li",
"children":[
"Polycystic ovary syndrome"
]
},
" ",
{
"type":"p",
"hlId":"6e2a05",
"class":"cell txt li",
"children":[
"Other conditions associated with insulin resistance (severe obesity, acanthosis nigricans)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c54277",
"class":"cell txt l",
"children":[
"Screen adults aged 35 to 70 years who have overweight or obesity as part of risk assessment for cardiovascular disease."
]
},
" ",
{
"type":"p",
"hlId":"dab5d3",
"class":"cell txt l",
"children":[
"Screening for other modifiable risk factors for CVD"
]
},
" ",
{
"type":"p",
"hlId":"c58b34",
"class":"cell txt li",
"children":[
"Overweight"
]
},
" ",
{
"type":"p",
"hlId":"9f8251",
"class":"cell txt li",
"children":[
"Obesity"
]
},
" ",
{
"type":"p",
"hlId":"4d56a5",
"class":"cell txt li",
"children":[
"Physical inactivity"
]
},
" ",
{
"type":"p",
"hlId":"030502",
"class":"cell txt li",
"children":[
"Abnormal lipid levels"
]
},
" ",
{
"type":"p",
"hlId":"d974e1",
"class":"cell txt li",
"children":[
"High blood pressure"
]
},
" ",
{
"type":"p",
"hlId":"759f43",
"class":"cell txt li",
"children":[
"Smoking"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e9c41d",
"class":"cell txt l",
"children":[
"Additional screening criteria"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b7afcd",
"class":"cell txt l",
"children":[
"All adults aged 35 years or older"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"26aeab",
"class":"cell txt l",
"children":[
"—"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"26a7c0",
"class":"cell txt l",
"children":[
"Additional screening considerations"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c6f5cc",
"class":"cell txt l",
"children":[
"Consider screening patients taking medications known to increase the risk of diabetes, such as glucocorticoids, thiazide diuretics, HIV medications, and atypical antipsychotics."
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"bc02bc",
"class":"cell txt l",
"children":[
"Diabetes may occur in younger patients or at a lower BMI. Consider screening earlier if one of the following risk factors is present:"
]
},
" ",
{
"type":"p",
"hlId":"1953ff",
"class":"cell txt li",
"children":[
"Family history of diabetes"
]
},
" ",
{
"type":"p",
"hlId":"35f7b8",
"class":"cell txt li",
"children":[
"History of gestational diabetes"
]
},
" ",
{
"type":"p",
"hlId":"e0eff6",
"class":"cell txt li",
"children":[
"Polycystic ovary syndrome"
]
},
" ",
{
"type":"p",
"hlId":"f4cbff",
"class":"cell txt li",
"children":[
"High-risk race/ethnicity (Black, Hispanic/Latino, Asian American, American Indian/Alaskan Native, Native Hawaiian/Pacific Islander)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"93de31",
"class":"cell txt l",
"children":[
"Screening intervals"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3ea71d",
"class":"cell txt l",
"children":[
"Rescreen every 3 years if results are normal"
]
},
" ",
{
"type":"p",
"hlId":"422028",
"class":"cell txt l",
"children":[
"Monitor patients with a history of prediabetes (hemoglobin A",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1c"
]
},
" 5.7%-6.4%, IGT, or IFG) annually"
]
},
" ",
{
"type":"p",
"hlId":"7ca072",
"class":"cell txt l",
"children":[
"Test patients with a history of gestational diabetes at least every 3 years"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"be2a45",
"class":"cell txt l",
"children":[
"Data supporting optimal screening intervals are limited. Rescreening every 3 years may be reasonable."
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"ADA = American Diabetes Association; CVD = cardiovascular disease; IFG = impaired fasting glucose; IGT = impaired glucose tolerance; USPSTF = U.S. Preventive Services Task Force."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
"An optional ADA screening tool for diabetes risk can be found at ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.diabetes.org/risk-test",
"target":"_blank"
},
"children":[
"www.diabetes.org/risk-test"
]
},
"."
],
[
"Recommendations from Davidson KW, Barry MJ, Mangione CM, et al; U.S. Preventive Services Task Force. Screening for prediabetes and type 2 diabetes: U.S. Preventive Services Task Force recommendation statement. JAMA. 2021;326:736-743. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/34427594",
"target":"_blank"
},
"children":[
"PMID: 34427594"
]
},
" doi:10.1001/jama.2021.12531; American Diabetes Association Professional Practice Committee. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes—2022. Diabetes Care. 2022;45:S17-S38. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/34964875",
"target":"_blank"
},
"children":[
"PMID: 34964875"
]
},
" doi:10.2337/dc22-S002"
]
]
},
"mk19_b_en_t02":{
"id":"mk19_b_en_t02",
"number":2,
"bookId":"en",
"title":{
"__html":"Diagnostic Criteria for Prediabetes and Diabetes Mellitus<sup>a</sup>"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"e6f596",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 2. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_en_t02"
}
]
},
"Diagnostic Criteria for Prediabetes and Diabetes Mellitus",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0cbc66",
"class":"col hd l",
"children":[
"Test"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"79d1ac",
"class":"col hd l",
"children":[
"Normal Range"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"09daa0",
"class":"col hd l",
"children":[
"Prediabetes"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"52d261",
"class":"col hd l",
"children":[
"Diabetes"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d29959",
"class":"cell txt l",
"children":[
"Random plasma glucose"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"26aeab",
"class":"cell txt l",
"children":[
"—"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"26aeab",
"class":"cell txt l",
"children":[
"—"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8e8357",
"class":"cell txt l",
"children":[
"Classic hyperglycemic symptoms or hyperglycemic crisis, and a random glucose ≥200 mg/dL (11.1 mmol/L)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"54c668",
"class":"cell txt l",
"children":[
"Fasting plasma glucose",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9ffc45",
"class":"cell txt l",
"children":[
"<100 mg/dL (5.6 mmol/L)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"cab865",
"class":"cell txt l",
"children":[
"100-125 mg/dL (5.6-6.9 mmol/L)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a14e50",
"class":"cell txt l",
"children":[
"≥126 mg/dL (7.0 mmol/L)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"980401",
"class":"cell txt l",
"children":[
"2-H plasma glucose during an OGTT",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"c"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"836fb8",
"class":"cell txt l",
"children":[
"<140 mg/dL (7.8 mmol/L)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1371ba",
"class":"cell txt l",
"children":[
"140-199 mg/dL (7.8-11.0 mmol/L)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7930f5",
"class":"cell txt l",
"children":[
"≥200 mg/dL (11.1 mmol/L)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3a1b7d",
"class":"cell txt l",
"children":[
"Hemoglobin A",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1c"
]
},
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"d,e"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1fe20e",
"class":"cell txt l",
"children":[
"<5.7% (39 mmol/mol)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c12c61",
"class":"cell txt l",
"children":[
"5.7%-6.4% (39-47 mmol/mol)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"736c72",
"class":"cell txt l",
"children":[
"≥6.5% (48 mmol/mol)"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"OGTT = oral glucose tolerance test."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
"In the absence of unequivocal hyperglycemia, diagnosis requires two abnormal test results from the same sample or in two separate test samples."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
},
"Fasting for at least 8 hours."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"c"
]
},
"An OGTT involves the consumption of a 75-g glucose load dissolved in water. A carbohydrate intake of at least 150 g/d should be assured for 3 days before oral glucose tolerance testing."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"d"
]
},
"The American Diabetes Association recommends a National Glycohemoglobin Standardization Program (NGSP)-certified hemoglobin A",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1c"
]
},
" assay that is standardized to the Diabetes Control and Complication Trial (DCCT) assay."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"e"
]
},
"The Veterans Affairs/Department of Defense guidelines recommend confirmation of diabetes based on an elevated hemoglobin A",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1c"
]
},
" value of 6.5% to 6.9% with an elevated fasting plasma glucose of ≥126 mg/dL (7.0 mmol/L) because of strong evidence supporting racial differences between glycemic control and hemoglobin A",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1c"
]
},
" values for diagnosis and treatment."
],
[
"Recommendations from American Diabetes Association Professional Practice Committee. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes—2022. Diabetes Care. 2022;45:S17-S38. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/34964875",
"target":"_blank"
},
"children":[
"PMID: 34964875"
]
},
" doi:10.2337/dc22-S002"
],
[
"Data from U.S. Department of Veterans Affairs/U.S. Department of Defense. VA/DoD clinical practice guidelines: Management of diabetes mellitus in primary care (2017). ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.healthquality.va.gov/guidelines/CD/diabetes/",
"target":"_blank"
},
"children":[
"www.healthquality.va.gov/guidelines/CD/diabetes/"
]
},
". Updated March 11, 2021. Accessed July 21, 2021."
]
]
},
"mk19_b_en_t03":{
"id":"mk19_b_en_t03",
"number":3,
"bookId":"en",
"title":{
"__html":"Comparison of Screening Tests for Diabetes Mellitus"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"ad4edf",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 3. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_en_t03"
}
]
},
"Comparison of Screening Tests for Diabetes Mellitus"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0cbc66",
"class":"col hd c",
"children":[
"Test"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f7b2ce",
"class":"col hd c",
"children":[
"Advantages"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"90843c",
"class":"col hd c",
"children":[
"Disadvantages"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"20d62f",
"class":"cell txt l",
"children":[
"Hemoglobin A",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1c"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"196c23",
"class":"cell txt l",
"children":[
"Convenient: Does not require fasting and has no restrictions on collection time"
]
},
" ",
{
"type":"p",
"hlId":"efd59c",
"class":"cell txt l",
"children":[
"Not altered by conditions such as illness or stress"
]
},
" ",
{
"type":"p",
"hlId":"6d6619",
"class":"cell txt l",
"children":[
"Measures blood glucose concentration over the previous 90 days"
]
},
" ",
{
"type":"p",
"hlId":"00ef9a",
"class":"cell txt l",
"children":[
"Minimal biologic variability within patient"
]
},
" ",
{
"type":"p",
"hlId":"b24581",
"class":"cell txt l",
"children":[
"Blood sample remains stable"
]
},
" ",
{
"type":"p",
"hlId":"ae0c5a",
"class":"cell txt l",
"children":[
"Standardized assay"
]
},
" ",
{
"type":"p",
"hlId":"8ba196",
"class":"cell txt l",
"children":[
"Test accuracy is monitored"
]
},
" ",
{
"type":"p",
"hlId":"3acd2d",
"class":"cell txt l",
"children":[
"Measurement correlates with microvascular and macrovascular outcomes"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"491b9a",
"class":"cell txt l",
"children":[
"Lower sensitivity for diagnosis compared with FPG or 2-h PG during OGTT"
]
},
" ",
{
"type":"p",
"hlId":"8c3dca",
"class":"cell txt l",
"children":[
"Erroneous increases or decreases in hemoglobin A",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1c"
]
},
" result secondary to factors affecting erythrocyte survival",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
":"
]
},
" ",
{
"type":"p",
"hlId":"1222c5",
"class":"cell txt li",
"children":[
"Iron deficiency anemia"
]
},
" ",
{
"type":"p",
"hlId":"7ab270",
"class":"cell txt li",
"children":[
"Blood loss/hemolysis"
]
},
" ",
{
"type":"p",
"hlId":"bad2e0",
"class":"cell txt li",
"children":[
"Kidney disease"
]
},
" ",
{
"type":"p",
"hlId":"21be40",
"class":"cell txt li",
"children":[
"Liver disease"
]
},
" ",
{
"type":"p",
"hlId":"0b1e9b",
"class":"cell txt li",
"children":[
"Pregnancy"
]
},
" ",
{
"type":"p",
"hlId":"d62dc8",
"class":"cell txt l",
"children":[
"Hemoglobin variants in racial/ethnic high-risk groups: African, Southeast Asian, and Mediterranean heritage",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
}
]
},
" ",
{
"type":"p",
"hlId":"909e87",
"class":"cell txt l",
"children":[
"Higher value in Black persons compared with non-Hispanic White persons",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"c"
]
}
]
},
" ",
{
"type":"p",
"hlId":"f211c3",
"class":"cell txt l",
"children":[
"Affected by some glucose-6-phosphate dehydrogenase variants",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"d"
]
}
]
},
" ",
{
"type":"p",
"hlId":"e74159",
"class":"cell txt l",
"children":[
"Unavailable in some areas of the world"
]
},
" ",
{
"type":"p",
"hlId":"920c5f",
"class":"cell txt l",
"children":[
"Expensive"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e2fe35",
"class":"cell txt l",
"children":[
"FPG"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"12a8b2",
"class":"cell txt l",
"children":[
"Inexpensive"
]
},
" ",
{
"type":"p",
"hlId":"375b45",
"class":"cell txt l",
"children":[
"Widely available"
]
},
" ",
{
"type":"p",
"hlId":"1be818",
"class":"cell txt l",
"children":[
"Automated assay"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"cfbbea",
"class":"cell txt l",
"children":[
"Inconvenient: ≥8-h fasting required and restriction on time of collection"
]
},
" ",
{
"type":"p",
"hlId":"a88072",
"class":"cell txt l",
"children":[
"Affected by illness and stress"
]
},
" ",
{
"type":"p",
"hlId":"70b873",
"class":"cell txt l",
"children":[
"Measures single point in time"
]
},
" ",
{
"type":"p",
"hlId":"9e5c29",
"class":"cell txt l",
"children":[
"High biological variability within patient"
]
},
" ",
{
"type":"p",
"hlId":"d9ab44",
"class":"cell txt l",
"children":[
"Blood sample unstable after collection"
]
},
" ",
{
"type":"p",
"hlId":"4a9f91",
"class":"cell txt l",
"children":[
"Diurnal variation"
]
},
" ",
{
"type":"p",
"hlId":"b46408",
"class":"cell txt l",
"children":[
"Diabetes complications not as closely linked to FPG compared with hemoglobin A",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1c"
]
}
]
},
" ",
{
"type":"p",
"hlId":"fae847",
"class":"cell txt l",
"children":[
"Sample source (capillary, venous, or arterial blood) alters the measurement"
]
},
" ",
{
"type":"p",
"hlId":"3fc99e",
"class":"cell txt l",
"children":[
"Assay standardization incomplete"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1a5356",
"class":"cell txt l",
"children":[
"2-h PG during an OGTT"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e3abce",
"class":"cell txt l",
"children":[
"Highly sensitive to detect risk of developing diabetes"
]
},
" ",
{
"type":"p",
"hlId":"a87730",
"class":"cell txt l",
"children":[
"Detects early abnormalities in glucose metabolism"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"09e776",
"class":"cell txt l",
"children":[
"Similar disadvantages as FPG test"
]
},
" ",
{
"type":"p",
"hlId":"436fe0",
"class":"cell txt l",
"children":[
"Prolonged patient preparation"
]
},
" ",
{
"type":"p",
"hlId":"f4cef4",
"class":"cell txt l",
"children":[
"Risk of hypoglycemia at 4-6 h in normal persons"
]
},
" ",
{
"type":"p",
"hlId":"ec98f0",
"class":"cell txt l",
"children":[
"Poor reproducibility"
]
},
" ",
{
"type":"p",
"hlId":"920c5f",
"class":"cell txt l",
"children":[
"Expensive"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"FPG = fasting plasma glucose; OGTT = oral glucose tolerance test; PG = prandial glucose."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
"Blood glucose tests should be used instead of hemoglobin A",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1c"
]
},
" to screen for diabetes in the setting of altered erythrocyte turnover."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
},
"Some methods used to measure hemoglobin A",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1c"
]
},
" can accurately measure hemoglobin A",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1c"
]
},
" in individuals with hemoglobin variants who are heterozygous for hemoglobin S, hemoglobin E, hemoglobin C, hemoglobin D, and increased hemoglobin F. For individuals who are homozygous for hemoglobin S, hemoglobin C, or hemoglobin SC, blood glucose should be used instead of hemoglobin A",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1c"
]
},
" for diagnostic purposes. Black persons who are heterozygous for hemoglobin S can have a hemoglobin A",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1c"
]
},
" 0.3% lower than individuals without the trait for any level of mean glycemia."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"c"
]
},
"Hemoglobin A",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1c"
]
},
" is higher in Black persons compared with non-Hispanic White persons in the setting of similar FPG and postprandial glucose values. Despite this relationship, the risk of complications associated with A",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1c"
]
},
" remains similar in Black persons and non-Hispanic White persons."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"d"
]
},
"There is an association between a lower hemoglobin A",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1c"
]
},
" and hemizygous men and homozygous women with X-linked glucose-6-phosphate dehydrogenase G202A by 0.8% and 0.7%, respectively."
],
[
"Data from American Diabetes Association. 2. Classification and diagnosis of diabetes: Standards of Medical Care in Diabetes-2021. Diabetes Care. 2021;44:S15-S33. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/33298413",
"target":"_blank"
},
"children":[
"PMID: 33298413"
]
},
" doi:10.2337/dc21-S002"
],
[
"Data from American Diabetes Association. 6. Glycemic targets: Standards of Medical Care in Diabetes-2021. Diabetes Care. 2021;44:S73-S84. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/33298417",
"target":"_blank"
},
"children":[
"PMID: 33298417"
]
},
" doi:10.2337/dc21-S006"
],
[
"Data from Sacks DB. A1C versus glucose testing: a comparison. Diabetes Care. 2011;34:518-23. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/21270207",
"target":"_blank"
},
"children":[
"PMID: 21270207"
]
},
" doi:10.2337/dc10-1546"
],
[
"Data from NGSP: Harmonizing Hemoglobin A1c Testing web site. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ngsp.org",
"target":"_blank"
},
"children":[
"www.ngsp.org"
]
},
". Accessed January 2020."
],
[
"Data from National Institute of Diabetes and Digestive and Kidney Diseases. Comparing tests for diabetes and prediabetes. Mar. 2014. NIH Publication No. 14-7850. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"https://www.niddk.nih.gov/health-information/diabetes",
"target":"_blank"
},
"children":[
"https://www.niddk.nih.gov/health-information/diabetes"
]
},
" Accessed January 2020."
]
]
},
"mk19_b_en_t04":{
"id":"mk19_b_en_t04",
"number":4,
"bookId":"en",
"title":{
"__html":"Classification of Diabetes Mellitus"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"b1aecf",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 4. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_en_t04"
}
]
},
"Classification of Diabetes Mellitus"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b9b07c",
"class":"col hd l",
"children":[
"Type 1 Diabetes",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e5d5fc",
"class":"cell txt l",
"children":[
"Immune-mediated (including LADA) (type 1A)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"26ab6e",
"class":"cell txt l",
"children":[
"Idiopathic (type 1B)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6d4396",
"class":"col hd l",
"children":[
"Type 2 Diabetes",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
}
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d8dca8",
"class":"col hd l",
"children":[
"Gestational Diabetes",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"c"
]
}
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"54b53a",
"class":"col hd l",
"children":[
"Other Types"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a4bd36",
"class":"cell txt l",
"children":[
"Genetic defects in β-cell function (including MODY syndromes)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"289d6b",
"class":"cell txt l",
"children":[
"Genetic defects in insulin action"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d78640",
"class":"cell txt l",
"children":[
"Diseases of the exocrine pancreas"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5f8896",
"class":"cell txt li",
"children":[
"Pancreatitis, trauma/pancreatectomy, neoplasia, cystic fibrosis, hemochromatosis, fibrocalculous pancreatopathy"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"78420e",
"class":"cell txt l",
"children":[
"Endocrinopathies "
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6a1031",
"class":"cell txt li",
"children":[
"Acromegaly, Cushing syndrome, glucagonoma, pheochromocytoma, hyperthyroidism"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1aea71",
"class":"cell txt li",
"children":[
"Somatostatinoma, aldosteronoma"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b856c3",
"class":"cell txt l",
"children":[
"Drug-related"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e9eb8e",
"class":"cell txt li",
"children":[
"Glucocorticoids, thiazides, β-blockers, diazoxide, tacrolimus, immune checkpoint inhibitors, cyclosporine, niacin, HIV protease inhibitors, pentamidine, atypical antipsychotics (clozapine, olanzapine), Vacor (pyrinuron) (rat poison)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2c194f",
"class":"cell txt l",
"children":[
"Infections"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3251c0",
"class":"cell txt li",
"children":[
"Congenital rubella"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3e2f8b",
"class":"cell txt li",
"children":[
"Cytomegalovirus"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3b8bff",
"class":"cell txt li",
"children":[
"Coxsackievirus B"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"724525",
"class":"cell txt li",
"children":[
"SARS-CoV-2"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c74a82",
"class":"cell txt l",
"children":[
"Genetic syndromes"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7a2dfd",
"class":"cell txt li",
"children":[
"Down syndrome"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"612913",
"class":"cell txt li",
"children":[
"Wolfram syndrome (DIDMOAD)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_2-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b7bf96",
"class":"cell txt li",
"children":[
"Klinefelter, Turner, and Prader-Willi syndromes; myotonic dystrophy"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"DIDMOAD = diabetes insipidus, diabetes mellitus, optic atrophy, and deafness; LADA = late autoimmune diabetes in adults; MODY = maturity-onset diabetes of the young."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
"β-cell destruction typically leading to absolute insulin deficiency."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
},
"Insulin resistance with progressive relative insulin deficiency."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"c"
]
},
"Second or third trimester diagnosis of diabetes without a diagnosis of diabetes before pregnancy."
],
[
"Recommendations from American Diabetes Association Professional Practice Committee. 2. Classification and diagnosis of diabetes: standards of medical care in diabetes—2022. Diabetes Care. 2022;45:S17-S38. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/34964875",
"target":"_blank"
},
"children":[
"PMID: 34964875"
]
},
" doi:10.2337/dc22-S002; American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2014;37 Suppl 1:S81-90. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/24357215",
"target":"_blank"
},
"children":[
"PMID: 24357215"
]
},
" doi:10.2337/dc14-S081"
],
[
"Data from Naylor R, Knight Johnson A, del Gaudio D. Maturity Onset Diabetes of the Young Overview. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2020. 2018 May 24. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/29792621",
"target":"_blank"
},
"children":[
"PMID: 29792621"
]
}
]
]
},
"mk19_b_en_t05":{
"id":"mk19_b_en_t05",
"number":5,
"bookId":"en",
"title":{
"__html":"Criteria for the Definition of Metabolic Syndrome"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"afac57",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 5. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_en_t05"
}
]
},
"Criteria for the Definition of Metabolic Syndrome"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"53b0c1",
"class":"col hd l",
"children":[
"Qualifying Criteria"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c8f502",
"class":"col hd l",
"children":[
"NCEP ATP III 2005"
]
},
" ",
{
"type":"p",
"hlId":"b0803d",
"class":"col hd l",
"children":[
"(Meets at Least 3 of 5 Criteria)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"31c8a8",
"class":"col hd l",
"children":[
"International Diabetes Federation (2006)"
]
},
" ",
{
"type":"p",
"hlId":"b62734",
"class":"col hd l",
"children":[
"(Required Central Obesity and at Least 2 of 4 Remaining Criteria)"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3d7e93",
"class":"cell txt l",
"children":[
"Waist circumference"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"39bf59",
"class":"cell txt l",
"children":[
"Men ≥40 in (102 cm)"
]
},
" ",
{
"type":"p",
"hlId":"002bfc",
"class":"cell txt l",
"children":[
"Women ≥35 in (88 cm)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e7fc8c",
"class":"cell txt l",
"children":[
"European descent"
]
},
" ",
{
"type":"p",
"hlId":"a57b6d",
"class":"cell txt li",
"children":[
"Men ≥37 in (94 cm)"
]
},
" ",
{
"type":"p",
"hlId":"89fbbc",
"class":"cell txt li",
"children":[
"Women ≥31 in (80 cm)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6bff81",
"class":"cell txt l",
"children":[
"South Asian"
]
},
" ",
{
"type":"p",
"hlId":"4c54ad",
"class":"cell txt li",
"children":[
"Men ≥35 in (90 cm)",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
},
" ",
{
"type":"p",
"hlId":"89fbbc",
"class":"cell txt li",
"children":[
"Women ≥31 in (80 cm)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3b2611",
"class":"cell txt l",
"children":[
"Chinese"
]
},
" ",
{
"type":"p",
"hlId":"4c54ad",
"class":"cell txt li",
"children":[
"Men ≥35 in (90 cm)",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
},
" ",
{
"type":"p",
"hlId":"89fbbc",
"class":"cell txt li",
"children":[
"Women ≥31 in (80 cm)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f32ced",
"class":"cell txt l",
"children":[
"Japanese"
]
},
" ",
{
"type":"p",
"hlId":"4c54ad",
"class":"cell txt li",
"children":[
"Men ≥35 in (90 cm)",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
},
" ",
{
"type":"p",
"hlId":"89fbbc",
"class":"cell txt li",
"children":[
"Women ≥31 in (80 cm)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0df7c3",
"class":"cell txt l",
"children":[
"South/Central American"
]
},
" ",
{
"type":"p",
"hlId":"4c54ad",
"class":"cell txt li",
"children":[
"Men ≥35 in (90 cm)",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
},
" ",
{
"type":"p",
"hlId":"89fbbc",
"class":"cell txt li",
"children":[
"Women ≥31 in (80 cm)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"115a9c",
"class":"cell txt l",
"children":[
"Sub-Saharan African"
]
},
" ",
{
"type":"p",
"hlId":"a57b6d",
"class":"cell txt li",
"children":[
"Men ≥37 in (94 cm)"
]
},
" ",
{
"type":"p",
"hlId":"89fbbc",
"class":"cell txt li",
"children":[
"Women ≥31 in (80 cm)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d6e6bf",
"class":"cell txt l",
"children":[
"Eastern Mediterranean and Middle Eastern"
]
},
" ",
{
"type":"p",
"hlId":"a57b6d",
"class":"cell txt li",
"children":[
"Men ≥37 in (94 cm)"
]
},
" ",
{
"type":"p",
"hlId":"89fbbc",
"class":"cell txt li",
"children":[
"Women ≥31 in (80 cm)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f43cb7",
"class":"cell txt l",
"children":[
"Fasting TG"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1c1129",
"class":"cell txt l",
"children":[
"≥150 mg/dL (1.7 mmol/L) or"
]
},
" ",
{
"type":"p",
"hlId":"a9ec4a",
"class":"cell txt l",
"children":[
"Drug therapy treating increased TG"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1c1129",
"class":"cell txt l",
"children":[
"≥150 mg/dL (1.7 mmol/L) or"
]
},
" ",
{
"type":"p",
"hlId":"a9ec4a",
"class":"cell txt l",
"children":[
"Drug therapy treating increased TG"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8a43cb",
"class":"cell txt l",
"children":[
"HDL cholesterol"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9af106",
"class":"cell txt l",
"children":[
"Men <40 mg/dL (1.0 mmol/L)"
]
},
" ",
{
"type":"p",
"hlId":"a89644",
"class":"cell txt l",
"children":[
"Women <50 mg/dL (1.3 mmol/L) or"
]
},
" ",
{
"type":"p",
"hlId":"44e191",
"class":"cell txt l",
"children":[
"Drug therapy targeting decreased HDL cholesterol"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9af106",
"class":"cell txt l",
"children":[
"Men <40 mg/dL (1.0 mmol/L)"
]
},
" ",
{
"type":"p",
"hlId":"a89644",
"class":"cell txt l",
"children":[
"Women <50 mg/dL (1.3 mmol/L) or"
]
},
" ",
{
"type":"p",
"hlId":"44e191",
"class":"cell txt l",
"children":[
"Drug therapy targeting decreased HDL cholesterol"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"398b09",
"class":"cell txt l",
"children":[
"Blood pressure"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"aaa0ed",
"class":"cell txt l",
"children":[
"Systolic ≥130 mm Hg"
]
},
" ",
{
"type":"p",
"hlId":"a4b716",
"class":"cell txt l",
"children":[
"Diastolic ≥85 mm Hg or"
]
},
" ",
{
"type":"p",
"hlId":"22706a",
"class":"cell txt l",
"children":[
"Drug therapy for hypertension"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"aaa0ed",
"class":"cell txt l",
"children":[
"Systolic ≥130 mm Hg"
]
},
" ",
{
"type":"p",
"hlId":"a4b716",
"class":"cell txt l",
"children":[
"Diastolic ≥85 mm Hg or"
]
},
" ",
{
"type":"p",
"hlId":"22706a",
"class":"cell txt l",
"children":[
"Drug therapy for hypertension"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ed5473",
"class":"cell txt l",
"children":[
"Fasting glucose"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1f4ff7",
"class":"cell txt l",
"children":[
"Blood glucose ≥100 mg/dL (5.5 mmol/L) or"
]
},
" ",
{
"type":"p",
"hlId":"c17bec",
"class":"cell txt l",
"children":[
"Drug therapy for increased glucose"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1f4ff7",
"class":"cell txt l",
"children":[
"Blood glucose ≥100 mg/dL (5.5 mmol/L) or"
]
},
" ",
{
"type":"p",
"hlId":"c17bec",
"class":"cell txt l",
"children":[
"Drug therapy for increased glucose"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"NCEP ATP III = National Cholesterol Education Program - Adult Treatment Panel III; TG = triglycerides."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
"Waist circumference is 90 cm (35 inches) according to the International Diabetes Foundation and 88 cm (35 inches) according to the NCEP ATP III."
],
[
"Data from Alberti KG, Eckel RH, Grundy SM, et al; International Diabetes Federation Task Force on Epidemiology and Prevention. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120:1640-5. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/19805654",
"target":"_blank"
},
"children":[
"PMID: 19805654"
]
},
" doi:10.1161/CIRCULATIONAHA.109.192644"
],
[
"Data from International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome. 2006. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.idf.org/e-library/consensus-statements/60-idfconsensus-worldwide-definitionof-the-metabolic-syndrome.html",
"target":"_blank"
},
"children":[
"www.idf.org/e-library/consensus-statements/60-idfconsensus-worldwide-definitionof-the-metabolic-syndrome.html"
]
},
". Accessed Jan 2020."
]
]
},
"mk19_b_en_t06":{
"id":"mk19_b_en_t06",
"number":6,
"bookId":"en",
"title":{
"__html":"Strategies to Prevent or Delay Onset of Type 2 Diabetes Mellitus"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"773bbf",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 6. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_en_t06"
}
]
},
"Strategies to Prevent or Delay Onset of Type 2 Diabetes Mellitus"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c143a2",
"class":"col hd l",
"children":[
"Intervention"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2e0c72",
"class":"col hd l",
"children":[
"Effectiveness"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c05135",
"class":"cell txt l",
"children":[
"Diet and exercise",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a,b"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0aadfc",
"class":"cell txt l",
"children":[
"Shown to delay onset of diabetes by up to 10-20 years"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7a08af",
"class":"cell txt l",
"children":[
"Smoking cessation"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"869e58",
"class":"cell txt l",
"children":[
"Modestly effective as long as it does not cause weight gain, but is always recommended"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c3492f",
"class":"cell txt l",
"children":[
"Bariatric surgery"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"eaede2",
"class":"cell txt l",
"children":[
"Effective if used in persons with extreme obesity (BMI >40)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a657af",
"class":"cell txt l",
"children":[
"Metformin",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"193ca9",
"class":"cell txt l",
"children":[
"Shown to delay onset of diabetes by up to 10 years"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"45fbd7",
"class":"cell txt l",
"children":[
"Lipase inhibitors (orlistat)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2c4ebc",
"class":"cell txt l",
"children":[
"Shown to delay onset of diabetes up to 4 years"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"acc0b2",
"class":"cell txt l",
"children":[
"α-Glucosidase inhibitors (acarbose, voglibose)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fdecac",
"class":"cell txt l",
"children":[
"Shown to delay onset of diabetes up to 3 years"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"924dc9",
"class":"cell txt l",
"children":[
"Thiazolidinediones (troglitazone, rosiglitazone, pioglitazone)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fdecac",
"class":"cell txt l",
"children":[
"Shown to delay onset of diabetes up to 3 years"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-8 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6c1d81",
"class":"cell txt l",
"children":[
"Glucagon-like peptide 1 receptor agonists (exenatide, liraglutide)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"381bc7",
"class":"cell txt l",
"children":[
"Significant weight loss and improvements in glycemic control in persons at high risk in short-term studies"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-9 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"363a1a",
"class":"cell txt l",
"children":[
"Insulin and insulin secretagogues (sulfonylureas, meglitinides)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"122052",
"class":"cell txt l",
"children":[
"Ineffective"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-10 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d761b1",
"class":"cell txt l",
"children":[
"ACE inhibitors and angiotensin receptor blockers"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"122052",
"class":"cell txt l",
"children":[
"Ineffective"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-11 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0f960b",
"class":"cell txt l",
"children":[
"Estrogen-progestin"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"88273a",
"class":"cell txt l",
"children":[
"Modest effect only"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
"Preferred."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
},
"Intensive behavioral lifestyle intervention with a goal of achieving and maintaining a 7% weight reduction and at least 150 min/wk of moderate intensity physical activity."
],
[
"Data from American Diabetes Association. 3. Prevention or delay of type 2 diabetes: Standards of Medical Care in Diabetes-2021. Diabetes Care. 2021;44:S34-S39. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/33298414",
"target":"_blank"
},
"children":[
"PMID: 33298414"
]
},
" doi:10.2337/dc21-S003"
],
[
"Data from Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm - 2018 Executive Summary. Endocr Pract. 2018;24:91-120. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/29368965",
"target":"_blank"
},
"children":[
"PMID: 29368965"
]
},
" doi:10.4158/CS-2017-0153"
]
]
},
"mk19_b_en_t07":{
"id":"mk19_b_en_t07",
"number":7,
"bookId":"en",
"title":{
"__html":"Comparison of Hemoglobin A<sub>1c</sub> Value and Estimated Plasma Glucose Level"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"0e5836",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 7. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_en_t07"
}
]
},
"Comparison of Hemoglobin A",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1c"
]
},
" Value and Estimated Plasma Glucose Level"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"20d62f",
"class":"col hd l",
"children":[
"Hemoglobin A",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1c"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"565093",
"class":"col hd l",
"children":[
"Estimated Average Plasma Glucose Level"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"565093",
"class":"col hd l",
"children":[
"Estimated Average Plasma Glucose Level"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"701d52",
"class":"col hd l",
"children":[
"(%)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f72a25",
"class":"col hd l",
"children":[
"mg/dL (95% CI)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7872ac",
"class":"col hd l",
"children":[
"mmol/L (95% CI)"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"167909",
"class":"cell txt l",
"children":[
"6"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"dd1a2e",
"class":"cell txt l",
"children":[
"126 (100-152)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5be759",
"class":"cell txt l",
"children":[
"7.0 (5.5-8.5)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8f14e4",
"class":"cell txt l",
"children":[
"7"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6873bd",
"class":"cell txt l",
"children":[
"154 (123-185)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"799805",
"class":"cell txt l",
"children":[
"8.6 (6.8-10.3)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c9f0f8",
"class":"cell txt l",
"children":[
"8"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"06ad76",
"class":"cell txt l",
"children":[
"183 (147-217)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f1d06c",
"class":"cell txt l",
"children":[
"10.2 (8.1-12.1)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"45c48c",
"class":"cell txt l",
"children":[
"9"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"48b8e4",
"class":"cell txt l",
"children":[
"212 (170-249)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"bba58b",
"class":"cell txt l",
"children":[
"11.8 (9.4-13.9)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d3d944",
"class":"cell txt l",
"children":[
"10"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"271ec7",
"class":"cell txt l",
"children":[
"240 (193-282)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c5b810",
"class":"cell txt l",
"children":[
"13.4 (10.7-15.7)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6512bd",
"class":"cell txt l",
"children":[
"11"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a2abb4",
"class":"cell txt l",
"children":[
"269 (217-314)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"15f9cd",
"class":"cell txt l",
"children":[
"14.9 (12.0-17.5)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c20ad4",
"class":"cell txt l",
"children":[
"12"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3e6640",
"class":"cell txt l",
"children":[
"298 (240-347)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"368639",
"class":"cell txt l",
"children":[
"16.5 (13.3-19.3)"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"Data from American Diabetes Association. 6. Glycemic targets: Standards of Medical Care in Diabetes-2021. Diabetes Care. 2021;44:S73-S84. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/33298417",
"target":"_blank"
},
"children":[
"PMID: 33298417"
]
},
" doi:10.2337/dc21-S006"
]
]
},
"mk19_b_en_t08":{
"id":"mk19_b_en_t08",
"number":8,
"bookId":"en",
"title":{
"__html":"American Diabetes Association Recommended Outpatient Glycemic Goals for Adults With Diabetes Mellitus"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"e327b7",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 8. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_en_t08"
}
]
},
"American Diabetes Association Recommended Outpatient Glycemic Goals for Adults With Diabetes Mellitus"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"dfd4de",
"class":"col hd l",
"children":[
"State of Health"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b393b7",
"class":"col hd l",
"children":[
"Characteristics of Patients"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"610112",
"class":"col hd l",
"children":[
"Hemoglobin A",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1c"
]
},
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5acb82",
"class":"col hd l",
"children":[
"Preprandial Capillary Glucose"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"97fd82",
"class":"col hd l",
"children":[
"Postprandial Capillary Glucose (1-2 H After Meal)",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e0a844",
"class":"col hd l",
"children":[
"Bedtime Capillary Glucose"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"396d45",
"class":"cell txt l",
"children":[
"Healthy"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"43f665",
"class":"cell txt l",
"children":[
"Early in disease course"
]
},
" ",
{
"type":"p",
"hlId":"1b44c3",
"class":"cell txt l",
"children":[
"Few comorbidities"
]
},
" ",
{
"type":"p",
"hlId":"157ae3",
"class":"cell txt l",
"children":[
"Preconception"
]
},
" ",
{
"type":"p",
"hlId":"02567c",
"class":"cell txt l",
"children":[
"Patient preference"
]
},
" ",
{
"type":"p",
"hlId":"7a083c",
"class":"cell txt l",
"children":[
"Life expectancy >10 years"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"30aca7",
"class":"cell txt l",
"children":[
"<7.0%"
]
},
" ",
{
"type":"p",
"hlId":"2c6a39",
"class":"cell txt l",
"children":[
"<6.5% for select patients",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"c"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"199de2",
"class":"cell txt l",
"children":[
"80-130 mg/dL"
]
},
" ",
{
"type":"p",
"hlId":"978749",
"class":"cell txt l",
"children":[
"(4.4-7.2 mmol/L)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ffd45e",
"class":"cell txt l",
"children":[
"<180 mg/dL",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
}
]
},
" ",
{
"type":"p",
"hlId":"05e180",
"class":"cell txt l",
"children":[
"(10.0 mmol/L)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2ada57",
"class":"cell txt l",
"children":[
"Complex health issues"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0275c8",
"class":"cell txt l",
"children":[
"Significant comorbidities including advanced atherosclerosis or microvascular complications"
]
},
" ",
{
"type":"p",
"hlId":"77204c",
"class":"cell txt l",
"children":[
"Longer duration of diabetes with difficulty achieving glycemic goals despite appropriate management"
]
},
" ",
{
"type":"p",
"hlId":"3d5fde",
"class":"cell txt l",
"children":[
"Frequent hypoglycemia"
]
},
" ",
{
"type":"p",
"hlId":"397faa",
"class":"cell txt l",
"children":[
"Hypoglycemia unawareness"
]
},
" ",
{
"type":"p",
"hlId":"6c60eb",
"class":"cell txt l",
"children":[
"Life expectancy <10 years"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"226692",
"class":"cell txt l",
"children":[
"<8.0%"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"656316",
"class":"cell txt l",
"children":[
"Older adults"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"396d45",
"class":"cell txt l",
"children":[
"Healthy"
]
},
" ",
{
"type":"p",
"hlId":"1b44c3",
"class":"cell txt li",
"children":[
"Few comorbidities"
]
},
" ",
{
"type":"p",
"hlId":"7d4402",
"class":"cell txt li",
"children":[
"Extended life expectancy"
]
},
" ",
{
"type":"p",
"hlId":"b8a005",
"class":"cell txt li",
"children":[
"No impairment of cognition or function"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1dabba",
"class":"cell txt l",
"children":[
"<7.5%"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"96545b",
"class":"cell txt l",
"children":[
"90-130 mg/dL"
]
},
" ",
{
"type":"p",
"hlId":"66bbdf",
"class":"cell txt l",
"children":[
"(5.0-7.2 mmol/L)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f01c30",
"class":"cell txt l",
"children":[
"90-150 mg/dL"
]
},
" ",
{
"type":"p",
"hlId":"743048",
"class":"cell txt l",
"children":[
"(5.0-8.3 mmol/L)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ef2dd0",
"class":"cell txt l",
"children":[
"Complex/intermediate"
]
},
" ",
{
"type":"p",
"hlId":"fdb251",
"class":"cell txt li",
"children":[
"Multiple comorbidities"
]
},
" ",
{
"type":"p",
"hlId":"1bc4a1",
"class":"cell txt li",
"children":[
"Hypoglycemia risk"
]
},
" ",
{
"type":"p",
"hlId":"95bafd",
"class":"cell txt li",
"children":[
"Fall risk"
]
},
" ",
{
"type":"p",
"hlId":"a2935a",
"class":"cell txt li",
"children":[
"Multiple instrumental ADL impairments"
]
},
" ",
{
"type":"p",
"hlId":"661db2",
"class":"cell txt li",
"children":[
"Mild-to-moderate impairment in cognition"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"226692",
"class":"cell txt l",
"children":[
"<8.0%"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f01c30",
"class":"cell txt l",
"children":[
"90-150 mg/dL"
]
},
" ",
{
"type":"p",
"hlId":"743048",
"class":"cell txt l",
"children":[
"(5.0-8.3 mmol/L)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"762d62",
"class":"cell txt l",
"children":[
"100-180 mg/dL"
]
},
" ",
{
"type":"p",
"hlId":"9eca98",
"class":"cell txt l",
"children":[
"(5.6-10.0 mmol/L)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8c328e",
"class":"cell txt l",
"children":[
"Very complex/poor health"
]
},
" ",
{
"type":"p",
"hlId":"a8f446",
"class":"cell txt li",
"children":[
"Chronic comorbidities with end-stage disease"
]
},
" ",
{
"type":"p",
"hlId":"b64b4d",
"class":"cell txt li",
"children":[
"Long-term care placement"
]
},
" ",
{
"type":"p",
"hlId":"6f538e",
"class":"cell txt li",
"children":[
"Moderate-to-severe impairment in cognition"
]
},
" ",
{
"type":"p",
"hlId":"565c5f",
"class":"cell txt li",
"children":[
"Multiple ADL dependencies"
]
},
" ",
{
"type":"p",
"hlId":"57cc16",
"class":"cell txt li",
"children":[
"Limited life expectancy"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a060e6",
"class":"cell txt l",
"children":[
"<8.5%"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"762d62",
"class":"cell txt l",
"children":[
"100-180 mg/dL"
]
},
" ",
{
"type":"p",
"hlId":"9eca98",
"class":"cell txt l",
"children":[
"(5.6-10.0 mmol/L)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"34e703",
"class":"cell txt l",
"children":[
"110-200 mg/dL"
]
},
" ",
{
"type":"p",
"hlId":"a06530",
"class":"cell txt l",
"children":[
"(6.1-11.1 mmol/L)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"51688b",
"class":"cell txt l",
"children":[
"Pregnant women",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"d"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"cc9230",
"class":"cell txt l",
"children":[
"Preexisting type 1 diabetes, preexisting type 2 diabetes, or gestational diabetes"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"44658f",
"class":"cell txt l",
"children":[
"6.0%-6.5% without severe hypoglycemia",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"e"
]
}
]
},
" ",
{
"type":"p",
"hlId":"ad6acd",
"class":"cell txt l",
"children":[
"(<6.0% may be optimal as pregnancy progresses)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9f9e1e",
"class":"cell txt l",
"children":[
"Fasting <95 mg/dL"
]
},
" ",
{
"type":"p",
"hlId":"a287c5",
"class":"cell txt l",
"children":[
"(5.3 mmol/L)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4607d4",
"class":"cell txt l",
"children":[
"1-h postprandial <140 mg/dL (7.8 mmol/L)"
]
},
" ",
{
"type":"p",
"hlId":"e81c4e",
"class":"cell txt l",
"children":[
"or"
]
},
" ",
{
"type":"p",
"hlId":"f36316",
"class":"cell txt l",
"children":[
"2-h postprandial <120 mg/dL (6.7 mmol/L)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"ADL = activities of daily living."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
"Recommended if goal can be met without severe recurrent hypoglycemia. If severe recurrent hypoglycemia is present, there is no recommended hemoglobin A",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1c"
]
},
" goal, because modification of the patient's diabetes regimen to resolve severe recurrent hypoglycemia should take precedence. When severe recurrent hypoglycemia has resolved, a hemoglobin A",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1c"
]
},
" goal can be chosen, and treatment decisions can again be made based on that individualized goal without frequent hypoglycemia. Hemoglobin A",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1c"
]
},
" should be measured at diagnosis followed by 3-month intervals as changes to lifestyle modifications and/or pharmacologic therapies occur. Hemoglobin A",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1c"
]
},
" measurements can be reduced to every 6 months when glycemic targets are achieved."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
},
"When the hemoglobin A",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1c"
]
},
" is not at goal despite meeting preprandial glucose goals, the postprandial glucose values should be targeted. Elevated postprandial glucose values have a greater impact on A",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1c"
]
},
" values near 7%."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"c"
]
},
"This goal can be considered for patients with an early diagnosis of diabetes mellitus, no significant cardiovascular disease, long life expectancy, or diabetes managed with lifestyle modifications or metformin."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"d"
]
},
"Both preprandial and postprandial glucose monitoring are recommended in pregnant women."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"e"
]
},
"Preprandial and postprandial glucose measurements should be the primary evaluation of glycemic control, as hemoglobin A",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1c"
]
},
" values decrease with increased erythrocyte turnover associated with pregnancy."
],
[
"Recommendations from American Diabetes Association. 6. Glycemic targets: Standards of Medical Care in Diabetes-2021. Diabetes Care. 2021;44:S73-S84. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/33298417",
"target":"_blank"
},
"children":[
"PMID: 33298417"
]
},
" doi:10.2337/dc21-S006"
],
[
"Recommendations from American Diabetes Association. 12. Older adults: Standards of Medical Care in Diabetes-2021. Diabetes Care. 2021;44:S168-S179. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/33298423",
"target":"_blank"
},
"children":[
"PMID: 33298423"
]
},
" doi:10.2337/dc21-S012"
],
[
"Recommendations from American Diabetes Association. 14. Management of diabetes in pregnancy: Standards of Medical Care in Diabetes-2021. Diabetes Care. 2021;44:S200-S210. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/33298425",
"target":"_blank"
},
"children":[
"PMID: 33298425"
]
},
" doi:10.2337/dc21-S014"
]
]
},
"mk19_b_en_t09":{
"id":"mk19_b_en_t09",
"number":9,
"bookId":"en",
"title":{
"__html":"Pharmacokinetic Properties of Insulin Products<sup>a</sup>"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"180640",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 9. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_en_t09"
}
]
},
"Pharmacokinetic Properties of Insulin Products",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"240421",
"class":"col hd l",
"children":[
"Insulin Type"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"598f11",
"class":"col hd l",
"children":[
"Onset"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a21e60",
"class":"col hd l",
"children":[
"Peak"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e02d2a",
"class":"col hd l",
"children":[
"Duration"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"cbc3a0",
"class":"cell txt l",
"children":[
"Rapid-acting analogues"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fb694b",
"class":"cell txt li",
"children":[
"Lispro, aspart, glulisine"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0b3bb8",
"class":"cell txt l",
"children":[
"5-15 min"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ca353d",
"class":"cell txt l",
"children":[
"45-90 min"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e21687",
"class":"cell txt l",
"children":[
"2-4 h"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f260ef",
"class":"cell txt li",
"children":[
"Inhaled insulin"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0b3bb8",
"class":"cell txt l",
"children":[
"5-15 min"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a4cb17",
"class":"cell txt l",
"children":[
"50 min"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"193866",
"class":"cell txt l",
"children":[
"2-3 h"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0859db",
"class":"cell txt l",
"children":[
"Concentrated rapid-acting analogue"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9f2080",
"class":"cell txt l",
"children":[
"Lispro (200 U/mL)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0b3bb8",
"class":"cell txt l",
"children":[
"5-15 min"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ca353d",
"class":"cell txt l",
"children":[
"45-90 min"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e21687",
"class":"cell txt l",
"children":[
"2-4 h"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"864471",
"class":"cell txt l",
"children":[
"Short-acting"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt li",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"13e2ab",
"class":"cell txt li",
"children":[
"Human regular"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6a3f37",
"class":"cell txt l",
"children":[
"0.5 h"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"292ea7",
"class":"cell txt l",
"children":[
"2-5 h"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7f56cf",
"class":"cell txt l",
"children":[
"4-8 h"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fac700",
"class":"cell txt l",
"children":[
"Intermediate-acting"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"cbcf3d",
"class":"cell txt li",
"children":[
"NPH insulin"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f9b592",
"class":"cell txt l",
"children":[
"1-3 h"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5ec7f3",
"class":"cell txt l",
"children":[
"4-10 h"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3f66df",
"class":"cell txt l",
"children":[
"10-18 h"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b7671c",
"class":"cell txt l",
"children":[
"Concentrated human regular"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a6bc7d",
"class":"cell txt li",
"children":[
"Human regular U-500"
]
},
" ",
{
"type":"p",
"hlId":"a8770b",
"class":"cell txt li",
"children":[
"(500 U/mL)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6a3f37",
"class":"cell txt l",
"children":[
"0.5 h"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"292ea7",
"class":"cell txt l",
"children":[
"2-5 h"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"df8a99",
"class":"cell txt l",
"children":[
"13-24 h"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"554548",
"class":"cell txt l",
"children":[
"Long-acting basal analogues"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fe9f2a",
"class":"cell txt li",
"children":[
"Detemir"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"14ee32",
"class":"cell txt l",
"children":[
"1-2 h"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"dae869",
"class":"cell txt l",
"children":[
"None",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"48991e",
"class":"cell txt l",
"children":[
"12-24 h",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"c"
]
}
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3f2417",
"class":"cell txt li",
"children":[
"Glargine"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"193866",
"class":"cell txt l",
"children":[
"2-3 h"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"dae869",
"class":"cell txt l",
"children":[
"None",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3f0669",
"class":"cell txt l",
"children":[
"20-24+ h"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"05524c",
"class":"cell txt li",
"children":[
"Degludec"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f9b592",
"class":"cell txt l",
"children":[
"1-3 h"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6adf97",
"class":"cell txt l",
"children":[
"None"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"733fdb",
"class":"cell txt l",
"children":[
"24-42 h"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-8 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6885fa",
"class":"cell txt l",
"children":[
"Concentrated basal analogue (ultra-long-acting)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt li",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-8 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a11fcb",
"class":"cell txt li",
"children":[
"Glargine (300 U/mL)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"05b7e6",
"class":"cell txt l",
"children":[
"6 h"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6adf97",
"class":"cell txt l",
"children":[
"None"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b30cd2",
"class":"cell txt l",
"children":[
"24-36 h"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-8 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"40a7a7",
"class":"cell txt li",
"children":[
"Degludec (200 U/mL)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f9b592",
"class":"cell txt l",
"children":[
"1-3 h"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6adf97",
"class":"cell txt l",
"children":[
"None"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"733fdb",
"class":"cell txt l",
"children":[
"24-42 h"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-9 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ecf22f",
"class":"cell txt l",
"children":[
"Premixed insulins",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"d"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-9 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"76f9fd",
"class":"cell txt li",
"children":[
"70% NPH/30% regular"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"32610e",
"class":"cell txt l",
"children":[
"0.5-1 h"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d6ef0f",
"class":"cell txt l",
"children":[
"2-10 h"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3f66df",
"class":"cell txt l",
"children":[
"10-18 h"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-9 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c88277",
"class":"cell txt li",
"children":[
"75% NPL/25% lispro"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a45353",
"class":"cell txt l",
"children":[
"10-20 min"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7c74d0",
"class":"cell txt l",
"children":[
"1-6 h"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3f66df",
"class":"cell txt l",
"children":[
"10-18 h"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-9 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"89e362",
"class":"cell txt li",
"children":[
"50% NPL/50% lispro"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a45353",
"class":"cell txt l",
"children":[
"10-20 min"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7c74d0",
"class":"cell txt l",
"children":[
"1-6 h"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3f66df",
"class":"cell txt l",
"children":[
"10-18 h"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-9 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e900b6",
"class":"cell txt li",
"children":[
"70% NPA/30% aspart"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a45353",
"class":"cell txt l",
"children":[
"10-20 min"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7c74d0",
"class":"cell txt l",
"children":[
"1-6 h"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3f66df",
"class":"cell txt l",
"children":[
"10-18 h"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-9 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"96453e",
"class":"cell txt li",
"children":[
"70% degludec/30% aspart"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0cd276",
"class":"cell txt l",
"children":[
"10-30 min"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9098e4",
"class":"cell txt l",
"children":[
"0.5-2 h"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7bfe3b",
"class":"cell txt l",
"children":[
"24+ h"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"NPA = neutral protamine aspart; NPH = neutral protamine Hagedorn; NPL = neutral protamine lispro."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
"The time course of each insulin varies significantly between persons and within the same person on different days. Therefore, the time periods listed should be considered general guidelines only."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
},
"Both detemir insulin and glargine insulin can produce a peak effect in some persons, especially at higher doses."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"c"
]
},
"The duration of action for detemir insulin varies depending on the dose given."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"d"
]
},
"Premixed insulins containing a larger proportion of rapid- or short-acting insulin tend to have larger peaks occurring at an earlier time than mixtures containing smaller proportions of rapid- and short-acting insulin."
]
]
},
"mk19_b_en_t10":{
"id":"mk19_b_en_t10",
"number":10,
"bookId":"en",
"title":{
"__html":"Pharmacologic Agents Used to Lower Blood Glucose Levels in Type 2 Diabetes Mellitus<sup>a,b</sup>"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"770d29",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 10. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_en_t10"
}
]
},
"Pharmacologic Agents Used to Lower Blood Glucose Levels in Type 2 Diabetes Mellitus",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a,b"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9bd813",
"class":"col hd l",
"children":[
"Class"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6cdc4b",
"class":"col hd l",
"children":[
"Mechanism of Action"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"544914",
"class":"col hd l",
"children":[
"Effect on Weight"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"90843c",
"class":"col hd l",
"children":[
"Disadvantages"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fa9373",
"class":"col hd l",
"children":[
"Long-Term Studies on Definitive Outcomes"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"38ef85",
"class":"cell txt l",
"children":[
"Insulin"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d222fb",
"class":"cell txt l",
"children":[
"Decreases hepatic glucose production"
]
},
" ",
{
"type":"p",
"hlId":"1dc9f5",
"class":"cell txt l",
"children":[
"Increases peripheral glucose uptake"
]
},
" ",
{
"type":"p",
"hlId":"937124",
"class":"cell txt l",
"children":[
"Suppresses ketogenesis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"aac247",
"class":"cell txt l",
"children":[
"Increase"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"428042",
"class":"cell txt l",
"children":[
"Hypoglycemia, training required, injectable forms, pulmonary toxicity with inhaled insulin"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"cd9e2f",
"class":"cell txt l",
"children":[
"Decrease in microvascular events (UKPDS)",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"c,d"
]
}
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ca3a81",
"class":"cell txt l",
"children":[
"Sulfonylureas (tolbutamide, chlorpropamide, glipizide, glyburide, gliclazide, glimepiride)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f3abac",
"class":"cell txt l",
"children":[
"Stimulates insulin secretion"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"aac247",
"class":"cell txt l",
"children":[
"Increase"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6e9a66",
"class":"cell txt l",
"children":[
"Hypoglycemia (especially in drugs with long half-lives or in older populations); lacks glucose-lowering durability"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ca9296",
"class":"cell txt l",
"children":[
"Decrease in microvascular events (UKPDS)",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"c"
]
},
"; possible increase in CVD events"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"19a17b",
"class":"cell txt l",
"children":[
"Biguanides (metformin)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d222fb",
"class":"cell txt l",
"children":[
"Decreases hepatic glucose production"
]
},
" ",
{
"type":"p",
"hlId":"41aa18",
"class":"cell txt l",
"children":[
"Increases insulin-mediated uptake of glucose in muscles"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e9bb53",
"class":"cell txt l",
"children":[
"Neutral"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"70da5c",
"class":"cell txt l",
"children":[
"Diarrhea and abdominal discomfort, vitamin B",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"12"
]
},
" deficiency, lactic acidosis (rare)"
]
},
" ",
{
"type":"p",
"hlId":"4de91f",
"class":"cell txt l",
"children":[
"Contraindicated with progressive liver, kidney, or cardiac failure"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ff1e35",
"class":"cell txt l",
"children":[
"Decrease in CVD events (UKPDS)",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"d"
]
}
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9552c2",
"class":"cell txt l",
"children":[
"α-Glucosidase inhibitors (acarbose, miglitol)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"190a99",
"class":"cell txt l",
"children":[
"Inhibits polysaccharide absorption"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e9bb53",
"class":"cell txt l",
"children":[
"Neutral"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"977cfd",
"class":"cell txt l",
"children":[
"Flatulence, abdominal discomfort"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2bb8b8",
"class":"cell txt l",
"children":[
"Possible decrease in CVD events in prediabetes (STOP-NIDDM)",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"e"
]
}
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f09885",
"class":"cell txt l",
"children":[
"Thiazolidinediones (rosiglitazone, pioglitazone)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b6884e",
"class":"cell txt l",
"children":[
"Increases peripheral uptake of glucose"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"aac247",
"class":"cell txt l",
"children":[
"Increase"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d8dbbd",
"class":"cell txt l",
"children":[
"Fluid retention, heart failure, edema, fractures, possible increased risk of bladder cancer with pioglitazone"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"082199",
"class":"cell txt l",
"children":[
"Possible decrease in CVD events with pioglitazone (PROactive)",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"f"
]
}
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"74a123",
"class":"cell txt l",
"children":[
"Meglitinides (repaglinide, nateglinide)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2ce90c",
"class":"cell txt l",
"children":[
"Stimulates insulin release"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"aac247",
"class":"cell txt l",
"children":[
"Increase"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c1870e",
"class":"cell txt l",
"children":[
"Hypoglycemia, frequent dosing"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6adf97",
"class":"cell txt l",
"children":[
"None"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d6e4b4",
"class":"cell txt l",
"children":[
"Amylin mimetic (pramlintide)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"455909",
"class":"cell txt l",
"children":[
"Slows gastric emptying"
]
},
" ",
{
"type":"p",
"hlId":"c4263f",
"class":"cell txt l",
"children":[
"Suppresses glucagon secretion"
]
},
" ",
{
"type":"p",
"hlId":"7386b0",
"class":"cell txt l",
"children":[
"Increases satiety"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9e661c",
"class":"cell txt l",
"children":[
"Decrease"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"db0b8c",
"class":"cell txt l",
"children":[
"Nausea, vomiting, exacerbation of gastroparesis, increased hypoglycemia risk with concomitant use of insulin, training required, injectable, frequent dosing"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6adf97",
"class":"cell txt l",
"children":[
"None"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-8 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"57241a",
"class":"cell txt l",
"children":[
"DPP-4 inhibitors (sitagliptin, saxagliptin, linagliptin, alogliptin)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a1629c",
"class":"cell txt l",
"children":[
"Glucose-dependent increase in insulin secretion"
]
},
" ",
{
"type":"p",
"hlId":"a61db1",
"class":"cell txt l",
"children":[
"Glucose-dependent suppression of glucagon secretion"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e9bb53",
"class":"cell txt l",
"children":[
"Neutral"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"168ed1",
"class":"cell txt l",
"children":[
"Hypoglycemia when used in combination with sulfonylureas, increased risk of infections, possible increased risk of pancreatitis, dermatologic reactions, requires dose adjustments for decreasing kidney function except for linagliptin"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"397f46",
"class":"cell txt l",
"children":[
"Increased heart failure hospitalizations (saxagliptin [SAVOR-TIMI 53])",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"g"
]
}
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-9 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"275dac",
"class":"cell txt l",
"children":[
"GLP-1 receptor agonists (exenatide, exenatide extended release, liraglutide, lixisenatide, dulaglutide, semaglutide, oral semaglutide)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a1629c",
"class":"cell txt l",
"children":[
"Glucose-dependent increase in insulin secretion"
]
},
" ",
{
"type":"p",
"hlId":"455909",
"class":"cell txt l",
"children":[
"Slows gastric emptying"
]
},
" ",
{
"type":"p",
"hlId":"a61db1",
"class":"cell txt l",
"children":[
"Glucose-dependent suppression of glucagon secretion"
]
},
" ",
{
"type":"p",
"hlId":"7386b0",
"class":"cell txt l",
"children":[
"Increases satiety"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9e661c",
"class":"cell txt l",
"children":[
"Decrease"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2a3577",
"class":"cell txt l",
"children":[
"Hypoglycemia when used in combination with sulfonylureas, nausea, vomiting, diarrhea, exacerbation of gastroparesis, increased heart rate, possible pancreatitis, C-cell hyperplasia and medullary thyroid tumors demonstrated in animal studies, training required, injectable (except oral semaglutide)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ee6497",
"class":"cell txt l",
"children":[
"Decrease in CVD events and mortality in individuals at high risk with type 2 diabetes with liraglutide (LEADER)",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"h"
]
}
]
},
" ",
{
"type":"p",
"hlId":"909e26",
"class":"cell txt l",
"children":[
"Decrease in new or worsening nephropathy in individuals at high risk with type 2 diabetes with liraglutide (LEADER)",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"h"
]
}
]
},
" ",
{
"type":"p",
"hlId":"565be8",
"class":"cell txt l",
"children":[
"Decrease in nonfatal MI, nonfatal stroke, or CV death with semaglutide (SUSTAIN-6)",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"i"
]
}
]
},
" ",
{
"type":"p",
"hlId":"24ef36",
"class":"cell txt l",
"children":[
"Decrease in new or worsening nephropathy in individuals at high risk with type 2 diabetes with semaglutide (SUSTAIN-6)",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"i"
]
}
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-10 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"cba84c",
"class":"cell txt l",
"children":[
"SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin, ertugliflozin)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"301a6a",
"class":"cell txt l",
"children":[
"Increases kidney excretion of glucose"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9e661c",
"class":"cell txt l",
"children":[
"Decrease"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d10443",
"class":"cell txt l",
"children":[
"Hypoglycemia with insulin secretagogues, dehydration/hypotension, acute kidney injury (canagliflozin, dapagliflozin), hypersensitivity reactions, increased ",
{
"type":"tag",
"tagName":"i",
"attrs":{
},
"children":[
"Candida"
]
},
" infections, urinary tract infections, Fournier gangrene, “euglycemic” DKA, increase in lower limb amputations (canagliflozin), hyperkalemia (canagliflozin), fractures (canagliflozin), bladder cancer (dapagliflozin)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"60f749",
"class":"cell txt l",
"children":[
"Decrease in CVD events and mortality in high-risk individuals with type 2 diabetes with empagliflozin (EMPA-REG OUTCOME)",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"j"
]
}
]
},
" ",
{
"type":"p",
"hlId":"5dffb1",
"class":"cell txt l",
"children":[
"Decrease in incident or worsening nephropathy in individuals at high CVD risk with type 2 diabetes (EMPA-REG OUTCOME)",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"j"
]
}
]
},
" ",
{
"type":"p",
"hlId":"e1d88f",
"class":"cell txt l",
"children":[
"Decrease in CVD events in high-risk individuals with type 2 diabetes with canagliflozin (CANVAS Program)",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"k"
]
}
]
},
" ",
{
"type":"p",
"hlId":"20e441",
"class":"cell txt l",
"children":[
"Decrease in CVD events and kidney failure in individuals with type 2 diabetes and kidney disease with canagliflozin (CREDENCE)",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"l"
]
}
]
},
" ",
{
"type":"p",
"hlId":"ccef54",
"class":"cell txt l",
"children":[
"Decreased risk of hospitalization for heart failure in patients with type 2 diabetes and established CVD with dapagliflozin (DECLARE-TIMI 58)",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"m"
]
}
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-11 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fd1d2d",
"class":"cell txt l",
"children":[
"Bile acid sequestrants (colesevelam)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9a1473",
"class":"cell txt l",
"children":[
"Incompletely understood:"
]
},
" ",
{
"type":"p",
"hlId":"26a808",
"class":"cell txt l",
"children":[
"Possible decrease in hepatic glucose production"
]
},
" ",
{
"type":"p",
"hlId":"43501d",
"class":"cell txt l",
"children":[
"Possible increase in incretin levels"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e9bb53",
"class":"cell txt l",
"children":[
"Neutral"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d9d6f5",
"class":"cell txt l",
"children":[
"Constipation, dyspepsia, increased triglycerides, possible interference with absorption of other medications"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6adf97",
"class":"cell txt l",
"children":[
"None"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-12 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"65e3a7",
"class":"cell txt l",
"children":[
"Dopamine-2 agonists (bromocriptine quick release)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5113bd",
"class":"cell txt l",
"children":[
"Increases insulin sensitivity"
]
},
" ",
{
"type":"p",
"hlId":"55ff47",
"class":"cell txt l",
"children":[
"Alters metabolism via hypothalamus"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e9bb53",
"class":"cell txt l",
"children":[
"Neutral"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b33100",
"class":"cell txt l",
"children":[
"Nausea, orthostasis, fatigue"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fb112c",
"class":"cell txt l",
"children":[
"Possible decrease in CVD events (Cycloset Safety Trial)",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"n"
]
}
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"CV = cardiovascular; CVD = cardiovascular disease; DKA = diabetic ketoacidosis; DPP-4 = dipeptidyl peptidase-4; GLP-1 = glucagon-like peptide-1; MI = myocardial infarction; SGLT2 = sodium-glucose cotransporter 2."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
"Data from American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes-2021. Diabetes Care. 2021;44:S111-S124. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/33298420",
"target":"_blank"
},
"children":[
"PMID: 33298420"
]
},
" doi:10.2337/dc21-S009"
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
},
"Data from Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, et al; American Association of Clinical Endocrinologists (AACE). Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm—2018 executive summary. Endocr Pract. 2018;24:91-120. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/29368965",
"target":"_blank"
},
"children":[
"PMID: 29368965"
]
},
" doi:10.4158/CS-2017-0153"
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"c"
]
},
"Data from Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:837-53. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/9742976",
"target":"_blank"
},
"children":[
"PMID: 9742976"
]
}
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"d"
]
},
"Data from Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352:854-65. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/9742977",
"target":"_blank"
},
"children":[
"PMID: 9742977"
]
}
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"e"
]
},
"Data from Chiasson JL, Josse RG, Gomis R, et al; STOP-NIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA. 2003;290:486-94. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/12876091",
"target":"_blank"
},
"children":[
"PMID: 12876091"
]
}
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"f"
]
},
"Data from Dormandy JA, Charbonnel B, Eckland DJ, et al; PROactive Investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet. 2005;366:1279-89. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/16214598",
"target":"_blank"
},
"children":[
"PMID: 16214598"
]
},
" doi:10.1016/S0140-6736(05)67528-9"
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"g"
]
},
"Data from Scirica BM, Bhatt DL, Braunwald E, et al; SAVOR-TIMI 53 Steering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369:1317-26. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/23992601",
"target":"_blank"
},
"children":[
"PMID: 23992601"
]
},
" doi:10.1056/NEJMoa1307684"
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"h"
]
},
"Data from Marso SP, Daniels GH, Brown-Frandsen K, et al; LEADER Steering Committee. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016;375:311-22. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/27295427",
"target":"_blank"
},
"children":[
"PMID: 27295427"
]
},
" doi:10.1056/NEJMoa1603827"
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"i"
]
},
"Data from Marso SP, Bain SC, Consoli A, et al; SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834-1844. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/27633186",
"target":"_blank"
},
"children":[
"PMID: 27633186"
]
},
" doi:10.1056/NEJMoa1607141"
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"j"
]
},
"Data from Zinman B, Wanner C, Lachin JM, et al; EMPA-REG OUTCOME Investigators. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373:2117-28. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/26378978",
"target":"_blank"
},
"children":[
"PMID: 26378978"
]
},
" doi:10.1056/NEJMoa1504720"
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"k"
]
},
"Data from Neal B, Perkovic V, Mahaffey KW, et al; CANVAS Program Collaborative Group. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017;377:644-657. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/28605608",
"target":"_blank"
},
"children":[
"PMID: 28605608"
]
},
" doi:10.1056/NEJMoa1611925"
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"l"
]
},
"Data from Perkovic V, Jardine MJ, Neal B, et al; CREDENCE Trial Investigators. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019;380:2295-2306. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/30990260",
"target":"_blank"
},
"children":[
"PMID: 30990260"
]
},
" doi:10.1056/NEJMoa1811744"
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"m"
]
},
"Data from Wiviott SD, Raz I, Bonaca MP, et al. The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)-TIMI 58 Trial. Am Heart J. 2018;200:83-89. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/29898853",
"target":"_blank"
},
"children":[
"PMID: 29898853"
]
},
" doi:10.1016/j.ahj.2018.01.012"
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"n"
]
},
"Data from Gaziano JM, Cincotta AH, O’Connor CM, et al. Randomized clinical trial of quick-release bromocriptine among patients with type 2 diabetes on overall safety and cardiovascular outcomes. Diabetes Care. 2010;33:1503-8. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/20332352",
"target":"_blank"
},
"children":[
"PMID: 20332352"
]
},
" doi:10.2337/dc09-2009"
]
]
},
"mk19_b_en_t11":{
"id":"mk19_b_en_t11",
"number":11,
"bookId":"en",
"title":{
"__html":"Pharmacologic Agents and Their Impact on Cardiovascular and Renal Outcomes<sup>a,b</sup>"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"e932b3",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 11. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_en_t11"
}
]
},
"Pharmacologic Agents and Their Impact on Cardiovascular and Renal Outcomes",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a,b"
]
}
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9bd813",
"class":"col hd l",
"children":[
"Class"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d409ee",
"class":"col hd l",
"children":[
"ASCVD Effects"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"eb0307",
"class":"col hd l",
"children":[
"Heart Failure Effects"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"101cc1",
"class":"col hd l",
"children":[
"Renal Effects"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"38ef85",
"class":"cell txt l",
"children":[
"Insulin"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e9bb53",
"class":"cell txt l",
"children":[
"Neutral"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e9bb53",
"class":"cell txt l",
"children":[
"Neutral"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e9bb53",
"class":"cell txt l",
"children":[
"Neutral"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ee61f9",
"class":"cell txt l",
"children":[
"Sulfonylureas (2nd generation)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e9bb53",
"class":"cell txt l",
"children":[
"Neutral"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e9bb53",
"class":"cell txt l",
"children":[
"Neutral"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e9bb53",
"class":"cell txt l",
"children":[
"Neutral"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3a4960",
"class":"cell txt l",
"children":[
"Metformin"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f591ae",
"class":"cell txt l",
"children":[
"Potential benefit"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e9bb53",
"class":"cell txt l",
"children":[
"Neutral"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e9bb53",
"class":"cell txt l",
"children":[
"Neutral"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"394da1",
"class":"cell txt l",
"children":[
"Thiazolidinediones"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d842a4",
"class":"cell txt l",
"children":[
"Potential benefit (pioglitazone)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9b0558",
"class":"cell txt l",
"children":[
"Increased risk"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e9bb53",
"class":"cell txt l",
"children":[
"Neutral"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"08c646",
"class":"cell txt l",
"children":[
"DPP-4 inhibitors"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e9bb53",
"class":"cell txt l",
"children":[
"Neutral"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"13fc45",
"class":"cell txt l",
"children":[
"Potential risk (saxagliptin)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e9bb53",
"class":"cell txt l",
"children":[
"Neutral"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3ec56e",
"class":"cell txt l",
"children":[
"GLP-1 receptor agonists"
]
},
" ",
{
"type":"p",
"hlId":"859162",
"class":"cell txt l",
"children":[
"(liraglutide, semaglutide, dulaglutide)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d0b37c",
"class":"cell txt l",
"children":[
"Benefit"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d0b37c",
"class":"cell txt l",
"children":[
"Benefit"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d0b37c",
"class":"cell txt l",
"children":[
"Benefit"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"331b7d",
"class":"cell txt l",
"children":[
"SGLT2 inhibitors"
]
},
" ",
{
"type":"p",
"hlId":"8b86e9",
"class":"cell txt l",
"children":[
"(empagliflozin, canagliflozin, dapagliflozin)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d0b37c",
"class":"cell txt l",
"children":[
"Benefit"
]
},
" ",
{
"type":"p",
"hlId":"95fe1d",
"class":"cell txt l",
"children":[
"FDA approved for CVD benefit: empagliflozin",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"c"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d0b37c",
"class":"cell txt l",
"children":[
"Benefit"
]
},
" ",
{
"type":"p",
"hlId":"91c756",
"class":"cell txt l",
"children":[
"FDA approved for heart failure indication: dapagliflozin",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"d"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d0b37c",
"class":"cell txt l",
"children":[
"Benefit"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"ASCVD = atherosclerotic cardiovascular disease; CVD = cardiovascular disease; DPP-4 = dipeptidyl peptidase-4; GLP-1 = glucagon-like peptide-1; SGLT2 = sodium-glucose cotransporter 2."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
"Data from American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes-2021. Diabetes Care. 2021;44:S111-S124. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/33298420",
"target":"_blank"
},
"children":[
"PMID: 33298420"
]
},
" doi:10.2337/dc21-S009"
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
},
"Data from Kristensen SL, Rørth R, Jhund PS, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol. 2019;7:776-785. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/31422062",
"target":"_blank"
},
"children":[
"PMID: 31422062"
]
},
" doi:10.1016/S2213-8587(19)30249-9"
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"c"
]
},
"Data from Zinman B, Wanner C, Lachin JM, et al; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117-28. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/26378978",
"target":"_blank"
},
"children":[
"PMID: 26378978"
]
},
" doi:10.1056/NEJMoa1504720"
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"d"
]
},
"Data from Wiviott SD, Raz I, Bonaca MP, et al. The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)-TIMI 58 Trial. Am Heart J. 2018;200:83-89. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/29898853",
"target":"_blank"
},
"children":[
"PMID: 29898853"
]
},
" doi:10.1016/j.ahj.2018.01.012"
],
[
"Table adapted from American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes-2021. Diabetes Care. 2021;44:S111-S124. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/33298420",
"target":"_blank"
},
"children":[
"PMID: 33298420"
]
},
" doi:10.2337/dc21-S009"
]
]
},
"mk19_b_en_t12":{
"id":"mk19_b_en_t12",
"number":12,
"bookId":"en",
"title":{
"__html":"Comparison of Insulin Dosing Algorithms from the ADA and AACE/ACE"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"658c00",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 12. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_en_t12"
}
]
},
"Comparison of Insulin Dosing Algorithms from the ADA and AACE/ACE"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"af36d3",
"class":"col hd l",
"children":[
"Insulin Initiation or Modification"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"347cbc",
"class":"col hd l",
"children":[
"ADA"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3484ec",
"class":"col hd l",
"children":[
"AACE/ACE"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c12c37",
"class":"cell txt l",
"children":[
"Basal insulin"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9deced",
"class":"cell txt l",
"children":[
"Starting dose:"
]
},
" ",
{
"type":"p",
"hlId":"c388e4",
"class":"cell txt l",
"children":[
"10 U/day or 0.1-0.2 U/kg/day"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9deced",
"class":"cell txt l",
"children":[
"Starting dose:"
]
},
" ",
{
"type":"p",
"hlId":"49f8f8",
"class":"cell txt l",
"children":[
"If hemoglobin A",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1c"
]
},
" <8%: 0.1-0.2 U/kg/day"
]
},
" ",
{
"type":"p",
"hlId":"d7b331",
"class":"cell txt l",
"children":[
"If hemoglobin A",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1c"
]
},
" >8%: 0.2-0.3 U/kg/day"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2ca34a",
"class":"cell txt l",
"children":[
"Basal insulin dose titration"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"30cfbd",
"class":"cell txt l",
"children":[
"For hyperglycemia:"
]
},
" ",
{
"type":"p",
"hlId":"1cabe8",
"class":"cell txt l",
"children":[
"Increase dose 1-2 times/week until glycemic goal met"
]
},
" ",
{
"type":"p",
"hlId":"39e270",
"class":"cell txt l",
"children":[
"Increase dose by:"
]
},
" ",
{
"type":"p",
"hlId":"2b9ec2",
"class":"cell txt l",
"children":[
"10%-15% or 2-4 U"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"30cfbd",
"class":"cell txt l",
"children":[
"For hyperglycemia:"
]
},
" ",
{
"type":"p",
"hlId":"d0014e",
"class":"cell txt l",
"children":[
"Increase dose every 2-3 days until glycemic goal met"
]
},
" ",
{
"type":"p",
"hlId":"39e270",
"class":"cell txt l",
"children":[
"Increase dose by:"
]
},
" ",
{
"type":"p",
"hlId":"e98cc1",
"class":"cell txt l",
"children":[
"2 U or"
]
},
" ",
{
"type":"p",
"hlId":"0f8146",
"class":"cell txt l",
"children":[
"20% if FBG >180 mg/dL (10 mmol/L)"
]
},
" ",
{
"type":"p",
"hlId":"f46bef",
"class":"cell txt l",
"children":[
"10% if FBG 140-180 mg/dL (7.8-9.9 mmol/L)"
]
},
" ",
{
"type":"p",
"hlId":"3cae2a",
"class":"cell txt l",
"children":[
"1 U if FBG 110-139 mg/dL (6.1-7.7 mmol/L)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1e86e4",
"class":"cell txt l",
"children":[
"For hypoglycemia:"
]
},
" ",
{
"type":"p",
"hlId":"5767aa",
"class":"cell txt l",
"children":[
"Decrease dose by: 10%-20% or 4 U"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1e86e4",
"class":"cell txt l",
"children":[
"For hypoglycemia:"
]
},
" ",
{
"type":"p",
"hlId":"99d815",
"class":"cell txt l",
"children":[
"Decrease dose by:"
]
},
" ",
{
"type":"p",
"hlId":"a723e5",
"class":"cell txt l",
"children":[
"10%-20% if FBG <70 mg/dL (3.9 mmol/L)"
]
},
" ",
{
"type":"p",
"hlId":"da5a30",
"class":"cell txt l",
"children":[
"20%-40% if FBG <40 mg/dL (2.2 mmol/L)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"48e3da",
"class":"cell txt l",
"children":[
"Prandial insulin plus basal insulin"
]
},
" ",
{
"type":"p",
"hlId":"d45af8",
"class":"cell txt l",
"children":[
"(1 meal)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e45f6b",
"class":"cell txt l",
"children":[
"Initiate prandial insulin at largest meal"
]
},
" ",
{
"type":"p",
"hlId":"9deced",
"class":"cell txt l",
"children":[
"Starting dose:"
]
},
" ",
{
"type":"p",
"hlId":"40c6ec",
"class":"cell txt l",
"children":[
"4 U, 10% of basal dose, or 0.1 U/kg"
]
},
" ",
{
"type":"p",
"hlId":"e61848",
"class":"cell txt l",
"children":[
"To avoid hypoglycemia, consider decreasing basal dose by same amount if hemoglobin A",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1c"
]
},
" <8%"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e45f6b",
"class":"cell txt l",
"children":[
"Initiate prandial insulin at largest meal"
]
},
" ",
{
"type":"p",
"hlId":"9deced",
"class":"cell txt l",
"children":[
"Starting dose:"
]
},
" ",
{
"type":"p",
"hlId":"5850ad",
"class":"cell txt l",
"children":[
"5 U or 10% of basal dose"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6604cc",
"class":"cell txt l",
"children":[
"Basal-bolus insulin regimen"
]
},
" ",
{
"type":"p",
"hlId":"22a1f5",
"class":"cell txt l",
"children":[
"(≥2 or more meals)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8078b4",
"class":"cell txt l",
"children":[
"Prandial insulin starting dose:"
]
},
" ",
{
"type":"p",
"hlId":"1ee340",
"class":"cell txt l",
"children":[
"4 U, 10% of basal dose, or 0.1 U/kg/meal"
]
},
" ",
{
"type":"p",
"hlId":"e61848",
"class":"cell txt l",
"children":[
"To avoid hypoglycemia, consider decreasing basal dose by same amount if hemoglobin A",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"1c"
]
},
" <8%"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8078b4",
"class":"cell txt l",
"children":[
"Prandial insulin starting dose:"
]
},
" ",
{
"type":"p",
"hlId":"ada358",
"class":"cell txt l",
"children":[
"0.3-0.5 U/kg = TDD"
]
},
" ",
{
"type":"p",
"hlId":"d8201e",
"class":"cell txt l",
"children":[
"50% of TDD = basal insulin"
]
},
" ",
{
"type":"p",
"hlId":"e38df6",
"class":"cell txt l",
"children":[
"50% of TDD = prandial insulin"
]
},
" ",
{
"type":"p",
"hlId":"8253e9",
"class":"cell txt l",
"children":[
"Each meal-time dose = 1/3 prandial insulin dose"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"46383d",
"class":"cell txt l",
"children":[
"Prandial insulin dose titration"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"30cfbd",
"class":"cell txt l",
"children":[
"For hyperglycemia:"
]
},
" ",
{
"type":"p",
"hlId":"703c1c",
"class":"cell txt l",
"children":[
"Increase dose 1-2 days/week until glycemic goal met"
]
},
" ",
{
"type":"p",
"hlId":"39e270",
"class":"cell txt l",
"children":[
"Increase dose by:"
]
},
" ",
{
"type":"p",
"hlId":"39804c",
"class":"cell txt l",
"children":[
"10%-15% or 1-2 U"
]
},
" ",
{
"type":"p",
"hlId":"ff8084",
"class":"cell txt l",
"children":[
"If hyperglycemia persists at other meals, add additional meal-time insulin doses (basal-bolus)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"30cfbd",
"class":"cell txt l",
"children":[
"For hyperglycemia:"
]
},
" ",
{
"type":"p",
"hlId":"d0014e",
"class":"cell txt l",
"children":[
"Increase dose every 2-3 days until glycemic goal met"
]
},
" ",
{
"type":"p",
"hlId":"39e270",
"class":"cell txt l",
"children":[
"Increase dose by:"
]
},
" ",
{
"type":"p",
"hlId":"57b534",
"class":"cell txt l",
"children":[
"10% or 1-2 U if BG >140 mg/dL (7.8 mmol/L) 2 h after meal or at next meal"
]
},
" ",
{
"type":"p",
"hlId":"ff8084",
"class":"cell txt l",
"children":[
"If hyperglycemia persists at other meals, add additional meal-time insulin doses (basal-bolus)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1e86e4",
"class":"cell txt l",
"children":[
"For hypoglycemia:"
]
},
" ",
{
"type":"p",
"hlId":"99d815",
"class":"cell txt l",
"children":[
"Decrease dose by:"
]
},
" ",
{
"type":"p",
"hlId":"33e815",
"class":"cell txt l",
"children":[
"10%-20% or 2-4 U"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1e86e4",
"class":"cell txt l",
"children":[
"For hypoglycemia:"
]
},
" ",
{
"type":"p",
"hlId":"f65ff6",
"class":"cell txt l",
"children":[
"Decrease TDD dose (basal and/or prandial) by:"
]
},
" ",
{
"type":"p",
"hlId":"6eb852",
"class":"cell txt l",
"children":[
"10%-20% if BG <70 mg/dL (3.9 mmol/L)"
]
},
" ",
{
"type":"p",
"hlId":"81f039",
"class":"cell txt l",
"children":[
"20%-40% if BG <40 mg/dL (2.2 mmol/L)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"813216",
"class":"cell txt l",
"children":[
"Premixed insulin twice daily"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9deced",
"class":"cell txt l",
"children":[
"Starting dose:"
]
},
" ",
{
"type":"p",
"hlId":"3411a0",
"class":"cell txt l",
"children":[
"Current basal dose given at breakfast and dinner distributed as 2/3 ",
{
"type":"tag",
"tagName":"small",
"attrs":{
},
"children":[
"AM"
]
},
" and 1/3 ",
{
"type":"tag",
"tagName":"small",
"attrs":{
},
"children":[
"PM"
]
},
" or 1/2 ",
{
"type":"tag",
"tagName":"small",
"attrs":{
},
"children":[
"AM"
]
},
" and 1/2 ",
{
"type":"tag",
"tagName":"small",
"attrs":{
},
"children":[
"PM"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8f4c1c",
"class":"cell txt l",
"children":[
"Premixed analogue insulin three times daily"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"88a880",
"class":"cell txt l",
"children":[
"Add additional insulin dose at lunch"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-8 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"64ec1b",
"class":"cell txt l",
"children":[
"Premixed insulin dose titration"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"30cfbd",
"class":"cell txt l",
"children":[
"For hyperglycemia:"
]
},
" ",
{
"type":"p",
"hlId":"703c1c",
"class":"cell txt l",
"children":[
"Increase dose 1-2 days/week until glycemic goal met"
]
},
" ",
{
"type":"p",
"hlId":"39e270",
"class":"cell txt l",
"children":[
"Increase dose by:"
]
},
" ",
{
"type":"p",
"hlId":"39804c",
"class":"cell txt l",
"children":[
"10%-15% or 1-2 U"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-8 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1e86e4",
"class":"cell txt l",
"children":[
"For hypoglycemia:"
]
},
" ",
{
"type":"p",
"hlId":"99d815",
"class":"cell txt l",
"children":[
"Decrease dose by:"
]
},
" ",
{
"type":"p",
"hlId":"33e815",
"class":"cell txt l",
"children":[
"10%-20% or 2-4 U"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"ADA = American Diabetes Association; AACE = American Association of Clinical Endocrinologists; ACE = American College of Endocrinology; BG = blood glucose; FBG = fasting blood glucose; TDD = total daily dose."
],
[
"Data from American Diabetes Association. 9. Pharmacologic approaches to glycemic treatment: Standards of Medical Care in Diabetes-2021. Diabetes Care. 2021;44:S111-S124. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/33298420",
"target":"_blank"
},
"children":[
"PMID: 33298420"
]
},
" doi:10.2337/dc21-S009"
],
[
"Data from Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive type 2 diabetes management algorithm - 2018 Executive Summary. Endocr Pract. 2018;24:91-120. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/29368965",
"target":"_blank"
},
"children":[
"PMID: 29368965"
]
},
" doi:10.4158/CS-2017-0153"
]
]
},
"mk19_b_en_t13":{
"id":"mk19_b_en_t13",
"number":13,
"bookId":"en",
"title":{
"__html":"Drug-Induced Hyperglycemia"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"53b128",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 13. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_en_t13"
}
]
},
"Drug-Induced Hyperglycemia"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"003ac0",
"class":"col hd l",
"children":[
"Drug Category"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5db77f",
"class":"col hd l",
"children":[
"Drug"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"467ae2",
"class":"col hd l",
"children":[
"Mechanism of Hyperglycemia"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f97fe8",
"class":"cell txt l",
"children":[
"Glucocorticoid"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"dfc09e",
"class":"cell txt l",
"children":[
"All systemic glucocorticoids"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b0b8a6",
"class":"cell txt l",
"children":[
"Decreased insulin production"
]
},
" ",
{
"type":"p",
"hlId":"97d40a",
"class":"cell txt l",
"children":[
"Increased peripheral insulin resistance"
]
},
" ",
{
"type":"p",
"hlId":"a3d1ee",
"class":"cell txt l",
"children":[
"Increased hepatic glucose production"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"84c49f",
"class":"cell txt l",
"children":[
"Immunosuppressants"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"269ba8",
"class":"cell txt l",
"children":[
"Calcineurin inhibitors"
]
},
" ",
{
"type":"p",
"hlId":"d9c866",
"class":"cell txt li",
"children":[
"Sirolimus"
]
},
" ",
{
"type":"p",
"hlId":"273268",
"class":"cell txt li",
"children":[
"Tacrolimus"
]
},
" ",
{
"type":"p",
"hlId":"d5ad08",
"class":"cell txt li",
"children":[
"Cyclosporine"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"50d165",
"class":"cell txt l",
"children":[
"Decreased insulin production and release"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fa3584",
"class":"cell txt l",
"children":[
"Antiretrovirals"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c2b382",
"class":"cell txt l",
"children":[
"Protease inhibitors"
]
},
" ",
{
"type":"p",
"hlId":"dd87a3",
"class":"cell txt l",
"children":[
"NRTIs"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"97d40a",
"class":"cell txt l",
"children":[
"Increased peripheral insulin resistance"
]
},
" ",
{
"type":"p",
"hlId":"ca3449",
"class":"cell txt l",
"children":[
"Pancreatic damage through drug-induced pancreatitis (didanosine)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fdfddc",
"class":"cell txt l",
"children":[
"Cardiovascular medications"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8f855e",
"class":"cell txt l",
"children":[
"Niacin"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a3d1ee",
"class":"cell txt l",
"children":[
"Increased hepatic glucose production"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"39895a",
"class":"cell txt l",
"children":[
"Statins"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2cda17",
"class":"cell txt l",
"children":[
"Impaired pancreatic β-cell function"
]
},
" ",
{
"type":"p",
"hlId":"218269",
"class":"cell txt l",
"children":[
"Increased peripheral resistance"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"89aad3",
"class":"cell txt l",
"children":[
"β-Blockers"
]
},
" ",
{
"type":"p",
"hlId":"842e4a",
"class":"cell txt li",
"children":[
"Atenolol"
]
},
" ",
{
"type":"p",
"hlId":"85931b",
"class":"cell txt li",
"children":[
"Metoprolol"
]
},
" ",
{
"type":"p",
"hlId":"26d2fb",
"class":"cell txt li",
"children":[
"Propranolol"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6f0cba",
"class":"cell txt l",
"children":[
"Decreased insulin release"
]
},
" ",
{
"type":"p",
"hlId":"97d40a",
"class":"cell txt l",
"children":[
"Increased peripheral insulin resistance"
]
},
" ",
{
"type":"p",
"hlId":"37d344",
"class":"cell txt l",
"children":[
"Carvedilol has a neutral effect on glucose"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5f096a",
"class":"cell txt l",
"children":[
"Thiazides"
]
},
" ",
{
"type":"p",
"hlId":"f678b0",
"class":"cell txt li",
"children":[
"Hydrochlorothiazide"
]
},
" ",
{
"type":"p",
"hlId":"833150",
"class":"cell txt li",
"children":[
"Chlorthalidone"
]
},
" ",
{
"type":"p",
"hlId":"94ece4",
"class":"cell txt li",
"children":[
"Chlorothiazide"
]
},
" ",
{
"type":"p",
"hlId":"e7e744",
"class":"cell txt li",
"children":[
"Indapamide"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0e039b",
"class":"cell txt l",
"children":[
"Decreased insulin secretion secondary to hypokalemia"
]
},
" ",
{
"type":"p",
"hlId":"fa632e",
"class":"cell txt l",
"children":[
"Increased insulin resistance"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d09464",
"class":"cell txt l",
"children":[
"Vasopressors"
]
},
" ",
{
"type":"p",
"hlId":"39e38c",
"class":"cell txt li",
"children":[
"Epinephrine"
]
},
" ",
{
"type":"p",
"hlId":"f7ac0c",
"class":"cell txt li",
"children":[
"Norepinephrine"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c1e96a",
"class":"cell txt l",
"children":[
"Decreased insulin secretion"
]
},
" ",
{
"type":"p",
"hlId":"148e2c",
"class":"cell txt l",
"children":[
"Increased glycogenolysis"
]
},
" ",
{
"type":"p",
"hlId":"945477",
"class":"cell txt l",
"children":[
"Increased hepatic glucose"
]
},
" ",
{
"type":"p",
"hlId":"fd8978",
"class":"cell txt l",
"children":[
"production"
]
},
" ",
{
"type":"p",
"hlId":"76bebc",
"class":"cell txt l",
"children":[
"Stimulation of glucagon and cortisol"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d7e5bf",
"class":"cell txt l",
"children":[
"Hormonal medications"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"16863c",
"class":"cell txt l",
"children":[
"Oral contraceptives"
]
},
" ",
{
"type":"p",
"hlId":"db9ed4",
"class":"cell txt li",
"children":[
"Combined estrogen-progestin"
]
},
" ",
{
"type":"p",
"hlId":"7833a1",
"class":"cell txt li",
"children":[
"Progestin only"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"acdff9",
"class":"cell txt l",
"children":[
"Abnormal hepatic glucose metabolism"
]
},
" ",
{
"type":"p",
"hlId":"97d40a",
"class":"cell txt l",
"children":[
"Increased peripheral insulin resistance"
]
},
" ",
{
"type":"p",
"hlId":"30070e",
"class":"cell txt l",
"children":[
"Decreased risk of hyperglycemia with low-dose pills containing ≤35 μg ethinyl estradiol"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b3ee77",
"class":"cell txt l",
"children":[
"Progestin"
]
},
" ",
{
"type":"p",
"hlId":"7b0cf8",
"class":"cell txt li",
"children":[
"Megestrol acetate"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"97d40a",
"class":"cell txt l",
"children":[
"Increased peripheral insulin resistance"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"8a8bd4",
"class":"cell txt l",
"children":[
"Growth hormone"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"97d40a",
"class":"cell txt l",
"children":[
"Increased peripheral insulin resistance"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-6 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e99cd7",
"class":"cell txt l",
"children":[
"Atypical antipsychotics"
]
},
" ",
{
"type":"p",
"hlId":"d74ae7",
"class":"cell txt l",
"children":[
"(second generation)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d0381e",
"class":"cell txt l",
"children":[
"Clozapine"
]
},
" ",
{
"type":"p",
"hlId":"394044",
"class":"cell txt l",
"children":[
"Olanzapine"
]
},
" ",
{
"type":"p",
"hlId":"5ba535",
"class":"cell txt l",
"children":[
"Ziprasidone"
]
},
" ",
{
"type":"p",
"hlId":"288839",
"class":"cell txt l",
"children":[
"Quetiapine"
]
},
" ",
{
"type":"p",
"hlId":"1b254d",
"class":"cell txt l",
"children":[
"Risperidone"
]
},
" ",
{
"type":"p",
"hlId":"00d49d",
"class":"cell txt l",
"children":[
"Iloperidone"
]
},
" ",
{
"type":"p",
"hlId":"3e1fdc",
"class":"cell txt l",
"children":[
"Paliperidone"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"71d1d6",
"class":"cell txt l",
"children":[
"Unclear"
]
},
" ",
{
"type":"p",
"hlId":"5c5eb1",
"class":"cell txt l",
"children":[
"Possible increased peripheral insulin resistance"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-7 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"445236",
"class":"cell txt l",
"children":[
"Antibiotics"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c58a32",
"class":"cell txt l",
"children":[
"Moxifloxacin"
]
},
" ",
{
"type":"p",
"hlId":"cd3671",
"class":"cell txt l",
"children":[
"Gatifloxacin"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"e6f5d6",
"class":"cell txt l",
"children":[
"Altered insulin secretion"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"NRTI = nucleoside reverse transcriptase inhibitor."
],
[
"Data from Fathallah N, Slim R, Larif S, et al. Drug-induced hyperglycaemia and diabetes. Drug Saf. 2015;38:1153-68. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/26370106",
"target":"_blank"
},
"children":[
"PMID: 26370106"
]
},
" doi:10.1007/s40264-015-0339-z"
],
[
"Data from Thomas Z, Bandali F, McCowen K, et al. Drug-induced endocrine disorders in the intensive care unit. Crit Care Med. 2010;38:S219-30. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/20502175",
"target":"_blank"
},
"children":[
"PMID: 20502175"
]
},
" doi:10.1097/CCM.0b013e3181dda0f2"
]
]
},
"mk19_b_en_t14":{
"id":"mk19_b_en_t14",
"number":14,
"bookId":"en",
"title":{
"__html":"Management of Hyperglycemic Crisis: Diabetic Ketoacidosis and Hyperglycemic Hyperosmolar Syndrome"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"305b6c",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 14. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_en_t14"
}
]
},
"Management of Hyperglycemic Crisis: Diabetic Ketoacidosis and Hyperglycemic Hyperosmolar Syndrome"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"c599fe",
"class":"col hd l",
"children":[
"Fluids"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"dd53f5",
"class":"col hd l",
"children":[
"Insulin (Regular)"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3a4edc",
"class":"col hd l",
"children":[
"Potassium"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"76630e",
"class":"col hd l",
"children":[
"Correction of Acidosis"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"70a0a5",
"class":"cell txt l",
"children":[
"Assess for volume status, then give 0.9% saline IV at 1 L/h initially in all patients, and continue if patient is severely hypovolemic. Switch to 0.45% saline at 250-500 mL/h if corrected serum sodium level becomes normal or high."
]
},
" ",
{
"type":"p",
"hlId":"a459d1",
"class":"cell txt l",
"children":[
"When the plasma glucose level reaches 200 mg/dL (11.1 mmol/L) in patients with DKA or 300 mg/dL (16.7 mmol/L) in HHS in the setting of continued IV insulin, switch to 5% dextrose with 0.45% saline at 150-250 mL/h to avoid hypoglycemia."
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ec3a15",
"class":"cell txt l",
"children":[
"Give regular insulin, 0.1 U/kg, as an IV bolus followed by 0.1 U/kg/h as an IV infusion."
]
},
" ",
{
"type":"p",
"hlId":"b776e0",
"class":"cell txt l",
"children":[
"If the plasma glucose level does not decrease by 10% in the first hour, give an additional bolus of 0.14 U/kg and resume previous infusion rate."
]
},
" ",
{
"type":"p",
"hlId":"956a23",
"class":"cell txt l",
"children":[
"When the plasma glucose level reaches 200 mg/dL (11.1 mmol/L) in DKA and 300 mg/dL (16.7 mmol/L) in HHS, reduce to 0.02-0.05 U/kg/h, and maintain the plasma glucose level between 150-200 mg/dL (8.3-11.1 mmol/L) until anion gap acidosis is resolved in DKA."
]
},
" ",
{
"type":"p",
"hlId":"a195a7",
"class":"cell txt l",
"children":[
"The plasma glucose should be maintained at 250-300 mg/dL in HHS until the patient is alert and the hyperosmolar state resolves."
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"2d3ebe",
"class":"cell txt l",
"children":[
"Assess for adequate kidney function, with adequate urine output (approximately 50 mL/h)."
]
},
" ",
{
"type":"p",
"hlId":"a075b3",
"class":"cell txt l",
"children":[
"If serum potassium is <3.3 mEq/L (3.3 mmol/L), do not start insulin; instead, give IV potassium chloride, 20-30 mEq/h, through a central line catheter until potassium level is >3.3 mEq/L (3.3 mmol/L). Then add 20-30 mEq of potassium chloride to each liter of IV fluids to keep the serum potassium level in the 4.0-5.0 mEq/L (4.0-5.0 mmol/L) range."
]
},
" ",
{
"type":"p",
"hlId":"e393fc",
"class":"cell txt l",
"children":[
"If the serum potassium level is >5.2 mEq/L (5.2 mmol/L), do not give potassium chloride; instead, start insulin and IV fluids, and check the serum potassium level every 2 h."
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5d1280",
"class":"cell txt l",
"children":[
"If pH is <6.9, consider sodium bicarbonate, 100 mEq (100 mmol) in 400 mL of sterile water, and potassium chloride, 20 mEq (20 mmol), infused over 2 h."
]
},
" ",
{
"type":"p",
"hlId":"e128a5",
"class":"cell txt l",
"children":[
"If pH is 6.9 or greater, do not give sodium bicarbonate."
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"DKA = diabetic ketoacidosis; HHS = hyperglycemic hyperosmolar syndrome; IV = intravenous."
],
[
"Recommendations from Kitabchi AE, Umpierrez GE, Miles JM, et al. Hyperglycemic crises in adult patients with diabetes. Diabetes Care. 2009;32:1335-43. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/19564476",
"target":"_blank"
},
"children":[
"PMID: 19564476"
]
},
" doi:10.2337/dc09-9032"
]
]
},
"mk19_b_en_t15":{
"id":"mk19_b_en_t15",
"number":15,
"bookId":"en",
"title":{
"__html":"Screening Recommendations for Chronic Complications of Diabetes Mellitus"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"a88655",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 15. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_en_t15"
}
]
},
"Screening Recommendations for Chronic Complications of Diabetes Mellitus"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f7919b",
"class":"col hd l",
"children":[
"Chronic Complication"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"aa0301",
"class":"col hd l",
"children":[
"Clinical Situation"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"1f4446",
"class":"col hd l",
"children":[
"When to Start Screening"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5b3ef3",
"class":"col hd l",
"children":[
"Screening Frequency"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"014766",
"class":"col hd l",
"children":[
"Preferred Screening Test"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"7e3967",
"class":"cell txt l",
"children":[
"Retinopathy"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d0f23a",
"class":"cell txt l",
"children":[
"Type 1 diabetes"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"cf7421",
"class":"cell txt l",
"children":[
"At 5 years after diagnosis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"839ea9",
"class":"cell txt l",
"children":[
"Annually",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"4f9854",
"class":"cell txt l",
"children":[
"Dilated and comprehensive eye examination",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
}
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"205680",
"class":"cell txt l",
"children":[
"Type 2 diabetes"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"803795",
"class":"cell txt l",
"children":[
"At diagnosis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"839ea9",
"class":"cell txt l",
"children":[
"Annually",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"9a9db4",
"class":"cell txt l",
"children":[
"In pregnant women with either type of diabetes"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6c832e",
"class":"cell txt l",
"children":[
"First trimester"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"15dd5d",
"class":"cell txt l",
"children":[
"Every trimester and then closely for 1 year postpartum"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"12a0a7",
"class":"cell txt l",
"children":[
"In women with either type of diabetes planning to conceive"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"231b5e",
"class":"cell txt l",
"children":[
"During preconception planning"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"76a3eb",
"class":"cell txt l",
"children":[
"Same as recommendations for pregnant women once conception occurs"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"de3212",
"class":"cell txt l",
"children":[
"Nephropathy"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d0f23a",
"class":"cell txt l",
"children":[
"Type 1 diabetes"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"cf7421",
"class":"cell txt l",
"children":[
"At 5 years after diagnosis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"352d22",
"class":"cell txt l",
"children":[
"Annually",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"c"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"3ded9a",
"class":"cell txt l",
"children":[
"Albumin-creatinine ratio on random spot urine, eGFR"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"205680",
"class":"cell txt l",
"children":[
"Type 2 diabetes"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"803795",
"class":"cell txt l",
"children":[
"At diagnosis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"352d22",
"class":"cell txt l",
"children":[
"Annually",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"c"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a675d2",
"class":"cell txt l",
"children":[
"Neuropathy"
]
},
" ",
{
"type":"p",
"hlId":"ab29ee",
"class":"cell txt l",
"children":[
"(distal symmetric polyneuropathy)",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"d"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d0f23a",
"class":"cell txt l",
"children":[
"Type 1 diabetes"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"cf7421",
"class":"cell txt l",
"children":[
"At 5 years after diagnosis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"10b342",
"class":"cell txt l",
"children":[
"Annually"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f91b0b",
"class":"cell txt l",
"children":[
"Skin assessment, evaluation for foot deformities, lower extremity pulse assessment, neurologic assessment (10-g monofilament plus 128-Hz tuning fork, ankle reflexes, pinprick, or temperature)"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"205680",
"class":"cell txt l",
"children":[
"Type 2 diabetes"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"803795",
"class":"cell txt l",
"children":[
"At diagnosis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"10b342",
"class":"cell txt l",
"children":[
"Annually"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"d41d8c",
"class":"cell txt l",
"children":[

]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a6c2a2",
"class":"cell txt l",
"children":[
"Cardiovascular disease"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"01da3e",
"class":"cell txt l",
"children":[
"Hypertension"
]
},
" ",
{
"type":"p",
"hlId":"5a1567",
"class":"cell txt l",
"children":[
"Dyslipidemia"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"803795",
"class":"cell txt l",
"children":[
"At diagnosis"
]
},
" ",
{
"type":"p",
"hlId":"c6fa25",
"class":"cell txt l",
"children":[
"At diagnosis and before initiating statin therapy"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"68153a",
"class":"cell txt l",
"children":[
"Every visit"
]
},
" ",
{
"type":"p",
"hlId":"92e864",
"class":"cell txt l",
"children":[
"Annually",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"e"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"63053f",
"class":"cell txt l",
"children":[
"Blood pressure measurement"
]
},
" ",
{
"type":"p",
"hlId":"6a0e57",
"class":"cell txt l",
"children":[
"Lipid profile"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"eGFR = estimated glomerular filtration rate."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
"It is reasonable to screen every 1 to 2 years if no diabetic retinopathy is present and to screen more often than annually if diabetic retinopathy is advanced or progressing rapidly."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
},
"Retinal photography is a possible alternative means of screening for diabetic retinopathy that may improve access to care and reduce costs. Retinal photography, when interpreted by eye care specialists, can detect most clinically significant diabetic retinopathy."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"c"
]
},
"The American Diabetes Association guidelines state that it is reasonable to assess progression of disease and response to therapeutic interventions with continued monitoring of urinary albumin-creatinine excretion."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"d"
]
},
"Although diabetes commonly causes peripheral neuropathy, other differential diagnoses to consider during the screening process include vitamin B",
{
"type":"tag",
"tagName":"sub",
"attrs":{
},
"children":[
"12"
]
},
" deficiency, alcoholism, hypothyroidism, kidney disease, malignancy and chemotherapies, vasculitis, and inherited neuropathies."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"e"
]
},
"Annual or periodic screening is needed to monitor therapeutic response after initiation of statin therapy. Screening may be performed every 5 years in patients not on statin therapy."
],
[
"Recommendations from American Diabetes Association. 10. Cardiovascular disease and risk management: Standards of Medical Care in Diabetes-2021. Diabetes Care. 2021;44:S125-S150. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/33298421",
"target":"_blank"
},
"children":[
"PMID: 33298421"
]
},
" doi:10.2337/dc21-S010"
],
[
"Recommendations from American Diabetes Association. 11. Microvascular complications and foot care: Standards of Medical Care in Diabetes-2021. Diabetes Care. 2021;44:S151-S167. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/33298422",
"target":"_blank"
},
"children":[
"PMID: 33298422"
]
},
" doi:10.2337/dc21-S011"
],
[
"Recommendations from Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm – 2018 Executive Summary. Endocr Pract. 2018;24:91-120. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/29368965",
"target":"_blank"
},
"children":[
"PMID: 29368965"
]
},
" doi:10.4158/CS-2017-0153"
]
]
},
"mk19_b_en_t16":{
"id":"mk19_b_en_t16",
"number":16,
"bookId":"en",
"title":{
"__html":"Differential Diagnosis of Spontaneous Fasting Hypoglycemia<sup>a</sup> in a Person Without Diabetes Mellitus"
},
"jsonContent":{
"type":"tag",
"tagName":"table",
"attrs":{
"className":"table"
},
"children":[
{
"type":"tag",
"tagName":"caption",
"attrs":{
},
"children":[
{
"type":"p",
"hlId":"097d03",
"children":[
{
"type":"tag",
"tagName":"b",
"attrs":{
"className":"table-number"
},
"children":[
{
"type":"tag",
"tagName":"span",
"attrs":{
},
"children":[
"Table 16. "
]
},
{
"type":"new-window-link",
"targetType":"table",
"targetId":"mk19_b_en_t16"
}
]
},
"Differential Diagnosis of Spontaneous Fasting Hypoglycemia",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
" in a Person Without Diabetes Mellitus"
]
}
]
},
{
"type":"tag",
"tagName":"thead",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"523223",
"class":"col hd l",
"children":[
"Diagnosis"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"06a979",
"class":"col hd c",
"children":[
"Serum Insulin"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ffde68",
"class":"col hd c",
"children":[
"Plasma C-Peptide",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f32c9f",
"class":"col hd c",
"children":[
"Plasma Proinsulin",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"0ce56d",
"class":"col hd c",
"children":[
"Serum β-hydroxybutyrate",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"c"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"b6b615",
"class":"col hd l",
"children":[
"Serum Insulin Antibodies"
]
},
" "
]
},
{
"type":"tag",
"tagName":"th",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"77f671",
"class":"col hd l",
"children":[
"Urine or Blood Metabolites of Sulfonylureas or Meglitinides"
]
},
" "
]
}
]
}
]
},
{
"type":"tag",
"tagName":"tbody",
"attrs":{
},
"children":[
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-1 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"47a54d",
"class":"cell txt l",
"children":[
"Insulinoma",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"d, e"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fa1be6",
"class":"cell txt c",
"children":[
"↑"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fa1be6",
"class":"cell txt c",
"children":[
"↑"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fa1be6",
"class":"cell txt c",
"children":[
"↑"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a014e2",
"class":"cell txt c",
"children":[
"↓"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ffb935",
"class":"cell txt l",
"children":[
"Negative"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ffb935",
"class":"cell txt l",
"children":[
"Negative"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-2 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"5de41f",
"class":"cell txt l",
"children":[
"Surreptitious use of sulfonylureas or meglitinides"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fa1be6",
"class":"cell txt c",
"children":[
"↑"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fa1be6",
"class":"cell txt c",
"children":[
"↑"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fa1be6",
"class":"cell txt c",
"children":[
"↑"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a014e2",
"class":"cell txt c",
"children":[
"↓"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ffb935",
"class":"cell txt l",
"children":[
"Negative"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"328929",
"class":"cell txt l",
"children":[
"Positive"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-3 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"94e3c4",
"class":"cell txt l",
"children":[
"Surreptitious use of insulin"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fa1be6",
"class":"cell txt c",
"children":[
"↑"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a014e2",
"class":"cell txt c",
"children":[
"↓"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a014e2",
"class":"cell txt c",
"children":[
"↓"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a014e2",
"class":"cell txt c",
"children":[
"↓"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ffb935",
"class":"cell txt l",
"children":[
"Negative"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ffb935",
"class":"cell txt l",
"children":[
"Negative"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-4 row-even"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"f2ef4a",
"class":"cell txt l",
"children":[
"Insulin autoimmune hypoglycemia"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fa1be6",
"class":"cell txt c",
"children":[
"↑"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fa1be6",
"class":"cell txt c",
"children":[
"↑"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"fa1be6",
"class":"cell txt c",
"children":[
"↑"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a014e2",
"class":"cell txt c",
"children":[
"↓"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"328929",
"class":"cell txt l",
"children":[
"Positive"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ffb935",
"class":"cell txt l",
"children":[
"Negative"
]
},
" "
]
}
]
},
{
"type":"tag",
"tagName":"tr",
"attrs":{
"className":"group_1-5 row-odd"
},
"children":[
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"6e53a2",
"class":"cell txt l",
"children":[
"IGF-II",
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"f"
]
}
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a014e2",
"class":"cell txt c",
"children":[
"↓"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a014e2",
"class":"cell txt c",
"children":[
"↓"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a014e2",
"class":"cell txt c",
"children":[
"↓"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"a014e2",
"class":"cell txt c",
"children":[
"↓"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ffb935",
"class":"cell txt l",
"children":[
"Negative"
]
},
" "
]
},
{
"type":"tag",
"tagName":"td",
"attrs":{
"rowSpan":"1",
"colSpan":"1"
},
"children":[
" ",
{
"type":"p",
"hlId":"ffb935",
"class":"cell txt l",
"children":[
"Negative"
]
},
" "
]
}
]
}
]
}
]
},
"footnotes":[
[
"IGF = insulin-like growth factor."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"a"
]
},
"Symptomatic hypoglycemia, fasting plasma glucose 55 mg/dL (3.1 mmol/L) or lower, and prompt symptomatic relief with correction of hypoglycemia (Whipple triad)."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"b"
]
},
"C-peptide and proinsulin indicate endogenous insulin production."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"c"
]
},
"β-Hydroxybutyrate will be suppressed in the presence of insulin but elevated with hypoglycemia that is not mediated by insulin."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"d"
]
},
"Blood specimens should be collected at the end of testing and glucagon should be administered followed by serial glucose measurements over 30 minutes. Insulin suppresses glycogenolysis and preserves glycogen stores. In the setting of an insulinoma, glucose will increase in response to glucagon as the glycogen stores are used."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"e"
]
},
"Similar results can also be seen with non-insulinoma pancreatogenous hypoglycemia syndrome or post-gastric bypass hypoglycemia."
],
[
{
"type":"tag",
"tagName":"sup",
"attrs":{
},
"children":[
"f"
]
},
"Insulin-like growth factor (IGF)-II or its precursors may be produced by tumors and induce hypoglycemia by stimulating the insulin receptors with subsequent increases in glucose use."
],
[
"Data from Cryer PE, Axelrod L, Grossman AB, et al; Endocrine Society. Evaluation and management of adult hypoglycemic disorders: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2009;94:709-28. ",
{
"type":"tag",
"tagName":"a",
"attrs":{
"href":"http://www.ncbi.nlm.nih.gov/pubmed/19088155",
"target":"_blank"
},
"children":[
"PMID: 19088155"
]
},
" doi:10.1210/jc.2008-1410"
]
]
}
}
}